<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne - Liu, H - 2020 | Cochrane Library</title> <meta content="Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne - Liu, H - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011368.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne - Liu, H - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011368.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011368.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne" name="citation_title"/> <meta content="Haibo Liu" name="citation_author"/> <meta content="Jinling Hospital, Nanjing University School of Medicine" name="citation_author_institution"/> <meta content="Haiyan Yu" name="citation_author"/> <meta content="Sir Run Run Shaw Hospital, Zhejiang University School of Medicine" name="citation_author_institution"/> <meta content="Jun Xia" name="citation_author"/> <meta content="The University of Nottingham Ningbo" name="citation_author_institution"/> <meta content="Ling Liu" name="citation_author"/> <meta content="Jinling Hospital, Nanjing University School of Medicine" name="citation_author_institution"/> <meta content="Guan J Liu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Hong Sang" name="citation_author"/> <meta content="Jinling Hospital, Nanjing University School of Medicine" name="citation_author_institution"/> <meta content="shzwqzsl@163.com" name="citation_author_email"/> <meta content="Frank Peinemann" name="citation_author"/> <meta content="Children's Hospital, University of Cologne" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD011368.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/05/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011368.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011368.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011368.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acne Vulgaris [*drug therapy]; Adapalene [adverse effects, therapeutic use]; Anti-Bacterial Agents [therapeutic use]; Benzoyl Peroxide [therapeutic use]; Bias; Clindamycin [adverse effects, therapeutic use]; Dermatologic Agents [adverse effects, *therapeutic use]; Dicarboxylic Acids [adverse effects, therapeutic use]; Erythromycin [adverse effects, therapeutic use]; Glycolates [therapeutic use]; Keratolytic Agents [therapeutic use]; Mandelic Acids [therapeutic use]; Niacinamide [adverse effects, therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Pyruvic Acid [adverse effects, therapeutic use]; Quality of Life; Salicylic Acid [therapeutic use]; Sulfur [therapeutic use]; Tretinoin [therapeutic use]; Zinc [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011368.pub2&amp;doi=10.1002/14651858.CD011368.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="1pyM3CVc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011368\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011368\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011368.pub2",title:"Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha\\u2010hydroxy acid) for acne",firstPublishedDate:"May 1, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011368.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011368.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011368.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011368.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011368.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011368.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011368.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011368.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011368.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011368.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17295 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011368.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-sec-0342"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-sec-0327"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/appendices#CD011368-sec-0347"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/supinfo/CD011368StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/supinfo/CD011368StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#CD011368-cr-0004">Haibo Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#CD011368-cr-0005">Haiyan Yu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#CD011368-cr-0006">Jun Xia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#CD011368-cr-0007">Ling Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#CD011368-cr-0008">Guan J Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#CD011368-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Hong Sang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information#CD011368-cr-0010">Frank Peinemann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information/en#CD011368-sec-0362">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 May 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011368.pub2">https://doi.org/10.1002/14651858.CD011368.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011368-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011368-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011368-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011368-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011368-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011368-abs-0004">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011368-abs-0001" lang="en"> <section id="CD011368-sec-0001"> <h3 class="title" id="CD011368-sec-0001">Background</h3> <p>Acne is an inflammatory disorder with a high global burden. It is common in adolescents and primarily affects sebaceous gland‐rich areas. The clinical benefit of the topical acne treatments azelaic acid, salicylic acid, nicotinamide, sulphur, zinc, and alpha‐hydroxy acid is unclear. </p> </section> <section id="CD011368-sec-0002"> <h3 class="title" id="CD011368-sec-0002">Objectives</h3> <p>To assess the effects of topical treatments (azelaic acid, salicylic acid, nicotinamide, zinc, alpha‐hydroxy acid, and sulphur) for acne. </p> </section> <section id="CD011368-sec-0003"> <h3 class="title" id="CD011368-sec-0003">Search methods</h3> <p>We searched the following databases up to May 2019: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers. </p> </section> <section id="CD011368-sec-0004"> <h3 class="title" id="CD011368-sec-0004">Selection criteria</h3> <p>Clinical randomised controlled trials of the six topical treatments compared with other topical treatments, placebo, or no treatment in people with acne. </p> </section> <section id="CD011368-sec-0005"> <h3 class="title" id="CD011368-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Key outcomes included participants' global self‐assessment of acne improvement (PGA), withdrawal for any reason, minor adverse events (assessed as total number of participants who experienced at least one minor adverse event), and quality of life. </p> </section> <section id="CD011368-sec-0006"> <h3 class="title" id="CD011368-sec-0006">Main results</h3> <p>We included 49 trials (3880 reported participants) set in clinics, hospitals, research centres, and university settings in Europe, Asia, and the USA. </p> <p>The vast majority of participants had mild to moderate acne, were aged between 12 to 30 years (range: 10 to 45 years), and were female. Treatment lasted over eight weeks in 59% of the studies. Study duration ranged from three months to three years. </p> <p>We assessed 26 studies as being at high risk of bias in at least one domain, but most domains were at low or unclear risk of bias. </p> <p>We grouped outcome assessment into short‐term (less than or equal to 4 weeks), medium‐term (from 5 to 8 weeks), and long‐term treatment (more than 8 weeks). The following results were measured at the end of treatment, which was mainly long‐term for the PGA outcome and mixed length (medium‐term mainly) for minor adverse events. </p> <p><b>Azelaic acid</b> </p> <p>In terms of treatment response (PGA), azelaic acid is probably less effective than benzoyl peroxide (risk ratio (RR) 0.82, 95% confidence interval (CI) 0.72 to 0.95; 1 study, 351 participants), but there is probably little or no difference when comparing azelaic acid to tretinoin (RR 0.94, 95% CI 0.78 to 1.14; 1 study, 289 participants) (both moderate‐quality evidence). There may be little or no difference in PGA when comparing azelaic acid to clindamycin (RR 1.13, 95% CI 0.92 to 1.38; 1 study, 229 participants; low‐quality evidence), but we are uncertain whether there is a difference between azelaic acid and adapalene (1 study, 55 participants; very low‐quality evidence). </p> <p>Low‐quality evidence indicates there may be no differences in rates of withdrawal for any reason when comparing azelaic acid with benzoyl peroxide (RR 0.88, 95% CI 0.60 to 1.29; 1 study, 351 participants), clindamycin (RR 1.30, 95% CI 0.48 to 3.56; 2 studies, 329 participants), or tretinoin (RR 0.66, 95% CI 0.29 to 1.47; 2 studies, 309 participants), but we are uncertain whether there is a difference between azelaic acid and adapalene (1 study, 55 participants; very low‐quality evidence). </p> <p>In terms of total minor adverse events, we are uncertain if there is a difference between azelaic acid compared to adapalene (1 study; 55 participants) or benzoyl peroxide (1 study, 30 participants) (both very low‐quality evidence). There may be no difference when comparing azelaic acid to clindamycin (RR 1.50, 95% CI 0.67 to 3.35; 1 study, 100 participants; low‐quality evidence). Total minor adverse events were not reported in the comparison of azelaic acid versus tretinoin, but individual application site reactions were reported, such as scaling. </p> <p><b>Salicylic acid</b> </p> <p>For PGA, there may be little or no difference between salicylic acid and tretinoin (RR 1.00, 95% CI 0.92 to 1.09; 1 study, 46 participants; low‐quality evidence); we are not certain whether there is a difference between salicylic acid and pyruvic acid (1 study, 86 participants; very low‐quality evidence); and PGA was not measured in the comparison of salicylic acid versus benzoyl peroxide. </p> <p>There may be no difference between groups in withdrawals when comparing salicylic acid and pyruvic acid (RR 0.89, 95% CI 0.53 to 1.50; 1 study, 86 participants); when salicylic acid was compared to tretinoin, neither group had withdrawals (both based on low‐quality evidence (2 studies, 74 participants)). We are uncertain whether there is a difference in withdrawals between salicylic acid and benzoyl peroxide (1 study, 41 participants; very low‐quality evidence). </p> <p>For total minor adverse events, we are uncertain if there is any difference between salicylic acid and benzoyl peroxide (1 study, 41 participants) or tretinoin (2 studies, 74 participants) (both very low‐quality evidence). This outcome was not reported for salicylic acid versus pyruvic acid, but individual application site reactions were reported, such as scaling and redness. </p> <p><b>Nicotinamide</b> </p> <p>Four studies evaluated nicotinamide against clindamycin or erythromycin, but none measured PGA. Low‐quality evidence showed there may be no difference in withdrawals between nicotinamide and clindamycin (RR 1.12, 95% CI 0.49 to 2.60; 3 studies, 216 participants) or erythromycin (RR 1.40, 95% CI 0.46 to 4.22; 1 study, 158 participants), or in total minor adverse events between nicotinamide and clindamycin (RR 1.20, 95% CI 0.73 to 1.99; 3 studies, 216 participants; low‐quality evidence). Total minor adverse events were not reported in the nicotinamide versus erythromycin comparison. </p> <p><b>Alpha‐hydroxy (fruit) acid</b> </p> <p>There may be no difference in PGA when comparing glycolic acid peel to salicylic‐mandelic acid peel (RR 1.06, 95% CI 0.88 to 1.26; 1 study, 40 participants; low‐quality evidence), and we are uncertain if there is a difference in total minor adverse events due to very low‐quality evidence (1 study, 44 participants). Neither group had withdrawals (2 studies, 84 participants; low‐quality evidence). </p> </section> <section id="CD011368-sec-0007"> <h3 class="title" id="CD011368-sec-0007">Authors' conclusions</h3> <p>Compared to benzoyl peroxide, azelaic acid probably leads to a worse treatment response, measured using PGA. When compared to tretinoin, azelaic acid probably makes little or no difference to treatment response. For other comparisons and outcomes the quality of evidence was low or very low. </p> <p>Risk of bias and imprecision limit our confidence in the evidence. We encourage the comparison of more methodologically robust head‐to‐head trials against commonly used active drugs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011368-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011368-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011368-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011368-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011368-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011368-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011368-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011368-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011368-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011368-abs-0003">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011368-abs-0002" lang="en"> <h3>Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc, and fruit acid (alpha‐hydroxy acid) for acne </h3> <p><b>Background</b> </p> <p>Acne vulgaris ('acne') is a costly and common skin disorder in which hair follicles become blocked. Acne affects up to 85% of adolescents and young adults. Topical retinoids (treatment derived from vitamin A) and antimicrobials (treatment that kills micro‐organisms such as bacteria) are common treatments. Other topical medications are also used, but there are concerns about their efficacy and safety. </p> <p><b>Review question</b> </p> <p>This Cochrane Review aimed to assess the effects of six topical treatments (azelaic acid, salicylic acid, nicotinamide, sulphur, zinc, and alpha‐hydroxy acid (organic acids found in food, sometimes known as fruit acid) on people with acne when compared with an inactive substance (placebo), no treatment, or other topical treatments. The evidence is current to May 2019. </p> <p><b>Study characteristics</b> </p> <p>We included 49 trials (3880 reported participants). At least one study assessed each eligible treatment. </p> <p>Most trial participants were female, aged between 12 and 30 years, with mild to moderate acne. Nearly 60% of the trials treated participants for longer than eight weeks. Study duration ranged from three months to three years. </p> <p>Nine trials reported pharmaceutical support. The studies were mainly conducted in Europe, Asia, and the USA, in clinics, hospitals, research centres, and universities. </p> <p><b>Key results</b> </p> <p>The following results were measured at the end of treatment, which was mainly long term (more than 8 weeks) for the outcome 'Participants' global self‐assessment of acne improvement' (PGA) and mixed in length, but mainly medium term (from 5 to 8 weeks), for 'Total number of participants who experienced at least one minor side effect'. </p> <p>Azelaic acid probably leads to worse PGA when compared to benzoyl peroxide, but when compared to tretinoin, there is probably little or no difference (both moderate‐quality evidence). When comparing azelaic acid to clindamycin, there may be little or no difference in PGA (low‐quality evidence), but we are uncertain whether azelaic acid reduces PGA compared to adapalene (very low‐quality evidence). </p> <p>In terms of participant withdrawal (for any reason), there may be no difference when azelaic acid is compared with benzoyl peroxide, clindamycin, and tretinoin (all low‐quality evidence). We are uncertain whether azelaic acid reduces withdrawals when compared to adapalene (very low‐quality evidence). </p> <p>We are uncertain whether azelaic acid has fewer total minor adverse events when compared to adapalene or benzoyl peroxide (very‐low quality evidence). When comparing azelaic acid to clindamycin, there may be no difference in total adverse events (low‐quality evidence). The studies that compared azelaic acid with tretinoin only reported individual side effects (e.g. scaling). </p> <p>We are uncertain if there is a difference between salicylic acid and pyruvic acid on PGA score (very low‐quality evidence). There may be little or no difference between salicylic acid and tretinoin in PGA (low‐quality evidence). No study comparing salicylic acid with benzoyl peroxide assessed PGA. There may be no difference in withdrawals when comparing salicylic acid and pyruvic acid; there were no withdrawals when salicylic acid was compared to tretinoin (both low‐quality evidence). We are uncertain if there is a difference in withdrawals between salicylic acid and benzoyl peroxide (very low‐quality evidence). </p> <p>We are uncertain whether salicylic acid reduces total minor adverse events when compared to benzoyl peroxide or tretinoin (very low‐quality evidence). For salicylic acid compared with pyruvic acid only individual application site reactions were reported (e.g. scaling and redness). </p> <p>None of the four studies assessing nicotinamide (compared to clindamycin or erythromycin) assessed PGA. Nicotinamide may make no difference to withdrawals when compared to clindamycin or erythromycin, and may make no difference to total minor adverse events when compared to clindamycin (both low‐quality evidence); however, no studies comparing nicotinamide with erythromycin looked at total minor adverse events. </p> <p>Glycolic acid peels may make no difference to PGA when compared to salicylic‐mandelic acid peels (low‐quality evidence), we are uncertain of the effect on total minor adverse events (very low‐quality evidence), and there were no withdrawals (low‐quality evidence). </p> <p><b>Quality of the evidence</b> </p> <p>Our evidence quality was mixed for the PGA outcome (very low to moderate), mainly low quality for withdrawals, and very low quality for total minor side effects. We had some concerns with the small size of the studies and how they were conducted. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011368-sec-0342" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011368-sec-0342"></div> <h3 class="title" id="CD011368-sec-0343">Implications for practice</h3> <section id="CD011368-sec-0343"> <p>Presently, clinicians often choose topical retinoids and antimicrobials as the first choice of treatment for mild and moderate acne (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>; <a href="./references#CD011368-bbs2-0204" title="TitusS , HodgeJ . Diagnosis and treatment of acne. American Family Physician2012;86(8):734-40. [MEDLINE: 23062156]">Titus 2012</a>; <a href="./references#CD011368-bbs2-0205" title="WellD . Acne vulgaris: A review of causes and treatment options. Nurse Practitioner2013;38(10):22-31; quiz 32. [MEDLINE: 24048347]">Well 2013</a>). The data in this review show there is no high‐quality evidence to determine the effects of the topical treatments azelaic acid, salicylic acid, nicotinamide, sulphur, zinc, and alpha‐hydroxy acid over the commonly used topical drugs. In some cases, the comparative studies suggest no difference between these topical treatments and commonly used retinoids or antimicrobials, but we cannot draw definitive conclusions due to very low‐ to low‐quality evidence. The limited number of trials and other issues (e.g. inadequate reporting) make it hard to obtain high‐quality evidence. </p> <p>We cannot draw conclusions about the effect of the following comparisons on the outcome 'participants' global self‐assessment of acne improvement', as the quality of evidence is very low or the outcome was not reported. </p> <p> <ul id="CD011368-list-0008"> <li> <p>Azelaic acid compared to adapalene</p> </li> <li> <p>Salicylic acid compared to pyruvic acid</p> </li> <li> <p>Salicylic acid compared to benzoyl peroxide</p> </li> <li> <p>Nicotinamide compared to clindamycin</p> </li> <li> <p>Nicotinamide compared to erythromycin</p> </li> </ul> </p> <p>In terms of treatment response (participants' global self‐assessment of acne improvement; PGA), azelaic acid is probably less effective than benzoyl peroxide (moderate‐quality evidence), and there may be little or no difference in PGA when comparing azelaic acid to clindamycin (low‐quality evidence). There is probably little or no difference when comparing azelaic acid to tretinoin (moderate‐quality evidence). There may be little or no difference in PGA between salicylic acid and tretinoin (low‐quality evidence). There may be no difference in PGA when comparing glycolic acid peel to salicylic‐mandelic acid peel (low‐quality evidence). </p> <p>We cannot draw conclusions about the effect of the following comparisons on the outcome 'withdrawal for any reason', as the quality of evidence is very low or the outcome was not reported. </p> <p> <ul id="CD011368-list-0009"> <li> <p>Azelaic acid compared to adapalene</p> </li> <li> <p>Salicylic acid compared to benzoyl peroxide</p> </li> </ul> </p> <p>Based on low‐quality evidence, there may be no differences in rates of withdrawal for any reason when comparing the following. </p> <p> <ul id="CD011368-list-0010"> <li> <p>Azelaic acid with benzoyl peroxide, clindamycin, or tretinoin</p> </li> <li> <p>Salicylic acid with pyruvic acid</p> </li> <li> <p>Nicotinamide with clindamycin or erythromycin</p> </li> </ul> </p> <p>There were no withdrawals in the comparisons of salicylic acid versus tretinoin and glycolic acid versus salicylic‐mandelic acid. </p> <p>We cannot draw conclusions about the effect of the following comparisons on minor adverse events, assessed as total number of participants who experienced at least one minor adverse event, as the quality of evidence is very low or the outcome was not reported. </p> <p> <ul id="CD011368-list-0011"> <li> <p>Azelaic acid compared to adapalene</p> </li> <li> <p>Azelaic acid compared to benzoyl peroxide</p> </li> <li> <p>Azelaic acid compared to tretinoin</p> </li> <li> <p>Salicylic acid compared to benzoyl peroxide</p> </li> <li> <p>Salicylic acid with pyruvic acid</p> </li> <li> <p>Salicylic acid was compared to tretinoin</p> </li> <li> <p>Nicotinamide compared to erythromycin</p> </li> <li> <p>Glycolic acid (alpha‐hydroxy acid) compared to salicylic‐mandelic acid (peel)</p> </li> </ul> </p> <p>There may be no difference in minor adverse events when comparing azelaic acid to clindamycin. </p> <p>The adverse events caused by these treatments included mainly application site reactions such as erythema, scaling, dry skin, burning, peeling, and itching, and the risk of specific adverse events (e.g. erythema) was mostly similar between treatment groups. </p> <p>We do not have sufficient evidence to determine the efficacy and safety of sulphur, zinc, and gluconolactone, which are no longer used in clinical practice. </p> <p>In the absence of high‐quality evidence for these treatments, clinical decisions may continue to be guided by clinical experiences and patients' preferences. </p> </section> <h3 class="title" id="CD011368-sec-0344">Implications for research</h3> <section id="CD011368-sec-0344"> <p>There is a need for further head‐to‐head comparisons of the topical treatments azelaic acid, salicylic acid, nicotinamide, and glycolic acid with commonly used active drugs (topical retinoids and antimicrobials). Moreover, trials comparing these topical treatments with vehicle/placebo or no treatment are also required. This will confirm their efficacy for treating mild to moderate acne. </p> <p>Randomised trials with a parallel or cross‐over design are necessary. With respect to cross‐over trials, study authors should report the outcome data as previously suggested (<a href="./references#CD011368-bbs2-0147" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [PMID: 11914310]">Elbourne 2002</a>). Study authors should clearly report the severity of illness. Participants irrespective of age, severity, or gender need to be included. Study authors should clearly report the co‐interventions in each treatment arm. A long‐term treatment duration (over 8 weeks) for future trials is suggested. We do not recommend trials authors measure the drug efficacy in the post‐treatment follow‐up period as these topical medications most probably have no long‐lasting effect after withdrawal of therapy. </p> <p>The variability in conducting and reporting of trials significantly hampered combining study results for meta‐analysis. We recommend standardisation of outcome reporting in future trials. The trial authors should use a standardised scale (e.g. measured by a four‐point scale: excellent, good, fair, and poor) to measure participants' global self‐assessment of acne improvement, and the authors should provide a clear description of how the outcome was measured. Study authors should also report the number of withdrawals from the trial and the reasons for withdrawals. In addition, development of a standardised scale for physicians' global evaluation of acne improvement is necessary, and the report of number of participants would be better. We recommend study authors report the total number of participants who experienced at least one adverse event, but not report adverse events as count data. It would also be useful if study authors presented the total number of participants who experienced individual side effects, e.g. redness. Assessment of quality of life using a validated instrument (e.g. Acne‐Specific Quality of Life Questionnaire; Acne‐QoL) is highly desirable. Adherence to recommendations from the Cochrane Skin ‐ Core Outcome Set Initiative would improve and standardise outcome measurement (<a href="./references#CD011368-bbs2-0136" title="Cochrane Skin - Core Outcome Set Initiative (CS-COUSIN). cs-cousin.org/ (accessed prior to 22 February 2019).">CS‐COUSIN 2019</a>). </p> <p>Unfortunately, the study authors often presented inadequate data or information, for example, randomisation was not clearly described, allocation concealment was not reported, it was unclear who was blinded, results were presented in figures with no raw data, standard deviations (SDs) were not mentioned and could not be obtained in any way, and exact P values were not reported. Furthermore, 11/49 studies had high attrition bias; therefore, efforts should be made to ensure participants remain in the study. We have to acknowledge that many included studies in this review predate the CONSORT recommendations (<a href="./references#CD011368-bbs2-0126" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276(8):637-9. [PMID: 8773637]">Begg 1996</a>; <a href="./references#CD011368-bbs2-0178" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA2001;285(15):1987-91. [PMID: 11308435]">Moher 2001</a>), but future studies should ensure they adhere to the CONSORT recommendations on trials to guarantee the full availability of all data. Many of our analyses were limited to single study data. These studies had small sample sizes; hence, we downgraded the majority of our evidence for imprecision. Future studies should ensure a sample size calculation is used. We could not assess publication bias because of the limited number of studies in each comparison. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011368-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011368-sec-0008"></div> <div class="table" id="CD011368-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Azelaic acid compared to adapalene</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to adapalene for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> industry‐sponsored, single‐site study in Germany (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical adapalene </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical adapalene</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Improved to very much improved</i><br/>(long term: treatment duration &gt; 8 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>842 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>749 per 1000</b><br/>(573 to 985) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/>(0.68 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b><br/>(17 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.64</b> <br/>(0.33 to 20.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>305 per 1000</b><br/>(124 to 750) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/>(0.47 to 2.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported no "significant difference" in the incidence of erythema, dryness, and itching between treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Dermatology Life Quality Index</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The authors reported that there was no "statistically significant" difference (P = 0.549) between azelaic acid and adapalene. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, and study had unclear allocation concealment and high risk of performance bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, with unclear allocation concealment and high risk of performance bias. Two levels for imprecision: very wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, with high risk of performance bias and unclear allocation concealment and blinding of outcome assessment. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>d</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear allocation concealment and high risk of performance bias. Two levels for imprecision: very small population size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azelaic acid compared to benzoyl peroxide</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres, recruitment in Germany, Netherlands, Norway, and Greece (1 study); not described (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good or very good improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>771 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>633 per 1000</b><br/>(555 to 733) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> <br/>(0.72 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b><br/>(147 to 317) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/>(0.60 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351<br/>(1 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(short term: treatment duration ≤ 4 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/>(7 to 659) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> <br/>(0.05 to 4.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported that people in the azelaic acid group experienced less dryness and desquamation, but more itching when compared to those in the benzoyl peroxide group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level to moderate quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance bias and other bias, and with high risk of attrition and reporting bias.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance bias and other bias, and with high risk of attrition and reporting bias. One level for imprecision: wide CI.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of detection bias and unclear risk of selection, performance, attrition bias.Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azelaic acid compared to clindamycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to clindamycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres, recruitment in Germany, Netherlands, Norway, and Greece (1 study); three clinics in Tehran (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical clindamycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical clindamycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good or very good improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>668 per 1000</b><br/>(544 to 816) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/>(0.92 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b><br/>(49 to 367) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b> <br/>(0.48 to 3.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.5</b> (0.67 to 3.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no difference in minor adverse events (such as scaling and dry skin) between azelaic acid 5% gel and clindamycin 2% gel. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, and other bias, and with high risk of attrition and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: both studies had unclear risk of selection and performance bias, and one study had a high risk of attrition and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance and detection bias. One level for imprecision: CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azelaic acid compared to tretinoin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to tretinoin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres in one study; not described (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical tretinoin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical tretinoin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good to excellent improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>586 per 1000</b><br/>(486 to 711) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.78 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><br/>(26 to 132) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> <br/>(0.29 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. The rate of erythema and scaling was considerably higher in the tretinoin group than that in the azelaic acid group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level to moderate quality evidence. One level for risk of bias: only one study included with a high risk of attrition bias and unclear risk of selection and performance bias.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: both studies with unclear risk of selection and performance bias, one study with high risk of attrition bias and the other with high risk of reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Salicylic acid compared to benzoyl peroxide</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither treatment group had any withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/>(1 to 391) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> <br/>(0.01 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported that zero out of 20 people in the 2% salicylic acid microgel group versus two out of 21 people in the benzoyl peroxide 10% cream group experienced minor adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>ARQL</i> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The authors stated that subjects treated with salicylic acid microgel experienced better improvement when compared to 10% benzoyl peroxide. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No numerical data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARQL</b> : acne‐related quality of life; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: very small total sample size.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear selection, performance, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: very small total sample size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Salicylic acid compared to pyruvic acid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to pyruvic acid for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Al‑Zahra Hospital Dermatology Clinic and Isfahan Skin Research Centre<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> topical pyruvic acid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical pyruvic acid</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good to excellent improvement</i> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b><br/>(269 to 727) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/>(0.68 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/>(222 to 628) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/>(0.53 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. Although the authors did report no "significant difference" in minor adverse events (scaling in the first to fourth sessions, redness, burning, and itching) between the two peeling (30% salicylic acid and 50% pyruvic acid). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition and other bias and unclear risk of selection and performance bias. One level for imprecision: wide CI and optimal sample size is not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for imprecision: wide CI and optimal sample size not met. One level for risk of bias: only one study included with high risk of attrition and other bias, and unclear risk of selection and performance bias.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Salicylic acid compared to tretinoin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to tretinoin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Skin Disease and Leishmaniasis Research Center and Isfahan University of Medical Sciences clinics (1 study); not described (1 study)<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> topical tretinoin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical tretinoin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> <br/><i>Moderate to excellent improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(920 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/>(0.92 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither study had any withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>741 per 1000</b><br/>(357 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.37</b> <br/>(0.66 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors in one study reported no "statistically significant" differences in the incidence of dryness, peeling, erythema, burning and itching between treatment groups at any study week. All side effects reported in the two studies were of mild to moderate intensity and transient. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>AQOL</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The authors reported no "significant differences" in AQOL between salicylic acid group (end of study: 0.95 ± 1.9) and tretinoin group (end of study: 0.91 ± 1.64) at baseline and at the end of the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AQOL</b> : acne quality of life; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of random sequence generation, allocation concealment, and blinding of participants and personnel. One level for imprecision: optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: both studies with unclear risk of selection bias, one with unclear risk of performance bias and the other with high risk of performance and unclear risk of reporting bias. One level for imprecision: small total sample size.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: two studies with unclear risk of selection bias and high risk of detection bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>d</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of random sequence generation, allocation concealment, and blinding of participants and personnel. Two levels for imprecision: very small population size and wide CI.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Nicotinamide compared to clindamycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nicotinamide compared to clindamycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres in USA (1 study); a teaching clinic of dermatology in Iran (1 study); St‐Alzahra hospital, Isfahan University of Medical Sciences, Isfahan, Iran (1 study)<br/><b>Intervention:</b> topical nicotinamide<br/><b>Comparison:</b> topical clindamycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical clindamycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical nicotinamide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/>(36 to 193) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/>(0.49 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two trials had no withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b><br/>(135 to 369) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> <br/>(0.73 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local application site reactions (e.g. itching, burning, crusting) were reported in two studies. In the third study, the authors reported no side effects during the treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: three studies included and all with unclear risk of bias, two with unclear risk of performance bias, one with high risk of attrition bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: all three studies with unclear risk of selection and detection bias, two out of three studies with unclear risk of performance bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Nicotinamide compared to erythromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nicotinamide compared to erythromycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Laboratoire Dermscan (Villeurbanne)<br/><b>Intervention:</b> topical nicotinamide<br/><b>Comparison:</b> topical erythromycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical erythromycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical nicotinamide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b><br/>(29 to 267) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> <br/>(0.46 to 4.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. There was "no difference" in occurrence of pertinent clinical signs and functional or physical signs between treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection and performance bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011368-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Glycolic acid (alpha‐hydroxy acid) compared to salicylic‐mandelic acid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Glycolic acid (alpha‐hydroxy acid) compared to salicylic‐mandelic acid for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Dermatology and Andrology Department of Beha University hospital, Egyptian patients (only study); recruitment in India (1 study)<br/><b>Intervention:</b> topical glycolic acid (alpha‐hydroxy acid)<br/><b>Comparison:</b> topical salicylic‐mandelic acid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic‐mandelic acid</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical glycolic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Fair to good improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>900 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>954 per 1000</b><br/>(792 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/>(0.88 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither study had any withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b><br/>(164 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.80</b> <br/>(0.72 to 4.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four (20%) participants in salicylic‐mandelic acid peel experienced a burning or stinging sensation against two (10%) in glycolic acid peel. Sixteen participants (80%) in salicylic‐mandelic acid peel developed visible desquamation against eight (40%) in glycolic acid peel (P = 0.025). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: two studies included, one with unclear risk of selection, performance and reporting bias, the other with unclear risk of performance bias. One level for imprecision: small total sample size.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of detection bias and unclear risk of selection, performance bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011368-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011368-sec-0009"></div> <p>Please see the glossary in <a href="#CD011368-tbl-0011">Table 1</a> for an explanation of medical terms used throughout the text. </p> <div class="table" id="CD011368-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of medical terms</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Medical term</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Explanation</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acne vulgaris</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A common chronic skin disorder of sebaceous follicles, mainly affecting the face, chest, and back<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemokine</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A group of small cytokines that act as chemical messengers to induce chemotaxis in leukocytes<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comedone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clogged hair follicle in the skin. It can present as a blackhead or whitehead<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cytokine</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A small protein released by cells that function as molecular messengers between cells<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythema</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness of the skin, caused by vascular congestion or increased perfusion<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperkeratosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thickening of the outer layer of skin often associated with a quantitative abnormality of keratin<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Keratinocytes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The predominant cell type in the epidermis, forming a touch protective layer<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microcomedones</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early and small plugging of the follicle with excess keratin and sebum<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nodule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A solid mass in the skin, more than 0.5 cm in diameter<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Papule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A circumscribed palpable elevation, less than 0.5 cm in diameter<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pilosebaceous unit</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A structure consisting of a hair follicle, sebaceous gland, and an arrector pili muscle<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Propionibacterium acnes</b> </p> <p><b>(Cutibacterium acnes)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gram‐positive bacterium related to acne development<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pustule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A visible accumulation of free pus<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scar</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin areas of fibrous tissue replacing normal skin after injury<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sebum</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The oily, waxy substance produced by sebaceous glands<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stratum corneum</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outermost layer of the epidermis, where cells have lost nuclei and cytoplasmic organelles<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Toll‐like receptor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A class of proteins that recognise conserved products unique to microbial metabolism in immune response<sup>c</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><i>Andrews' Diseases of the Skin: Clinical Dermatology</i>, 11th Edition, 2011, Elsevier Inc.<br/><sup>b</sup><i>Rook's Textbook of Dermatology</i> , Eighth Edition, 2010, Blackwell Publishing Ltd.<br/><i><sup>c</sup>Immunology</i>, Sixth Edition, 2001, Harcourt Asia Pte Ltd. </p> </div> </div> <section id="CD011368-sec-0010"> <h3 class="title" id="CD011368-sec-0010">Description of the condition</h3> <p>Acne is a common inflammatory disorder of pilosebaceous units (<a href="./references#CD011368-bbs2-0170" title="LandowK . Dispelling myths about acne. Postgraduate Medicine1997;102(2):94-9, 103-4, 110-2. [PMID: 9270703]">Landow 1997</a>). It results in non‐inflammatory lesions known as comedones (whiteheads or blackheads) and inflammatory lesions including papules, pustules, or nodules (<a href="./references#CD011368-bbs2-0185" title="RamliR , MalikAS , HaniAF , JamilA . Acne analysis, grading and computational assessment methods: an overview. Skin Research &amp; Technology2012;18(1):1-14. [MEDLINE: 21605170]">Ramli 2012</a>). Acne primarily affects sebaceous gland‐rich areas, such as the face, shoulders, back, and upper chest (<a href="./references#CD011368-bbs2-0164" title="KatsambasA , DessiniotiC . New and emerging treatments in dermatology: acne. Dermatologic Therapy2008;21(2):86-95.">Katsambas 2008</a>). </p> <p>Acne comprises acne vulgaris, acne variants, and acneiform eruptions in clinical practice (<a href="#CD011368-tbl-0012">Table 2</a>). Acne vulgaris is the most common type of acne, which mainly affects adolescents and young adults. Prevalence in young people aged 12 to 24 years is as high as 85% (<a href="./references#CD011368-bbs2-0127" title="BhateK , WilliamsHC . Epidemiology of acne vulgaris. British Journal of Dermatology2013;168(3):474-85.">Bhate 2013</a>). Acne severity in boys correlates with pubertal maturation. One study of healthy Danish boys showed that the mean age of onset of puberty has fallen from 11.92 between 1991 and 1993 to 11.66 between 2006 and 2008 (<a href="./references#CD011368-bbs2-0194" title="SorensenK , AksglaedeL , PetersenJH , JuulA . Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. Journal of Clinical Endocrinology and Metabolism2010;95(1):263-70. [PMID: 19926714]">Sorensen 2010</a>). Previous studies showed that 50% of boys aged 10 or 11 years had more than 10 comedones (<a href="./references#CD011368-bbs2-0173" title="LuckyAW , BiroFM , HusterGA , MorrisonJA , ElderN . Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age. Archives of Dermatology1991;127(2):210-6. [PMID: 1825016]">Lucky 1991</a>), and 78% of girls aged eight to 12 years had acne (<a href="./references#CD011368-bbs2-0174" title="LuckyAW , BiroFM , SimbartlLA , MorrisonJA , SorgNW . Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. The Journal of Pediatrics1997;130(1):30-9. [PMID: 9003848]">Lucky 1997</a>). Acne often begins in the early teens and it can persist through the third decade or even later, but the intensity and duration varies for each individual (<a href="./references#CD011368-bbs2-0127" title="BhateK , WilliamsHC . Epidemiology of acne vulgaris. British Journal of Dermatology2013;168(3):474-85.">Bhate 2013</a>). Recently, several reports have suggested increased prevalence of an adult form of acne vulgaris (<a href="./references#CD011368-bbs2-0167" title="KhungerN , KumarC . A clinico-epidemiological study of adult acne: is it different from adolescent acne?Indian Journal of Dermatology, Venereology &amp; Leprology2012;78(3):335-41. [MEDLINE: 22565434]">Khunger 2012</a>; <a href="./references#CD011368-bbs2-0184" title="RademakerM , WishartJM , BirchallNM . Isotretinoin 5 mg daily for low-grade adult acne vulgaris--a placebo-controlled, randomized double-blind study. Journal of the European Academy of Dermatology &amp; Venereology2014;28(6):747-54. [MEDLINE: 23617693]">Rademaker 2014</a>). Adult acne mainly affects women and the prevalence in adult women is estimated to be 14% (<a href="./references#CD011368-bbs2-0206" title="WilliamsC , LaytonAM . Persistent acne in women: implications for the patient and for therapy. American Journal of Clinical Dermatology2006;7(5):281-90. [MEDLINE: 17007539]">Williams 2006</a>). In addition, although uncommon, physicians can come across people with childhood acne classified according to the age of onset (neonatal, infantile, mid‐childhood, and prepubertal) (<a href="./references#CD011368-bbs2-0123" title="AntoniouC , DessiniotiC , StratigosAJ , KatsambasAD . Clinical and therapeutic approach to childhood acne: an update. Pediatric Dermatology2009;26(4):373-80. [PMID: 19689511]">Antoniou 2009</a>; <a href="./references#CD011368-bbs2-0169" title="KrakowskiAC , EichenfieldLF . Pediatric acne: clinical presentations, evaluation, and management. Journal of Drugs in Dermatology2007;6(6):589-93. [MEDLINE: 17668524]">Krakowski 2007</a>). </p> <div class="table" id="CD011368-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Clinical classification of acnea </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Acne vulgaris</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p>Acne variants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neonatal acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infantile acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne conglobata</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne fulminans</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAPHO syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAPA syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne excoriee des jeunes filles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne mechanica</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne with solid facial oedema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne with associated endocrinology abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p>Acneiform eruptions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steroid folliculitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug‐induced acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epidermal growth factor receptor inhibitor associated eruption</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Occupational acne and chloracne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gram‐negative folliculitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiation acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tropical acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne aestivalis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pseudoacne of the nasal crease</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apert syndrome</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><i>Fitzpatrick's Dermatology in General Medicine</i>, Eighth edition, 2012, The McGraw‐Hill Companies, Inc. </p> </div> </div> <p>To date, there are various grading systems for severity assessment, but with no consensus (<a href="./references#CD011368-bbs2-0172" title="LehmannHP , RobinsonKA , AndrewsJS , HollowayV , GoodmanSN . Acne therapy: a methodologic review. Journal of the American Academy of Dermatology2002;47(2):231-40. [MEDLINE: 12140469]">Lehmann 2002</a>; <a href="./references#CD011368-bbs2-0185" title="RamliR , MalikAS , HaniAF , JamilA . Acne analysis, grading and computational assessment methods: an overview. Skin Research &amp; Technology2012;18(1):1-14. [MEDLINE: 21605170]">Ramli 2012</a>). Moreover, there are no grading systems that fulfil all essential criteria required for an ideal acne grading scale (<a href="./references#CD011368-bbs2-0199" title="TanJ , WolfeB , WeissJ , Stein-GoldL , BikowskiJ , Del RossoJ , et al. Acne severity grading: determining essential clinical components and features using a Delphi consensus. Journal of the American Academy of Dermatology2012;67(2):187-93. [PMID: 22036609]">Tan 2012</a>; <a href="./references#CD011368-bbs2-0200" title="TanJK , JonesE , AllenE , PripotnevS , RazaA , WolfeB . Evaluation of essential clinical components and features of current acne global grading scales. Journal of the American Academy of Dermatology2013;69(5):754-61. [PMID: 23972509]">Tan 2013</a>). Acne experts suggest that scales served as investigator global assessment grading measures may be helpful to establish an ideal scale (<a href="./references#CD011368-bbs2-0200" title="TanJK , JonesE , AllenE , PripotnevS , RazaA , WolfeB . Evaluation of essential clinical components and features of current acne global grading scales. Journal of the American Academy of Dermatology2013;69(5):754-61. [PMID: 23972509]">Tan 2013</a>). There are various grading systems used in clinical practice. According to the predominant types of lesions, study authors can classify acne vulgaris as comedonal, papulopustular, and nodular acne (<a href="./references#CD011368-bbs2-0185" title="RamliR , MalikAS , HaniAF , JamilA . Acne analysis, grading and computational assessment methods: an overview. Skin Research &amp; Technology2012;18(1):1-14. [MEDLINE: 21605170]">Ramli 2012</a>), or classify acne vulgaris as mild, moderate, severe, and cystic acne (<a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>). However, when the predominant lesion type is difficult to determine, physicians may consider it as polymorphic acne (<a href="./references#CD011368-bbs2-0166" title="KharfiM , TekayaN , ZeglaouiF , EzzineN , MokhtarI , KamounF , et al. Comparative study of the efficacy and tolerance of 12% glycolic acid cream and 0.05% retinoic acid cream for polymorphic acne [Etude comparative de l'efficacite et de la tolerance d'une creme a 12% d'acide glycolyque et d'une creme a 0.05% d'acide retinoique dans l'acne polymorphe]. La Tunisie Medicale2001;79(6-7):374-7. [PMID: 11771434]">Kharfi 2001</a>). Study authors may also classify acne vulgaris as mild, moderate, and severe based on the acne grading of the face, back and chest (<a href="./references#CD011368-bbs2-0180" title="O'BrienSC , LewisJB , CunliffeWJ . The Leeds Revised Acne Grading System. Journal of Dermatological Treatments1998;9(4):215-20.">O'Brien 1998</a>). When conducting a clinical trial, study authors may classify acne based on different grading systems or scales such as the Allen‐Smith Scale (<a href="./references#CD011368-bbs2-0002" title="AksakalAB , KoruyucuM , OnderM , OztasMO , GurerMA . A comparative study of metronidazole 1% cream versus azelaic acid 20% cream in the treatment of acne. Gazi Medical Journal1997;8(4):144-7. [CENTRAL: CN-00195442] ">Aksakal 1997</a>), Cunliffe grading system (<a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>), investigator's static global assessment score (<a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>), and Michaelson acne severity index (<a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>). However, all the current acne grading systems have shortcomings and a consistently applied standard for grading acne severity is urgently needed (<a href="./references#CD011368-bbs2-0200" title="TanJK , JonesE , AllenE , PripotnevS , RazaA , WolfeB . Evaluation of essential clinical components and features of current acne global grading scales. Journal of the American Academy of Dermatology2013;69(5):754-61. [PMID: 23972509]">Tan 2013</a>). </p> <p>The mechanism that causes the disease is unknown, but it is widely accepted that increased sebum excretion induced by androgens, follicular hyperkeratinisation, <i>Cutibacterium acnes</i> (<i>C acnes</i> , formerly <i>Propionibacterium acnes</i>) (<a href="./references#CD011368-bbs2-0145" title="DrenoB , PecastaingsS , CorvecS , VeraldiS , KhammariA , RoquesC . Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. Journal of the European Academy of Dermatology and Venereology2018;32 Suppl 2:5-14. [PMID: 29894579]">Dreno 2018</a>), and bacterial hypercolonisation, as well as inflammation, are the major pathogenetic factors for acne (<a href="./references#CD011368-bbs2-0151" title="FriedlanderSF , EichenfieldLF , Fowler JF Jr, FriedRG , LevyML , WebsterGF . Acne epidemiology and pathophysiology. Seminars in Cutaneous Medicine &amp; Surgery2010;29(2 Suppl 1):2-4. [MEDLINE: 20610306]">Friedlander 2010</a>). A keratinous plug forms at the follicular infundibulum resulting from hyperkeratosis in the follicle, initiating the formation of microcomedones (<a href="./references#CD011368-bbs2-0137" title="CunliffeWJ , HollandDB , ClarkSM , StablesGI . Comedogenesis: some new aetiological, clinical and therapeutic strategies. British Journal of Dermatology2000;142(6):1084-91. [PMID: 10848729]">Cunliffe 2000</a>). Within these microcomedones is an anaerobic lipid‐rich environment suitable for the growth of <i>C acnes</i> (<a href="./references#CD011368-bbs2-0133" title="BrownSK , ShalitaAR . Acne vulgaris. Lancet1998;351(9119):1871-6. [PMID: 9652685]">Brown 1998</a>). The <i>C acnes</i> then hydrolyse triglycerides into glycerol and free fatty acids, which can initiate the inflammatory response (<a href="./references#CD011368-bbs2-0142" title="DessiniotiC , KatsambasAD . The role of Propionibacterium acnes in acne pathogenesis: facts and controversies. Clinics in Dermatology2010;28(1):2-7. [PMID: 20082942]">Dessinioti 2010</a>; <a href="./references#CD011368-bbs2-0203" title="ThiboutotD , ZaengleinA . Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris. www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris (accessed 2 June 2016).">Thiboutot 2016</a>). The cell surface toll‐like receptors, which play critical roles in the immune response against micro‐organisms, are involved in this bacteria‐mediated inflammatory response by triggering the release of pro‐inflammatory cytokines (<a href="./references#CD011368-bbs2-0168" title="KimJ . Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology2005;211(3):193-8.">Kim 2005</a>). </p> <p>Although acne vulgaris is not life‐threatening and usually regresses in the third decade (<a href="./references#CD011368-bbs2-0203" title="ThiboutotD , ZaengleinA . Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris. www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris (accessed 2 June 2016).">Thiboutot 2016</a>), it may cause serious psychological distress, as well as pain, and may considerably compromise the quality of life of the individual. Embarrassment, shame, and lack of confidence are important consequences resulting from acne vulgaris. Furthermore, scarring and embarrassment from acne begins at approximately the same age that adolescents are undergoing significant emotional and physical changes which, if combined, can be devastating. Indeed, there have been reports suggesting that severe acne can result in permanent physical scarring and even suicidal ideation (<a href="./references#CD011368-bbs2-0146" title="DunnLK , O'NeillJL , FeldmanSR . Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatology Online Journal2011;17(1):1.">Dunn 2011</a>; <a href="./references#CD011368-bbs2-0177" title="MiseryL . Consequences of psychological distress in adolescents with acne. Journal of Investigative Dermatology2011;131(2):290-2.">Misery 2011</a>). </p> </section> <section id="CD011368-sec-0011"> <h3 class="title" id="CD011368-sec-0011">Description of the intervention</h3> <p>Treatment options for acne are often targeted at the factors implicated in acne development, such as sebaceous hypersecretion, abnormal keratinisation, <i>C acnes</i> bacteria colonisation, and the inflammation process (<a href="./references#CD011368-bbs2-0204" title="TitusS , HodgeJ . Diagnosis and treatment of acne. American Family Physician2012;86(8):734-40. [MEDLINE: 23062156]">Titus 2012</a>). The choice of treatments depends on the type and extent of acne (<a href="./references#CD011368-bbs2-0155" title="GollnickHP , KrautheimA . Topical treatment in acne: current status and future aspects. Dermatology2003;206(1):29-36.">Gollnick 2003</a>). Topical therapy is the preferred choice of treatment for mild acne and is also useful for moderate to severe acne (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). The current mainstay of topical therapy for acne vulgaris includes retinoids (such as adapalene and tretinoin) and antimicrobials, such as benzoyl peroxide and antibiotics (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>; <a href="./references#CD011368-bbs2-0204" title="TitusS , HodgeJ . Diagnosis and treatment of acne. American Family Physician2012;86(8):734-40. [MEDLINE: 23062156]">Titus 2012</a>; <a href="./references#CD011368-bbs2-0205" title="WellD . Acne vulgaris: A review of causes and treatment options. Nurse Practitioner2013;38(10):22-31; quiz 32. [MEDLINE: 24048347]">Well 2013</a>). However, other topical medications such as azelaic acid, salicylic acid, topical nicotinamide, sulphur, zinc, and alpha‐hydroxy acid (such as glycolic acid and mandelic acid) are also effective for acne treatment (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>; <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>; <a href="./references#CD011368-bbs2-0076" title="HabbemaL , KoopmansB , MenkeHE , DoornweerdS , De BoulleK . A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. British Journal of Dermatology1989;121(4):497-502. [CENTRAL: CN-00194960] ">Habbema 1989</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>; <a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>). </p> </section> <section id="CD011368-sec-0012"> <h3 class="title" id="CD011368-sec-0012">How the intervention might work</h3> <section id="CD011368-sec-0013"> <h4 class="title">Topical azelaic acid</h4> <p>As an ingredient found in many whole grain cereals and animal products, azelaic acid is a well‐known aliphatic dicarboxylic acid, and it is useful in acne treatment due to its antimicrobial and anticomedonal properties (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). Twice‐daily application of 20% cream formation (Azelex) (<a href="./references#CD011368-bbs2-0204" title="TitusS , HodgeJ . Diagnosis and treatment of acne. American Family Physician2012;86(8):734-40. [MEDLINE: 23062156]">Titus 2012</a>), approved by the US Food and Drug Administration (FDA) for acne, can lead to an improvement of conditions within four weeks of initiation of therapy (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>; <a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>). Compared to Azelex, the 15% gel (Finacea) has better bioavailability (<a href="./references#CD011368-bbs2-0150" title="FramptonJE , WagstaffAJ . Azelaic acid 15% gel: in the treatment of papulopustular rosacea. American Journal of Clinical Dermatology2004;5(1):57-64. [PMID: 14979745]">Frampton 2004</a>; <a href="./references#CD011368-bbs2-0204" title="TitusS , HodgeJ . Diagnosis and treatment of acne. American Family Physician2012;86(8):734-40. [MEDLINE: 23062156]">Titus 2012</a>). Azelaic acid 20% cream monotherapy or in combination therapy with glycolic acid (<a href="./references#CD011368-bbs2-0158" title="GraupeK , CunliffeWJ , GollnickHP , ZaumseilRP . Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis1996;57(1 Suppl):20-35.">Graupe 1996</a>; <a href="./references#CD011368-bbs2-0195" title="SpellmanMC , PincusSH . Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne. Clinical Therapeutics1998;20(4):711-21.">Spellman 1998</a>), azelaic acid 20% (<a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a>) or 15% gel (<a href="./references#CD011368-bbs2-0201" title="ThiboutotD . Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. Journal of Drugs in Dermatology2008;7(1):13-6. [MEDLINE: 18246693]">Thiboutot 2008</a>), azelaic acid 5% gel in combination with clindamycin 2% (<a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>), or erythromycin 2% (<a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>), are all effective treatments for acne. Azelaic acid 20% cream can reduce the number of both non‐inflammatory and inflammatory lesions and has an efficacy comparable to the other approved standard treatments, including benzoyl peroxide and erythromycin, as well as tretinoin, but it is better tolerated by people with fewer side effects (<a href="./references#CD011368-bbs2-0193" title="SimonartT . Newer approaches to the treatment of acne vulgaris. American Journal of Clinical Dermatology2012;13(6):357-64. [PMID: 22920095]">Simonart 2012</a>; <a href="./references#CD011368-bbs2-0195" title="SpellmanMC , PincusSH . Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne. Clinical Therapeutics1998;20(4):711-21.">Spellman 1998</a>). </p> <p>Azelaic acid is able to competitively antagonise the activity of mitochondrial oxidoreductases and 5‐alpha‐reductase (<a href="./references#CD011368-bbs2-0182" title="PassiS , PicardoM , De LucaC , Nazzaro-PorroM . Mechanism of azelaic acid action in acne. Giornale Italiano di Dermatologia e Venereologia1989;124(10):455-63.">Passi 1989</a>; <a href="./references#CD011368-bbs2-0196" title="StamatiadisD , Bulteau-PortoisMC , MowszowiczI . Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. British Journal of Dermatology1988;119(5):627-32. [PMID: 3207614]">Stamatiadis 1988</a>). The mechanism of action of azelaic acid in acne treatment may relate to its inhibitory effects on mitochondrial oxidoreductase and DNA synthesis (<a href="./references#CD011368-bbs2-0148" title="FittonA , GoaKL . Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs1991;41(5):780-98.">Fitton 1991</a>). It has a predominant antibacterial activity on <i>C acnes</i> by inhibiting protein synthesis (<a href="./references#CD011368-bbs2-0129" title="BojarRA , HollandKT , CunliffeWJ . The in-vitro antimicrobial effects of azelaic acid upon Propionibacterium acnes strain P37. Journal of Antimicrobial Chemotherapy1991;28(6):843-53. [PMID: 1726169]">Bojar 1991</a>), and has a modest comedolytic effect by inhibiting the proliferation and differentiation of human keratinocytes, as well as an anti‐inflammatory action by inhibiting the generation of pro‐inflammatory oxygen derivatives in neutrophils (<a href="./references#CD011368-bbs2-0120" title="AkamatsuH , KomuraJ , AsadaY , MiyachiY , NiwaY . Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Archives of Dermatological Research1991;283(3):162-6. [PMID: 1867478]">Akamatsu 1991</a>; <a href="./references#CD011368-bbs2-0192" title="SieberMA , HegelJK . Azelaic acid: Properties and mode of action. Skin Pharmacology and Physiology2014;27(Suppl 1):9-17. [PMID: 24280644]">Sieber 2014</a>). It can also reduce sebum production on the forehead, chin, and cheek through its inhibitory effect on the conversion from testosterone to 5‐dehydrotestosterone (<a href="./references#CD011368-bbs2-0182" title="PassiS , PicardoM , De LucaC , Nazzaro-PorroM . Mechanism of azelaic acid action in acne. Giornale Italiano di Dermatologia e Venereologia1989;124(10):455-63.">Passi 1989</a>). </p> <p>Adverse effects of azelaic acid are mild and transient. About 5% to 10% of people report a burning or stinging sensation, tightness of the skin, and erythema in the treated area, but this usually only lasts for a few weeks (<a href="./references#CD011368-bbs2-0158" title="GraupeK , CunliffeWJ , GollnickHP , ZaumseilRP . Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis1996;57(1 Suppl):20-35.">Graupe 1996</a>). Azelaic acid can cause hypopigmentation, so physicians should monitor its use in people with dark skin (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). Azelaic acid is a US FDA pregnancy category B drug. It has minimal systemic absorption when used topically. Use in pregnancy and lactation should not be a cause for concern (<a href="./references#CD011368-bbs2-0131" title="BozzoP , Chua-GochecoA , EinarsonA . Safety of skin care products during pregnancy. Canadian Family Physician2011;57(6):665-7.">Bozzo 2011</a>), although the excretion of azelaic acid into milk has been demonstrated, and caution is advised in nursing mothers (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). </p> </section> <section id="CD011368-sec-0014"> <h4 class="title">Topical salicylic acid</h4> <p>Salicylic acid is often incorrectly recognised as a beta‐hydroxy acid but it is actually an O‐hydroxybenzoic acid (<a href="./references#CD011368-bbs2-0165" title="KempiakSJ , UebelhoerN . Superficial chemical peels and microdermabrasion for acne vulgaris. Seminars in Cutaneous Medicine &amp; Surgery2008;27(3):212-20.">Kempiak 2008</a>), and it is useful in the treatment of acne vulgaris due to its keratolytic and comedolytic effects (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). Salicylic acid is a component of most over‐the‐counter acne preparations (<a href="./references#CD011368-bbs2-0193" title="SimonartT . Newer approaches to the treatment of acne vulgaris. American Journal of Clinical Dermatology2012;13(6):357-64. [PMID: 22920095]">Simonart 2012</a>). Its concentration varies from 0.5% to 3.0% (<a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>; <a href="./references#CD011368-bbs2-0210" title="ZanderE , WeismanS . Treatment of acne vulgaris with salicylic acid pads. Clinical Therapeutics1992;14(2):247-53.">Zander 1992</a>), and it is available in washes (<a href="./references#CD011368-bbs2-0135" title="ChoiYS , SuhHS , YoonMY , MinSU , KimJS , JungJY , et al. A study of the efficacy of cleansers for acne vulgaris. Journal of Dermatological Treatment2010;21(3):201-5.">Choi 2010</a>), creams (<a href="./references#CD011368-bbs2-0211" title="ZhengY , WanM , ChenH , YeC , ZhaoY , YiJ , et al. Clinical evidence on the efficacy and safety of an antioxidant optimized 1.5% salicylic acid (SA) cream in the treatment of facial acne: an open, baseline-controlled clinical study. Skin Research &amp; Technology2013;19(2):125-30.">Zheng 2013</a>), and lotions (<a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>). Chemical peel of salicylic acid at a concentration of 20% to 30% is also available and useful in acne treatment (<a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>). Salicylic acid monotherapy (<a href="./references#CD011368-bbs2-0198" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC , et al. Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651-63.">Strauss 2007</a>), or combination therapy with benzoyl peroxide (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0188" title="SeidlerEM , KimballAB . Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52-62.">Seidler 2010</a>), or clindamycin phosphate (<a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>; <a href="./references#CD011368-bbs2-0099" title="NCT00361322. Efficacy and safety of a preparation containing an antibiotic and anti-Inflammatory agent in acne vulgaris. clinicaltrials.gov/show/nct00361322 (first received 8 August 2006). TouitouE , GodinB , ShumilovM , BishoutyN , AinbinderD , ShouvalR , et al. Efficacy and tolerability of clindamycin phosphate and salicylic acid gel in the treatment of mild to moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2008;22(5):629-31. [CENTRAL: CN-00631273] ">Touitou 2008</a>) can improve acne lesions. Salicylic acid 20% or 30% peels (<a href="./references#CD011368-bbs2-0165" title="KempiakSJ , UebelhoerN . Superficial chemical peels and microdermabrasion for acne vulgaris. Seminars in Cutaneous Medicine &amp; Surgery2008;27(3):212-20.">Kempiak 2008</a>), or salicylic 20%/mandelic acid 10% peels (<a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a>) are also effective for the treatment of acne vulgaris. Previous studies have shown that topical salicylic acid has mild to moderate activity against both non‐inflammatory lesions and inflammatory lesions in acne vulgaris (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0140" title="DegitzK , OchsendorfF . Pharmacotherapy of acne. Expert Opinion on Pharmacotherapy2008;9(6):955-71. [MEDLINE: 18377339]">Degitz 2008</a>; <a href="./references#CD011368-bbs2-0202" title="ThiboutotD , GollnickH , BettoliV , DrenoB , KangS , LeydenJJ , et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. Journal of the American Academy of Dermatology2009;60(5 Suppl):S1-50. [MEDLINE: 19376456]">Thiboutot 2009</a>). It is approved for use in children with acne (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). </p> <p>Salicylic acid can break down the follicular keratotic plugs through dissolving the intercellular cement holding the stratum corneum cells and promoting the desquamation of follicular epithelium (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). It also has anti‐inflammatory capabilities, affecting the arachidonic acid cascade (<a href="./references#CD011368-bbs2-0081" title="LeeHS , KimIH , MonheitGD . Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatologic Surgery2003;29(12):1196-9. [PMID: 14725662]">Lee 2003</a>). </p> <p>When used at concentrations of 2% or higher, salicylic acid can cause local skin peeling and discomfort to some degree (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0130" title="BoutliF , ZiogaM , KoussidouT , IoannidesD , MourellouO . Comparison of chloroxylenol 0.5% plus salicylic acid 2% cream and benzoyl peroxide 5% gel in the treatment of acne vulgaris: a randomized double-blind study. Drugs Under Experimental &amp; Clinical Research2003;29(3):101-5.">Boutli 2003</a>). Salicylic acid is a FDA pregnancy category C drug (<a href="./references#CD011368-bbs2-0165" title="KempiakSJ , UebelhoerN . Superficial chemical peels and microdermabrasion for acne vulgaris. Seminars in Cutaneous Medicine &amp; Surgery2008;27(3):212-20.">Kempiak 2008</a>). There are no studies conducted in lactating women on topical use of salicylic acid and little is known about the excretion of salicylic acid in breast milk. Therefore, physicians advise women during lactation to avoid the use of salicylate (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>; <a href="./references#CD011368-bbs2-0131" title="BozzoP , Chua-GochecoA , EinarsonA . Safety of skin care products during pregnancy. Canadian Family Physician2011;57(6):665-7.">Bozzo 2011</a>). </p> </section> <section id="CD011368-sec-0015"> <h4 class="title">Topical nicotinamide</h4> <p>Nicotinamide serves as the active form of niacin, having anti‐inflammatory effects in acne (<a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>). Twice‐daily application of 4% or 5% nicotinamide gel for eight weeks can lead to significant improvement of acne conditions (<a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>; <a href="./references#CD011368-bbs2-0189" title="ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [PMID: 7657446]">Shalita 1995a</a>). Researchers published the first study that assessed nicotinamide in 1995 and the data suggest that 4% nicotinamide gel has comparable efficacy to 1% clindamycin gel in the treatment of inflammatory acne vulgaris (<a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>). Another study also supports the comparable efficacy of 4% nicotinamide gel to 1% clindamycin gel in moderate inflammatory acne vulgaris (<a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>). When used at a concentration of 5%, nicotinamide gel is as effective as clindamycin 2% gel for the treatment of mild to moderate acne vulgaris (<a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>). Nicotinamide 4% linoleic acid‐rich phosphatidylcholine produced global clinical improvements in acne (<a href="./references#CD011368-bbs2-0179" title="MorgantiP , BerardescaE , GuarneriB , GuarneriF , FabriziG , PalomboP , et al. Topical clindamycin 1% vs. linoleic acid-rich phosphatidylcholine and nicotinamide 4% in the treatment of acne: a multicentre-randomized trial. International Journal of Cosmetic Science2011;33(5):467-76.">Morganti 2011</a>). </p> <p>The mechanisms of action are mainly due to its potent anti‐inflammatory effect (<a href="./references#CD011368-bbs2-0189" title="ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [PMID: 7657446]">Shalita 1995a</a>), and inhibition of sebum production (<a href="./references#CD011368-bbs2-0143" title="DraelosZD . The effect of a daily facial cleanser for normal to oily skin on the skin barrier of subjects with acne. Cutis2006;78(1 Suppl):34-40. [PMID: 16910029]">Draelos 2006a</a>). Nicotinamide exerts its anti‐inflammatory effects by inhibiting <i>C acnes</i>‐induced chemokine IL‐8 production in keratinocytes through interfering with NF‐kappa B by inhibiting PARP‐1 and mitogen‐activated protein kinases (MAPK) pathways (<a href="./references#CD011368-bbs2-0157" title="GrangePA , RaingeaudJ , CalvezV , DupinN . Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. Journal of Dermatological Science2009;56(2):106-12.">Grange 2009</a>). </p> <p>Only mild stinging or burning at the application site is reported during topical use of nicotinamide (<a href="./references#CD011368-bbs2-0189" title="ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [PMID: 7657446]">Shalita 1995a</a>). It is safe for women in pregnancy, although the FDA pregnancy category rating of topical nicotinamide is not available (<a href="./references#CD011368-bbs2-0187" title="RolfeHM . A review of nicotinamide: treatment of skin diseases and potential side effects. Journal of Cosmetic Dermatology2014;13(4):324-8. [PMID: 25399625]">Rolfe 2014</a>). Nicotinamide is excreted in breast milk, but no data regarding topical nicotinamide use in women who are pregnant or lactating are available (<a href="./references#CD011368-bbs2-0187" title="RolfeHM . A review of nicotinamide: treatment of skin diseases and potential side effects. Journal of Cosmetic Dermatology2014;13(4):324-8. [PMID: 25399625]">Rolfe 2014</a>; <a href="./references#CD011368-bbs2-0197" title="StocktonDL , PallerAS . Drug administration to the pregnant or lactating woman: a reference guide for dermatologists. Journal of the American Academy of Dermatology1990;23(1):87-103. [PMID: 2195076]">Stockton 1990</a>). </p> </section> <section id="CD011368-sec-0016"> <h4 class="title">Topical sulphur</h4> <p>Sulphur is a yellow non‐metallic chemical element with antifungal, antibacterial, and keratolytic properties (<a href="./references#CD011368-bbs2-0075" title="GuptaAK , NicolK . The use of sulfur in dermatology. Journal of Drugs in Dermatology2004;3(4):427-31. ">Gupta 2004</a>). The topical sulphur‐containing preparations at concentrations of 1% to 10% are helpful for acne treatment (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>), even though they may be both comedonal and comedolytic (<a href="./references#CD011368-bbs2-0176" title="Mills OH Jr, KligmanAM . Is sulphur helpful or harmful in acne vulgaris?British Journal of Dermatology1972;86(6):620-7.">Mills 1972</a>). Sulphur is available in the form of lotions, foam, creams, ointments, and soaps. When used together with benzoyl peroxide or sodium sulphacetamide, sulphur shows a better therapeutic effect on acne vulgaris. For example, sodium sulphacetamide 10% with sulphur 5% emollient foam (<a href="./references#CD011368-bbs2-0141" title="Del RossoJQ . The use of sodium sulfacetamide 10%-sulfur 5% emollient foam in the treatment of acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2009;2(8):26-9.">Del Rosso 2009</a>), sodium sulphacetamide with sulphur lotion (<a href="./references#CD011368-bbs2-0132" title="BrenemanDL , ArianoMC . Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. International Journal of Dermatology1993;32(5):365-7.">Breneman 1993</a>), and benzoyl peroxide 10% plus sulphur in the range 2% to 5% cream (<a href="./references#CD011368-bbs2-0064" title="DantoJL , MaddinWS , StewartWD , NelsonAJ . A controlled trial of benzoyl peroxide and precipitated sulfur cream in acne vulgaris. Applied Therapeutics1966;8(7):624-5. [CENTRAL: CN-00000721] ">Danto 1966</a>; <a href="./references#CD011368-bbs2-0102" title="WilkinsonRD , AdamJE , MurrayJJ , CraigGE . Benzoyl peroxide and sulfur: foundation for acne management. Canadian Medical Association Journal1966;95(1):28-9. [PMID: 4223133 ]">Wilkinson 1966</a>) are all effective acne treatments. </p> <p>The mechanism of action may be due to sulphur's keratolytic action and consequent inhibitory effect on the proliferation of <i>C acnes</i> (<a href="./references#CD011368-bbs2-0075" title="GuptaAK , NicolK . The use of sulfur in dermatology. Journal of Drugs in Dermatology2004;3(4):427-31. ">Gupta 2004</a>). It is thought that sulphur interacts with cysteine in keratinocytes resulting in the production of hydrogen sulphide, which has a keratolytic effect by rupturing the disulphide bonds of cysteine ​​molecules in keratin (<a href="./references#CD011368-bbs2-0181" title="PaceWE . A benzoyl peroxide-sulfur cream for acne vulgaris. Canadian Medical Association Journal1965;93:252-4. [MEDLINE: 14328040]">Pace 1965</a>). </p> <p>Adverse events are rare during topical use of sulphur. Commonly reported adverse effects include dryness and itching of the skin (<a href="./references#CD011368-bbs2-0132" title="BrenemanDL , ArianoMC . Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. International Journal of Dermatology1993;32(5):365-7.">Breneman 1993</a>; <a href="./references#CD011368-bbs2-0075" title="GuptaAK , NicolK . The use of sulfur in dermatology. Journal of Drugs in Dermatology2004;3(4):427-31. ">Gupta 2004</a>; <a href="./references#CD011368-bbs2-0097" title="TarimciN , SenerS , KilinçT . Topical sodium sulfacetamide/sulfur lotion. Journal of Clinical Pharmacy and Therapeutics1997;22(4):301. [CENTRAL: CN-00149589] ">Tarimci 1997</a>). Sulphur is a FDA pregnancy category C drug (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). Little is known about the excretion of sulphur in breast milk. Therefore, caution should be used by breastfeeding mothers (<a href="./references#CD011368-bbs2-0121" title="AkhavanA , BershadS . Topical acne drugs: review of clinical properties, systemic exposure, and safety. American Journal of Clinical Dermatology2003;4(7):473-92.">Akhavan 2003</a>). </p> </section> <section id="CD011368-sec-0017"> <h4 class="title">Topical zinc</h4> <p>Zinc is known as an essential trace element (<a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>). It has antimicrobial as well as anti‐inflammatory actions and it is useful for many dermatological problems (<a href="./references#CD011368-bbs2-0076" title="HabbemaL , KoopmansB , MenkeHE , DoornweerdS , De BoulleK . A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. British Journal of Dermatology1989;121(4):497-502. [CENTRAL: CN-00194960] ">Habbema 1989</a>; <a href="./references#CD011368-bbs2-0191" title="SharquieKE , KhorsheedAA , Al-NuaimyAA . Topical zinc sulphate solution for treatment of viral warts. Saudi Medical Journal2007;28(9):1418-21. [PMID: 17768472]">Sharquie 2007</a>; <a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>). Physicians often use zinc plus antibiotic combination products for acne treatment (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>; <a href="./references#CD011368-bbs2-0076" title="HabbemaL , KoopmansB , MenkeHE , DoornweerdS , De BoulleK . A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. British Journal of Dermatology1989;121(4):497-502. [CENTRAL: CN-00194960] ">Habbema 1989</a>). For example, researchers used the form of erythromycin (4%) plus zinc (1.2%) and clindamycin (1%) plus zinc (0.52%), which can be applied twice‐daily for 12 weeks or more (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>; <a href="./references#CD011368-bbs2-0076" title="HabbemaL , KoopmansB , MenkeHE , DoornweerdS , De BoulleK . A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. British Journal of Dermatology1989;121(4):497-502. [CENTRAL: CN-00194960] ">Habbema 1989</a>). Previous studies have documented that the combination of zinc with antibiotics is more advantageous to acne patients than antibiotics alone (<a href="./references#CD011368-bbs2-0138" title="CunliffeWJ , FernandezC , BojarR , KanisR , WestF . An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [PMID: 16302325]">Cunliffe 2005a</a>; <a href="./references#CD011368-bbs2-0076" title="HabbemaL , KoopmansB , MenkeHE , DoornweerdS , De BoulleK . A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. British Journal of Dermatology1989;121(4):497-502. [CENTRAL: CN-00194960] ">Habbema 1989</a>). Some reports suggest that zinc acetate contributes most to the antimicrobial action of an erythromycin/zinc combination (<a href="./references#CD011368-bbs2-0149" title="FluhrJW , BoschB , GloorM , HofflerU . In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with erythromycin. Zentralblatt fur Bakteriologie1999;289(4):445-56. [PMID: 10603662]">Fluhr 1999</a>). When used alone, topical zinc is also useful for acne patients. Recently, zinc sulphate solution has been showed to be effective in the treatment of acne vulgaris, though it may be less effective than tea lotion (<a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>). </p> <p>The mechanism of action may be due to zinc's antimicrobial, anti‐inflammatory, and other actions (<a href="./references#CD011368-bbs2-0149" title="FluhrJW , BoschB , GloorM , HofflerU . In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with erythromycin. Zentralblatt fur Bakteriologie1999;289(4):445-56. [PMID: 10603662]">Fluhr 1999</a>; <a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>). Several reports have documented the anti‐propionibacterial activity of zinc in vitro (<a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>; <a href="./references#CD011368-bbs2-0149" title="FluhrJW , BoschB , GloorM , HofflerU . In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with erythromycin. Zentralblatt fur Bakteriologie1999;289(4):445-56. [PMID: 10603662]">Fluhr 1999</a>). The efficacy on inflammatory lesions by zinc suggests the importance of its anti‐inflammatory actions on acne treatment (<a href="./references#CD011368-bbs2-0144" title="DrenoB , AmblardP , AgacheP , SirotS , LitouxP . Low doses of zinc gluconate for inflammatory acne. Acta Dermato-Venereologica1989;69(6):541-3. [PMID: 2575335]">Dreno 1989</a>). </p> <p>There are no important adverse effects reported during topical use of zinc (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>; <a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>). The adverse effects include burning sensation and itching, but they are always mild and transient (<a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>). Although the FDA pregnancy category rating of topical zinc is not available, oral zinc sulphate is a pregnancy category C drug (<a href="./references#CD011368-bbs2-0134" title="ChienAL , QiJ , RainerB , SachsDL , HelfrichYR . Treatment of acne in pregnancy. Journal of the American Board of Family Medicine2016;29(2):254-62. [PMID: 26957383]">Chien 2016</a>). </p> </section> <section id="CD011368-sec-0018"> <h4 class="title">Topical fruit acid (alpha‐hydroxy acid)</h4> <p>Alpha‐hydroxy acid (or fruit acid) refers to a special group of organic acids that can be found in natural foods (<a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>). It is useful in a variety of dermatological conditions with abnormal keratinisation (<a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>; <a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>). Glycolic acid belongs to alpha‐hydroxy acids, which can be used for chemical peeling at concentrations ranging from 20% to 70% (<a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>). Glycolic acid peel is the most common fruit peel (<a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>). In Asian acne patients, the use of 50% glycolic acid peels once in three weeks for 10 weeks can result in significant resolution of comedones, papules, and pustules (<a href="./references#CD011368-bbs2-0101" title="WangCM , HuangCL , HuCT , ChanHL . The effect of glycolic acid on the treatment of acne in Asian skin. Dermatologic Surgery1997;23(1):23-9. [PMID: 9107290]">Wang 1997</a>). Another study also suggests the efficacy of glycolic acid peels (20% to 70%) in the reduction of both non‐inflamed and inflamed lesions when applied twice every four weeks for six months (<a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>). Moreover, they are also useful in nodule‐cystic acne and acne scars (<a href="./references#CD011368-bbs2-0125" title="AtzoriL , BrunduMA , OrruA , BiggioP . Glycolic acid peeling in the treatment of acne. Journal of the European Academy of Dermatology and Venereology1999;12(2):119-22. [PMID: 10343939]">Atzori 1999</a>; <a href="./references#CD011368-bbs2-0101" title="WangCM , HuangCL , HuCT , ChanHL . The effect of glycolic acid on the treatment of acne in Asian skin. Dermatologic Surgery1997;23(1):23-9. [PMID: 9107290]">Wang 1997</a>). Therefore, glycolic acid peel is a useful alternative treatment for acne (<a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>). In addition to glycolic acid, gluconolactone (14%), another alpha‐hydroxy acid, has showed a significant therapeutic effect in reducing acne lesions (<a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>). </p> <p>The mechanism of action may be due to the modification of keratinisation by alpha‐hydroxy acids, and the anti‐inflammatory activity of alpha‐hydroxy acids may also play a role in acne improvement (<a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>). </p> <p>The adverse effects are always minimal during topical use of alpha‐hydroxy acids (<a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>; <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>), and patient tolerance is reported to be good (<a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>). Glycolic acid is a pregnancy category N drug (rating is not available) but there are no published reports demonstrating any adverse effects during pregnancy (<a href="./references#CD011368-bbs2-0134" title="ChienAL , QiJ , RainerB , SachsDL , HelfrichYR . Treatment of acne in pregnancy. Journal of the American Board of Family Medicine2016;29(2):254-62. [PMID: 26957383]">Chien 2016</a>). </p> </section> </section> <section id="CD011368-sec-0019"> <h3 class="title" id="CD011368-sec-0019">Why it is important to do this review</h3> <p>The Global Burden of Disease (GBD) 2010 and 2013 projects measured disease burden using disability‐adjusted life year (DALY) metrics (<a href="./references#CD011368-bbs2-0160" title="HayRJ , JohnsNE , WilliamsHC , BolligerIW , DellavalleRP , MargolisDJ , et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. Journal of Investigative Dermatology2014;134(6):1527-34. [MEDLINE: 24166134]">Hay 2014</a>; <a href="./references#CD011368-bbs2-0163" title="KarimkhaniC , DellavalleRP , CoffengLE , FlohrC , HayRJ , LanganSM , et al. Global skin disease morbidity and mortality: an update from the Global Burden of Disease Study 2013. JAMA Dermatology2017;153(5):406-12. [PMID: 28249066]">Karimkhani 2017</a>); of the 15 dermatologic conditions, acne vulgaris was the skin disease with the second highest percentage of total DALYs either in the GBD 2010 or GBD 2013 study (<a href="./references#CD011368-bbs2-0160" title="HayRJ , JohnsNE , WilliamsHC , BolligerIW , DellavalleRP , MargolisDJ , et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. Journal of Investigative Dermatology2014;134(6):1527-34. [MEDLINE: 24166134]">Hay 2014</a>; <a href="./references#CD011368-bbs2-0163" title="KarimkhaniC , DellavalleRP , CoffengLE , FlohrC , HayRJ , LanganSM , et al. Global skin disease morbidity and mortality: an update from the Global Burden of Disease Study 2013. JAMA Dermatology2017;153(5):406-12. [PMID: 28249066]">Karimkhani 2017</a>). Thus, the global burden of acne is very high (<a href="./references#CD011368-bbs2-0160" title="HayRJ , JohnsNE , WilliamsHC , BolligerIW , DellavalleRP , MargolisDJ , et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. Journal of Investigative Dermatology2014;134(6):1527-34. [MEDLINE: 24166134]">Hay 2014</a>; <a href="./references#CD011368-bbs2-0163" title="KarimkhaniC , DellavalleRP , CoffengLE , FlohrC , HayRJ , LanganSM , et al. Global skin disease morbidity and mortality: an update from the Global Burden of Disease Study 2013. JAMA Dermatology2017;153(5):406-12. [PMID: 28249066]">Karimkhani 2017</a>). A recent report, however, has demonstrated that the limited number of reviews and protocols published in the <i>Cochrane Database of Systematic Reviews</i> (CDSR) does not reflect disease disability estimates for acne and that this topic is underrepresented (<a href="./references#CD011368-bbs2-0162" title="KarimkhaniC , BoyersLN , PrescottL , WelchV , DelamereFM , NasserM , et al. Global burden of skin disease as reflected in Cochrane Database of Systematic Reviews. JAMA Dermatology2014;150(9):945-51. [PMID: 24807687]">Karimkhani 2014</a>). Cochrane Reviews on oral treatments including minocycline (<a href="./references#CD011368-bbs2-0153" title="GarnerSE , EadyA , BennettC , NewtonJN , ThomasK , PopescuCM . Minocycline for acne vulgaris: efficacy and safety. Cochrane Database of Systematic Reviews2012, Issue 8. Art. No: CD002086. [DOI: 10.1002/14651858.CD002086.pub2]">Garner 2012</a>) and contraceptive pills (<a href="./references#CD011368-bbs2-0124" title="ArowojoluAO , GalloMF , LopezLM , GrimesDA . Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD004425. [DOI: 10.1002/14651858.CD004425.pub6]">Arowojolu 2012</a>) for acne have been conducted. Topical treatments including retinoids, benzoyl peroxide (<a href="./references#CD011368-bbs2-0209" title="YangZ , ZhangY , LazicME , LiH , HuJ , ZhangY , et al. Topical benzoyl peroxide for acne. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD011154. [DOI: 10.1002/14651858.CD011154]">Yang 2014</a>), and antibiotics for acne are (or will be) dealt with in other Cochrane Reviews. </p> <p>We know of several reviews on some of these topical treatments for acne (<a href="./references#CD011368-bbs2-0152" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. American Journal of Clinical Dermatology2012;13(3):141-52. [MEDLINE: 22268388]">Gamble 2012</a>; <a href="./references#CD011368-bbs2-0159" title="HaiderA , ShawJC . Treatment of acne vulgaris. JAMA2004;292(6):726-35. [MEDLINE: 15304471]">Haider 2004</a>; <a href="./references#CD011368-bbs2-0171" title="LehmannHP , AndrewsJS , RobinsonKA , HollowayVL , GoodmanSN . Management of acne. Summary, Evidence Report/Technology Assessment: Number 17. AHRQ Publication No. 01-E018, March 2001. Agency for Healthcare Research and Quality, Rockville, MD.">Lehmann 2001</a>; <a href="./references#CD011368-bbs2-0183" title="PurdyS , deBerkerD . Acne vulgaris. Clinical Evidence2011;2011:1714. [MEDLINE: 21477388]">Purdy 2011</a>; <a href="./references#CD011368-bbs2-0188" title="SeidlerEM , KimballAB . Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52-62.">Seidler 2010</a>). Three of these reviews demonstrated that use of topical azelaic acid shows benefits for mild and moderate acne and is comparable to topical retinoid or benzoyl peroxide (<a href="./references#CD011368-bbs2-0152" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. American Journal of Clinical Dermatology2012;13(3):141-52. [MEDLINE: 22268388]">Gamble 2012</a>; <a href="./references#CD011368-bbs2-0159" title="HaiderA , ShawJC . Treatment of acne vulgaris. JAMA2004;292(6):726-35. [MEDLINE: 15304471]">Haider 2004</a>; <a href="./references#CD011368-bbs2-0183" title="PurdyS , deBerkerD . Acne vulgaris. Clinical Evidence2011;2011:1714. [MEDLINE: 21477388]">Purdy 2011</a>). However, there is only limited evidence to demonstrate that topical salicylic acid (<a href="./references#CD011368-bbs2-0152" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. American Journal of Clinical Dermatology2012;13(3):141-52. [MEDLINE: 22268388]">Gamble 2012</a>), nicotinamide (<a href="./references#CD011368-bbs2-0183" title="PurdyS , deBerkerD . Acne vulgaris. Clinical Evidence2011;2011:1714. [MEDLINE: 21477388]">Purdy 2011</a>), sulphur (<a href="./references#CD011368-bbs2-0152" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. American Journal of Clinical Dermatology2012;13(3):141-52. [MEDLINE: 22268388]">Gamble 2012</a>; <a href="./references#CD011368-bbs2-0171" title="LehmannHP , AndrewsJS , RobinsonKA , HollowayVL , GoodmanSN . Management of acne. Summary, Evidence Report/Technology Assessment: Number 17. AHRQ Publication No. 01-E018, March 2001. Agency for Healthcare Research and Quality, Rockville, MD.">Lehmann 2001</a>), zinc (<a href="./references#CD011368-bbs2-0152" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. American Journal of Clinical Dermatology2012;13(3):141-52. [MEDLINE: 22268388]">Gamble 2012</a>), and alpha‐hydroxy acid (<a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>) may be beneficial for acne treatment. A review on salicylic acid did not include adequate intervention arms and did not assess side effects of the treatments (<a href="./references#CD011368-bbs2-0188" title="SeidlerEM , KimballAB . Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52-62.">Seidler 2010</a>). In summary, most of the up to date evidence on these medications is from summary reviews (<a href="./references#CD011368-bbs2-0152" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. American Journal of Clinical Dermatology2012;13(3):141-52. [MEDLINE: 22268388]">Gamble 2012</a>; <a href="./references#CD011368-bbs2-0159" title="HaiderA , ShawJC . Treatment of acne vulgaris. JAMA2004;292(6):726-35. [MEDLINE: 15304471]">Haider 2004</a>; <a href="./references#CD011368-bbs2-0183" title="PurdyS , deBerkerD . Acne vulgaris. Clinical Evidence2011;2011:1714. [MEDLINE: 21477388]">Purdy 2011</a>; <a href="./references#CD011368-bbs2-0190" title="SharadJ . Glycolic acid peel therapy - a current review. Clinical, Cosmetic and Investigational Dermatology2013;6:281-8. [PMID: 24399880]">Sharad 2013</a>), and the only two systematic reviews identified are either out of date (<a href="./references#CD011368-bbs2-0171" title="LehmannHP , AndrewsJS , RobinsonKA , HollowayVL , GoodmanSN . Management of acne. Summary, Evidence Report/Technology Assessment: Number 17. AHRQ Publication No. 01-E018, March 2001. Agency for Healthcare Research and Quality, Rockville, MD.">Lehmann 2001</a>), or without clear assessment of the quality of evidence (<a href="./references#CD011368-bbs2-0188" title="SeidlerEM , KimballAB . Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52-62.">Seidler 2010</a>). </p> <p>Given the various limitations of previous reviews and the new evidence from recent studies on the use of azelaic and salicylic acids, nicotinamide, sulphur, zinc, and alpha‐hydroxy acid, we feel it is important to systematically assess their benefits and harms for the treatment of acne vulgaris using Cochrane methodology. </p> <p>The plans for this review were published as a protocol with a slightly different title, 'Topical azelaic acid, salicylic acid, nicotinamide, and sulphur for acne' (<a href="./references#CD011368-bbs2-0212" title="LiuH , YuH , XiaJ , LiuL , LiuGJ , SangH . Topical azelaic acid, salicylic acid, nicotinamide, and sulphur for acne. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD011368. [DOI: 10.1002/14651858.CD011368]">Liu 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011368-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011368-sec-0020"></div> <p>To assess the effects of topical treatments (azelaic acid, salicylic acid, nicotinamide, zinc, alpha‐hydroxy acid, and sulphur) for acne. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011368-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011368-sec-0021"></div> <section id="CD011368-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011368-sec-0023"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> <p>Randomised trials with a cross‐over design were eligible. We excluded cluster‐RCTs and quasi‐RCTs trials (e.g. trials that allocate by using date of birth, case record number, or alternation). </p> </section> <section id="CD011368-sec-0024"> <h4 class="title">Types of participants</h4> <p>We included participants with acne vulgaris who have been diagnosed based on clinical definition, regardless of age, gender, acne severity, and previous treatments. Studies were also eligible where participants were diagnosed as having papulopustular, inflammatory, juvenile, or polymorphic acne. </p> <p>We excluded trials in which participants had a diagnosis of other forms of acne variants or acneiform eruptions, as listed in <a href="#CD011368-tbl-0012">Table 2</a>. </p> </section> <section id="CD011368-sec-0025"> <h4 class="title">Types of interventions</h4> <p>Topical azelaic acid, topical salicylic acid, topical nicotinamide, topical sulphur, topical zinc, and topical fruit acid (alpha‐hydroxy acid) with any treatment regimen, duration, dose, and delivery mode, compared with: </p> <p> <ul id="CD011368-list-0001"> <li> <p>other topical treatments;</p> </li> <li> <p>placebo;</p> </li> <li> <p>no treatment.</p> </li> </ul> </p> <p>The trials that compared the intervention treatments with each other were eligible for inclusion. The concomitant use of other topical or oral medications for acne vulgaris had to be the same in both intervention arms. </p> </section> <section id="CD011368-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD011368-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011368-list-0002"> <li> <p>Participants' global self‐assessment of acne improvement (e.g. measured by a 4‐point scale: excellent, good, fair, and poor) </p> </li> <li> <p>Withdrawal for any reason</p> </li> </ul> </p> </section> <section id="CD011368-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011368-list-0003"> <li> <p>Change in lesion counts (total, or inflamed and non‐inflamed separately)</p> </li> <li> <p>Physicians' global evaluation of acne improvement</p> </li> <li> <p>Minor adverse events (assessed as the total number of participants who experienced at least 1 minor adverse event) </p> </li> <li> <p>Quality of life</p> </li> </ul> </p> </section> <section id="CD011368-sec-0029"> <h5 class="title">Timing</h5> <p>We assessed treatment efficacy by grouping the outcomes into short‐term treatment (less than or equal to 4 weeks), medium‐term treatment (from 5 to 8 weeks) and long‐term treatment (more than 8 weeks). Where there was more than one follow‐up point within the same time period, we used the longest one. </p> </section> </section> </section> <section id="CD011368-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD011368-sec-0031"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Skin Information Specialist searched the following databases up to 1 May 2019. </p> <p> <ul id="CD011368-list-0004"> <li> <p>Cochrane Skin Group Specialised Register using the search strategy in <a href="./appendices#CD011368-sec-0348">Appendix 1</a> </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 5) in the Cochrane Library using the search strategy in <a href="./appendices#CD011368-sec-0349">Appendix 2</a>. </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD011368-sec-0350">Appendix 3</a>. </p> </li> <li> <p>Embase via OVID (from 1974) using the strategy in <a href="./appendices#CD011368-sec-0351">Appendix 4</a>. </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD011368-sec-0352">Appendix 5</a>. </p> </li> </ul> </p> <section id="CD011368-sec-0032"> <h5 class="title">Trials registers</h5> <p>We (HL and HY) searched the following trials registers up to 1 May 2019 using the search terms (azelaic acid, salicylic acid, o‐hydroxybenzoic acid, nicotinamide, niacinamide, sulphur, sulfur, zinc, fruit acid, alpha‐hydroxy acid, and glycolic acid) combined with health condition 'acne'. </p> <p> <ul id="CD011368-list-0005"> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011368-sec-0033"> <h4 class="title">Searching other resources</h4> <section id="CD011368-sec-0034"> <h5 class="title">References from included studies</h5> <p>We checked the bibliographies of included studies for further references to relevant trials. </p> </section> <section id="CD011368-sec-0035"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse events of the target interventions. However, we examined data on adverse effects from the included studies we identified if present. </p> </section> </section> </section> <section id="CD011368-sec-0036"> <h3 class="title" id="CD011368-sec-0036">Data collection and analysis</h3> <section id="CD011368-sec-0037"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HL and HY) independently inspected the titles and abstracts of all studies identified for eligibility. For studies that appeared to be eligible, we retrieved the full text of reports for reassessment to see whether they met the inclusion criteria. We resolved discrepancies by discussion between review authors (HL and HY) and, if necessary, input by a third review author (JX or HS). </p> </section> <section id="CD011368-sec-0038"> <h4 class="title">Data extraction and management</h4> <p>For data collection, we used a data extraction form adapted from a standard one and the form was piloted followed by minor revisions. We extracted data on an intention‐to‐treat (ITT) basis and used Review Manager 5 for the analysis of data (<a href="./references#CD011368-bbs2-0186" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>Two review authors (HL and HY) independently extracted data from eligible studies using an ITT approach and one review author (FP) extracted data from studies published in German. We collected both qualitative and quantitative information according to Table 7.3.a, 'Checklist of items to consider in data collection or data extraction', in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011368-bbs2-0161" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), and we collected characteristics of the included studies in sufficient detail to populate a table of '<a href="./references#CD011368-sec-0368" title="">Characteristics of included studies</a>'. Where further information was required, we contacted the authors for clarification. We resolved any disagreements by discussion and, if necessary, involved a third review author (JX or HS). In the case of data displayed only in graphs or figures, if we were unable to contact study authors, we extracted the data manually using a ruler but only included the data if two review authors independently collected the same results. </p> <p>The review authors were not blinded to journals, authors, or their academic affiliations. HL, HS and HY entered the data into the Review Manager 5 software (<a href="./references#CD011368-bbs2-0186" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD011368-sec-0039"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (HL and HS) independently assessed the methodological quality of eligible studies using the 'Risk of bias' tool, as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011368-bbs2-0161" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We resolved any disagreements by discussion and, if necessary, involved a third review author (JX or GL). We assessed the following domains for bias. </p> <p> <ul id="CD011368-list-0006"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We categorised the risk of bias in each domain as either 'low', 'high', or 'unclear'. Where two or more out of seven domains within a trial were rated as 'high' risk of bias, we considered including the trial in a sensitivity analysis. </p> </section> <section id="CD011368-sec-0040"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011368-sec-0041"> <h5 class="title">Interpretation</h5> <p>If possible, we compared the pooled estimates with the minimally important difference (MID) values for both primary and secondary outcomes to aid interpretation. We used the suggested MID from the literature, such as MID estimates for acne lesion counts (<a href="./references#CD011368-bbs2-0154" title="GerlingerC , SchmelterT . Determining the non-inferiority margin for patient reported outcomes. Pharmaceutical Statistics2011;10(5):410-3. [MEDLINE: 21932298]">Gerlinger 2011</a>), and Acne‐Specific Quality of Life Questionnaire (Acne‐QoL) outcomes (<a href="./references#CD011368-bbs2-0175" title="McLeodLD , FehnelSE , BrandmanJ , SymondsT . Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics2003;21(15):1069-79. [MEDLINE: 14596626]">McLeod 2003</a>). </p> </section> <section id="CD011368-sec-0042"> <h5 class="title">Dichotomous data</h5> <p>For binary outcomes, we calculated the risk ratio (RR) and its 95% confidence interval (CI) to summarise estimates of treatment effect, because the RR was more intuitive than the odds ratio (OR) (<a href="./references#CD011368-bbs2-0128" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405-11.">Boissel 1999</a>), which was often misinterpreted as RR by clinicians (<a href="./references#CD011368-bbs2-0139" title="DeeksJJ . Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21(11):1575-600.">Deeks 2002</a>). </p> </section> <section id="CD011368-sec-0043"> <h5 class="title">Continuous data</h5> <section id="CD011368-sec-0044"> <h6 class="title">Summary statistic</h6> <p>For continuous outcomes, we calculated the mean difference (MD) and its 95% CI to summarise data, and used standardised mean difference (SMD) with 95% CI where different measurement scales had been used across studies. </p> </section> <section id="CD011368-sec-0045"> <h6 class="title">Skewed data</h6> <p>Data from continuous outcomes were often not normally distributed and statistics to summarise average (medians) and spread of data (quartiles, minimum and maximum, and ranges) were used in this case. We summarised such variables using the summary statistics for skewed data in additional tables rather than in the main analysis, and we did not analyse the treatment effect sizes to avoid applying parametric tests to data with skewed distribution. We classified data as skewed when the mean was less than twice the standard deviation (SD), but only when the data were from a scale or outcome measure that had positive values with a minimum value of zero (<a href="./references#CD011368-bbs2-0122" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200.">Altman 1996</a>). Sometimes trials used means to summarise skewed data from very large trials. In this situation, we entered the data into analysis but a sensitivity analysis was necessary. </p> </section> </section> <section id="CD011368-sec-0046"> <h5 class="title">Ordinal data</h5> <p>Results of participant and doctor evaluations may be presented as short ordinal data. In this situation, we converted this type of data into dichotomous data (e.g. 'improved' or 'not improved'), and we conducted a sensitivity analysis using different cut off points (e.g. 'greatly improved' or 'not greatly improved'). We treated long ordinal data as continuous data. </p> </section> </section> <section id="CD011368-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>We considered the individual participant to be our unit of analysis. For trials with a cross‐over design, we extracted data from a paired t‐test and approximated a paired analysis using the generic inverse variance method. We pooled the randomised cross‐over trials separately from parallel trials. </p> <p>Where a trial had more than two intervention arms, we identified the interventions relevant to our review and combined arms to create a single pair‐wise comparison. If the combination of groups was impossible, we directly included the correlated or eligible comparisons and addressed them in different meta‐analyses as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011368-bbs2-0161" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p>For 'split‐face' design trials, in which different body parts were randomised to different interventions, we treated them as specific forms of cross‐over trials, as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011368-bbs2-0161" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). In this case, we incorporated these trials to approximate a paired analysis using the generic inverse variance method and we conducted a sensitivity analysis. We conducted meta‐analyses of these trials separately from parallel trials. </p> <p>Finally, trials in which randomisation occurred at a per person level, but multiple body parts received the same intervention and a separate outcome measure was made for each body part, were similar to cluster‐randomised trials except that each participant was a cluster. We excluded these trials, as previously stated. </p> </section> <section id="CD011368-sec-0048"> <h4 class="title">Dealing with missing data</h4> <section id="CD011368-sec-0049"> <h5 class="title">Overall loss of credibility</h5> <p>Data lose their credibility after a certain degree of loss to follow‐up (<a href="./references#CD011368-bbs2-0207" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El-SayehH , et al. The Leeds Outcomes Stakeholders Survey (LOSS) Study. In: Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27. Sao Paulo: The Cochrane Collaboration, 2007.">Xia 2007</a>; <a href="./references#CD011368-bbs2-0208" title="XiaJ , AdamsC , BhagatN , BhagatV , BhoopathiP , El-SayehH , et al. Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin2009;33(7):254-7.">Xia 2009</a>). Where more than 50% of participants withdrew before the end of the trial, we excluded these data from the analysis (with the exception of outcome of 'withdrawal for any reason' and 'minor adverse events'). </p> </section> <section id="CD011368-sec-0050"> <h5 class="title">Binary data</h5> <p>Where there was attrition between 0% and 50% for a binary outcome, we managed data based on the ITT principle. We made 'lost to follow‐up' the worst outcome, that was to say, we imputed participants reported as 'lost to follow‐up' as treatment failures for analysis. This assumption was also applicable to negative outcomes such as adverse events. </p> </section> <section id="CD011368-sec-0051"> <h5 class="title">Continuous data</h5> <p>Where there was attrition between 0% and 50% for a continuous outcome, we reproduced the completer‐only data and used them within the analysis. In many cases, we could not extract the measures of variance for continuous data directly from the report. We calculated the SD from available data (e.g. 95% CI, standard error, exact P value, and t statistic) according to the method described in Section 7.7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011368-bbs2-0161" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We contacted the trial authors for further information. If these methods were unsuccessful, we used the mean SDs from other studies within the same analysis. </p> </section> </section> <section id="CD011368-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity across studies using the Chi² test and the I² statistic. If the I² statistic was equal to or greater than 50%, significant heterogeneity was present, and we investigated the included studies for their clinical, methodological, and statistical similarities. When necessary, we also employed prespecified subgroup analyses to explore any unexplained heterogeneity. If the I² statistic was equal to or greater than 80%, we presented the data in a forest plot but did not calculate a pooled estimate. </p> </section> <section id="CD011368-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots are useful to assess reporting biases but have limited power in the case of small‐study effects (<a href="./references#CD011368-bbs2-0161" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We had planned to assess reporting bias by using funnel plots. However, as none of the meta‐analyses had 10 or more studies on primary outcomes for a test intervention, we were not able to produce funnel plots. </p> </section> <section id="CD011368-sec-0054"> <h4 class="title">Data synthesis</h4> <p>We employed a random‐effect model for all pooled analyses. Where results were estimated for individual studies with low numbers of events (fewer than 10 in total), or where the total sample size was fewer than 30 participants and a RR was used, we reported the proportion of outcomes in each treatment group together with a P value from Fisher's Exact test. </p> </section> <section id="CD011368-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We set up subgroup analyses according to the different comparators used in the control group and the different time periods of treatment duration for the test interventions. However, we did not conduct a test for subgroup differences due to a lack of adequate numbers of studies per group. In future updates, we plan to conduct subgroup analyses if we find substantial heterogeneity in a meta‐analysis with at least 10 trials on primary outcomes. We will consider the forms, concentrations, and dosing regimens of the interventions for subgroup analyses. </p> </section> <section id="CD011368-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>Where possible, we employed sensitivity analyses by excluding low methodological quality trials from the meta‐analysis: those with 'high' risk of bias for two or more of the seven domains as defined in the 'Risk of bias' tables. Where inclusion or exclusion of these low methodological quality trials did not make significant changes to treatment efficacy, we retained these trials in the final meta‐analysis. </p> <p>If trials were reported with randomisation and balanced baseline demographic characteristics in each group, we included the trials and entered them into a sensitivity analysis. </p> </section> <section id="CD011368-sec-0057"> <h4 class="title">'Summary of findings' tables and GRADE assessments</h4> <p>We created 'Summary of findings' tables in our review, in which we summarised the primary outcomes (participants' global self‐assessment of acne improvement, and withdrawal for any reason), and secondary outcomes (minor adverse events and quality of life) for the most important comparisons. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence for these four outcomes, and documented all the assessments of the body of evidence using the <a href="./references#CD011368-bbs2-0156" title="GRADEpro GDT. Version accessed prior to 22 February 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> software (<a href="./references#CD011368-bbs2-0161" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011368-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011368-sec-0058"></div> <section id="CD011368-sec-0059"> <h3 class="title">Description of studies</h3> <section id="CD011368-sec-0060"> <h4 class="title">Results of the search</h4> <p>The <a href="#CD011368-sec-0031">Electronic searches</a> identified 386 records. Our screening of the bibliographies of included studies identified five studies. Our search in the trial registers identified 40 studies. Therefore, we had a total of 431 records. After removing duplicates, we had 429 records. We excluded 295 records based on titles and abstracts. We attempted to obtain the full texts or abstracts of the remaining 134 records. We excluded 55 studies reported in 60 references that did not meet the inclusion criteria (see <a href="./references#CD011368-sec-0369" title="">Characteristics of excluded studies</a>). We added 12 records to <a href="./references#CD011368-bbs1-0003" title="">Studies awaiting classification</a> and classified three studies as <a href="./references#CD011368-bbs1-0004" title="">Ongoing studies</a>. We included 49 studies reported in the remaining 59 references (see <a href="./references#CD011368-sec-0368" title="">Characteristics of included studies</a>). Please see the study flow diagram for a further description of our screening process (<a href="#CD011368-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011368-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011368-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD011368-sec-0061"> <h4 class="title">Included studies</h4> <p>We included a total number of 49 studies. Of these studies, 47 included 3880 participants, whereas the other two studies did not report the sample size (<a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>). See '<a href="./references#CD011368-sec-0368" title="">Characteristics of included studies</a>' tables for detailed descriptions of each included study. We attempted to contact eight authors in order to obtain additional data. Only two authors provided data, four authors did not respond to our enquiries, and the other two authors responded with insufficient information. </p> <section id="CD011368-sec-0062"> <h5 class="title">Trial size</h5> <p>The trial size ranged from n = 13 to n = 351. In 19 studies, all participants completed the trial (n = 871), while 23 studies had various numbers of participants leaving the study early (between 2% to 39.5%). Seven studies did not describe dropout information (<a href="./references#CD011368-bbs2-0007" title="CavicchiniS , CaputoR . Long-term treatment of acne with 20% azelaic acid cream. Acta Dermato-venereologica. Supplementum1989;69(143):40-4. [CENTRAL: CN-00351262] ">Cavicchini 1989</a>; <a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a>; <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>; <a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a>; <a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>; <a href="./references#CD011368-bbs2-0046" title="TechapichetvanichT , RajatanavinN , SahawatwongS . The combination of salicylic acid peel with 5% benzoyl peroxide and 1% clindamycin lotion in a treatment of acne vulgaris: a randomized, doubleblind, placebo controlled study. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB13. [CENTRAL: CN-00843979] ">Techapichetvanich 2011</a>). </p> </section> <section id="CD011368-sec-0063"> <h5 class="title">Unit of allocation</h5> <p>For unit of allocation, 42 studies randomised individual participants into parallel groups. Six studies with 175 participants were split‐face studies (<a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>; <a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>; <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>; <a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>; <a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>; <a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>). One study (n = 30) was a cross‐over randomised trial (<a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>). </p> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> and <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> were two studies described in one report. Likewise, <a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> and <a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> were two studies reported in the same paper. </p> </section> <section id="CD011368-sec-0064"> <h5 class="title">Participants</h5> <p>Forty‐seven trials included 3880 participants, and the other two trials did not report the sample size (<a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>). The authors in <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a> did not report the severity of acne and authors in <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a> included participants with mild to moderate acne. Of the 3880 participants from 47 trials, 2939 participants (75.7%) from 33 trials included mild to moderate acne vulgaris graded by various acne severity grading systems or scales. The severity of the remaining participants were as follows. </p> <p> <ul id="CD011368-list-0007"> <li> <p>140 participants from three studies had moderate to severe acne (<a href="./references#CD011368-bbs2-0002" title="AksakalAB , KoruyucuM , OnderM , OztasMO , GurerMA . A comparative study of metronidazole 1% cream versus azelaic acid 20% cream in the treatment of acne. Gazi Medical Journal1997;8(4):144-7. [CENTRAL: CN-00195442] ">Aksakal 1997</a>; <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>; <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>). </p> </li> <li> <p>20 participants from one study had mild to moderately severe acne (<a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>). </p> </li> <li> <p>188 participants from three studies had unknown severity illness (<a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>; <a href="./references#CD011368-bbs2-0038" title="PicosseFR , Dos Santos GuadanhimLR , NascimentoLS , PaivaJM , BagatinE . Azelaic acid as an option for maintenance treatment after oral isotretinoin: a comparative and longitudinal study-preliminary results. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB5. [EMBASE: 71894787]">Picosse 2015</a>; <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>). </p> </li> <li> <p>399 participants from five studies probably had mild to moderate acne (<a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a>; <a href="./references#CD011368-bbs2-0007" title="CavicchiniS , CaputoR . Long-term treatment of acne with 20% azelaic acid cream. Acta Dermato-venereologica. Supplementum1989;69(143):40-4. [CENTRAL: CN-00351262] ">Cavicchini 1989</a>; <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>; <a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a>; <a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>). </p> </li> <li> <p>150 participants from one study probably had moderate to severe acne (<a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a>). </p> </li> <li> <p>44 participants from one study probably had moderate to severe/cystic acne (<a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a>). </p> </li> </ul> </p> <p>With respect to seven studies with no acne severity grading, we presented a possible grading by using a simple system (mild, moderate, severe, cystic) based on the predominant lesions present as reported in <a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>. For a detailed description, please see <a href="#CD011368-tbl-0013">Table 3</a>. </p> <div class="table" id="CD011368-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Acne severity for all studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Acne severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "10‐50 inflamed lesions and 10‐100 non‐inflamed lesions above the mandibular line, no cystic or nodular lesions." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0002" title="AksakalAB , KoruyucuM , OnderM , OztasMO , GurerMA . A comparative study of metronidazole 1% cream versus azelaic acid 20% cream in the treatment of acne. Gazi Medical Journal1997;8(4):144-7. [CENTRAL: CN-00195442] ">Aksakal 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded by using the Allen‐Smith Scale (grades of 4 to 8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "10‐50 inflamed lesions and 10‐100 non‐inflamed lesions above the mandibular line, no cystic or nodular lesions." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique) (grades of 0.25 to 3.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with comedonic acne included, no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique) (grades of 0.5 to 3.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0007" title="CavicchiniS , CaputoR . Long-term treatment of acne with 20% azelaic acid cream. Acta Dermato-venereologica. Supplementum1989;69(143):40-4. [CENTRAL: CN-00351262] ">Cavicchini 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with papulopustular acne included, median number of inflamed lesions was less than 20 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, only mentioned "the trial was for the treatment of mild to moderate acne" in the Discussion section, no details </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds Revised Acne Grading Scale (grades of 2 to 7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using a simple system (based on the predominant lesions present: mild, moderate, severe, cystic) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, a minimum of 10 non‐inflamed lesions and a minimum of 10 inflamed lesions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably moderate to severe<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade Ⅱ or Ⅲ, Pillsbury classification system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds technique, no details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded according to the Hayashi classification system (mild, moderate, severe, or very severe) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably moderate to severe/cystic<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean baseline Michaelsson acne severity index score &gt; 80, the improvement of comedones, papules, pustules, nodules and cysts was assessed </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total lesion counts &gt; 30, no further details, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique), no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique), grades of 0.25 to 2.0, participants with non‐inflamed lesions and superficial inflamed lesions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique), no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "no more than five pustules forms and no cysts, nodules, and colloidal deep scar" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average baseline Michaelsson acne severity index in the two treatment arms was 64.1 ± 4.4 and 63.0 ± 5.1 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree Ⅱ or Ⅲ, Plewig‐Kligmann classification system, participants with papulopustular acne were included </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with comedonal acne, no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderately severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, a minimum of 10 papules and/or pustules</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade Ⅲ, the Leeds technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds technique, grades of 0.25 to 2.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjects with comedonal acne (at least 5 non‐inflamed lesions on each side of the face and &lt; 30 inflamed lesions on entire face) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0035" title="OzkanM , DurmazG , SabuncuI , SaracogluN , AkgunY , UrerSM . Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative staphylococci. Turkish Journal of Medical Sciences2000;30(5):483-7. [CENTRAL: CN-00424538] ">Ozkan 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds technique, ≤ 3.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "at least 10 inflammatory lesions on the face and with a maximum of three nodules" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clinical diagnosis of mild to moderate acne, ≥ 10 facial lesions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0038" title="PicosseFR , Dos Santos GuadanhimLR , NascimentoLS , PaivaJM , BagatinE . Azelaic acid as an option for maintenance treatment after oral isotretinoin: a comparative and longitudinal study-preliminary results. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB5. [EMBASE: 71894787]">Picosse 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators' static global assessment score of mild or moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐defined grading system (mild acne: the presence of non‐inflammatory lesions, and the number of the papules, and pustules to be &lt; 10 without any nodules or cysts; moderate acne: the presence of non‐inflammatory lesions and the number of the papules and pustules to be &lt; 20 without any nodules or cysts) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade Ⅰ or Ⅱ, Pillsbury classification system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐defined grading system (the presence of at least 10 papulopustular lesions on the face accompanied by a minimum of 5 comedones, as well as a grade of 4 to 6 on the Allen‐Smith Acne Severity Scale) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐defined grading system (the presence of at least 15 papules and/or pustules on the face) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild acne: the count of pustules &lt; 20 and the count of papules &lt; 10; moderate acne: the count of pustules ranged between 20 and 40 and the count of papules ranged between 10 and 30 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with mild or moderate comedonic or papulopustular acne, a minimum of 20 facial non‐inflammatory lesions and 10 inflamed lesions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0046" title="TechapichetvanichT , RajatanavinN , SahawatwongS . The combination of salicylic acid peel with 5% benzoyl peroxide and 1% clindamycin lotion in a treatment of acne vulgaris: a randomized, doubleblind, placebo controlled study. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB13. [CENTRAL: CN-00843979] ">Techapichetvanich 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using a modified Investigators' Static Global assessment (grades of 2 to 4) and the Leeds Revised Acne Grading Scale (grades of 2 to 7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with moderate inflammatory ance on face (≥ 5 inflammatory elements, papules or pustules) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Possible acne severity, graded by using a simple system based on the predominant lesions present (<a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>), grade 1 (mild): comedones, occasional papules; grade 2 (moderate): papules, comedones, few pustules; grade 3 (severe): predominant pustules, nodules, abscesses; grade 4 (cystic): mainly cysts, abscesses, widespread scarring. </p> </div> </div> <p>Forty‐one studies described the age of participants (ranging from 10 years to 45 years old). One study included participants ≥ 16 years old (range unclear) (<a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>), and one study reported the means and standard deviations (SDs) for age (range unclear) (<a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>). Six studies did not report this information. Most people were aged between 12 and 30 years old. As for sex distribution, 38 studies with 3154 participants described this information, of which 1295 were males and 1842 were females (there was no gender information about 17 withdrawals from <a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>, <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a> and <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>). Eleven studies did not report the exact number of male and female participants. </p> </section> <section id="CD011368-sec-0065"> <h5 class="title">Settings</h5> <p>Twenty‐two studies did not provide information on setting. Seven studies were multiple‐centre clinical trials (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>: 8 centres in the UK, 1 in France, and 1 in Germany; <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> and <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>: centres in Germany, Netherlands, Norway, and Greece; <a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>: centres in Japan; <a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a>: no details; <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>: 11 centres in Germany; <a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>: centres in the USA). </p> <p>Twenty studies were set in: clinics in Iran (<a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>; <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>; <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>), hospitals in India (<a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a>; <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>) and Iraq (<a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>), research centres in Iran (<a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a>), university settings (<a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>; <a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a> in Korea; <a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a> in India; <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> in Egypt; <a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a> in USA; <a href="./references#CD011368-bbs2-0035" title="OzkanM , DurmazG , SabuncuI , SaracogluN , AkgunY , UrerSM . Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative staphylococci. Turkish Journal of Medical Sciences2000;30(5):483-7. [CENTRAL: CN-00424538] ">Ozkan 2000</a> in Turkey; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a> in Iran; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> in Germany; <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> in USA), or other (<a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a> in USA; <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a> in Iran; <a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> in France). </p> </section> <section id="CD011368-sec-0066"> <h5 class="title">Interventions</h5> <p>For the treatment group, 18 studies assessed salicylic acid in the form of lotion (concentrations of 2% or 3%, e.g. <a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>), chemical peel (concentrations of 20% or 30%, e.g. <a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>), gel (concentration of 2%, e.g. <a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>), microgel (concentrations of 0.5% or 2%, e.g. <a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a>), and solution (concentration of 0.5%, e.g. <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a>), and 18 studies addressed azelaic acid in the form of cream (concentration of 20%, e.g. <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>) and gel (concentrations of 5%, 15%, or 20%, e.g. <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a>); four studies investigated nicotinamide in the form of gel (concentration of 4% or 5%, <a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>; <a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>; <a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a>), while three studies addressed zinc in the form of gel (concentration of 1%, <a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>), lotion (concentration of 1.2%, <a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>), and solution (concentration of 5%; <a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>); one study assessed sulphur in the form of lotion (concentration of 2%, <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>); five studies tested the efficacy and safety of glycolic acid (alpha‐hydroxy acid) in the form of chemical peel (concentration ranging from 20% to 70%, <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>; <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a>; <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>; <a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>; <a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>) and one study investigated gluconolactone (alpha‐hydroxy acid) in the form of lotion (concentration of 14%, <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>). In the <a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a> study, the authors compared salicylic acid with alpha‐hydroxy acid (glycolic acid). </p> <p>Seven studies used topical clindamycin, erythromycin, or benzoyl peroxide as co‐interventions (<a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>; <a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>; <a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>; <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>; <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>; <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>; <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>). Two studies included a co‐intervention of topical clindamycin plus benzoyl peroxide (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0046" title="TechapichetvanichT , RajatanavinN , SahawatwongS . The combination of salicylic acid peel with 5% benzoyl peroxide and 1% clindamycin lotion in a treatment of acne vulgaris: a randomized, doubleblind, placebo controlled study. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB13. [CENTRAL: CN-00843979] ">Techapichetvanich 2011</a>). One study used oral isotretinoin as co‐intervention (<a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>). The remaining 39 studies did not include co‐interventions. </p> <p>The treatment period of the interventions ranged from five days to 12 months. We grouped three studies into short‐term (less than or equal to 4 weeks) treatment duration (<a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>; <a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>), 15 studies into medium‐term (from 5 to 8 weeks) treatment duration, and 29 studies into long‐term (more than 8 weeks) treatment duration. Two studies did not report treatment duration (<a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a>; <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>). </p> <p>Three studies had a post‐treatment follow‐up period ranging from eight weeks to 12 weeks (<a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>; <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a>; <a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>). In <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>, one treatment arm had a post‐treatment follow‐up period of 24 weeks. Forty‐three studies did not report the post‐treatment follow‐up period. Two studies did not mention the treatment period of the interventions and the post‐treatment follow‐up period (<a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a>; <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>). </p> <p>None of the studies reported the precise duration of the trial (from recruitment to last follow‐up). Nine studies reported the study time period ranging from three months to three years (<a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>; <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a>; <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>; <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>; <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a>; <a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>; <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>). <a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a> ran through autumn, winter and early spring. Seven studies reported recruitment time periods ranging from six months to one year (<a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a>; <a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>; <a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>; <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>; <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>; <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>; <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>). </p> </section> <section id="CD011368-sec-0067"> <h5 class="title">Comparators</h5> <p>For the control group, 31 studies used active treatments, such as clindamycin, erythromycin, tretinoin, Jessner's solution, benzoyl peroxide, and so on. Fourteen studies had placebo/vehicle control or no treatment; and four studies had multiple treatment groups with both active therapy and placebo control (<a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a>; <a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>; <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>). In five included studies (<a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>; <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>; <a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a>; <a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a>; <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a>), study authors considered the term 'vehicle' to be the same as 'placebo'. In one study (<a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a>), the excipients used in the vehicle did not contain antimicrobial agents which may have some therapeutic effects. In another two studies (<a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a>; <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>), the study authors used a lotion base as placebo. Thus, 'vehicle' was equal to 'placebo' in this review and we pooled the two groups together in the same comparison. </p> </section> <section id="CD011368-sec-0068"> <h5 class="title">Outcomes</h5> <p>Nineteen studies reported global self‐assessment of acne improvement (assessed by the participants). Of the 19 studies, 16 used Likert‐type or Likert‐like scales, one used a visual analogue scale (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>), one used a questionnaire with known contents (<a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>), and one used a preference test (<a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>). Thirty studies did not report this primary outcome. Forty‐two studies reported the withdrawal information (19 studies reported no withdrawals), while seven studies did not report this outcome (<a href="./references#CD011368-bbs2-0007" title="CavicchiniS , CaputoR . Long-term treatment of acne with 20% azelaic acid cream. Acta Dermato-venereologica. Supplementum1989;69(143):40-4. [CENTRAL: CN-00351262] ">Cavicchini 1989</a>; <a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a>; <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>; <a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a>; <a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>; <a href="./references#CD011368-bbs2-0046" title="TechapichetvanichT , RajatanavinN , SahawatwongS . The combination of salicylic acid peel with 5% benzoyl peroxide and 1% clindamycin lotion in a treatment of acne vulgaris: a randomized, doubleblind, placebo controlled study. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB13. [CENTRAL: CN-00843979] ">Techapichetvanich 2011</a>). </p> <p>For secondary outcomes, 44 studies reported the change in lesion counts (assessed by the investigators or physicians), while five studies did not report this outcome (<a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>; <a href="./references#CD011368-bbs2-0035" title="OzkanM , DurmazG , SabuncuI , SaracogluN , AkgunY , UrerSM . Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative staphylococci. Turkish Journal of Medical Sciences2000;30(5):483-7. [CENTRAL: CN-00424538] ">Ozkan 2000</a>; <a href="./references#CD011368-bbs2-0038" title="PicosseFR , Dos Santos GuadanhimLR , NascimentoLS , PaivaJM , BagatinE . Azelaic acid as an option for maintenance treatment after oral isotretinoin: a comparative and longitudinal study-preliminary results. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB5. [EMBASE: 71894787]">Picosse 2015</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>). Seventeen studies described the physicians' global evaluation of acne improvement (assessed by the physicians) (15 studies used Likert‐like scales, two studies used visual analogue scales (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>; <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>); the remaining 32 did not report this outcome. </p> <p>Forty‐five studies reported minor adverse events (assessed as total number of participants who experienced at least 1 minor adverse event), but the number of participants who experienced adverse events was not always reported. Of the 45 studies, four reported no adverse events during the study (<a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>; <a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>; <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a>), eight used four‐point Likert scales or similar scales (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>; <a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>; <a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>; <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>; <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>; <a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a>; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>), and one used a visual analogue scale to assess the severity of adverse events (<a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>). Four trials did not report this outcome (<a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a>; <a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>; <a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a>; <a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>). </p> <p>Six studies reported quality of life assessed by the participants (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>; <a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a>; <a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>; <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>). Of these, three studies used the Acne‐Specific Quality of Life Questionnaire (Acne‐QoL) (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>; <a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a>), two studies used the Dermatology Life Quality Index (DLQI) Questionnaire (<a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>), and one study used preference test questions (<a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>). The rest of the studies (43) did not report quality of life. Of the 49 included studies, 24 studies reported other outcomes like skin barrier functions and acne severity Index. </p> </section> <section id="CD011368-sec-0069"> <h5 class="title">Funding</h5> <p>Thirty‐one trials did not describe the study funding sources. Authors from three trials were employees of a pharmaceutical company (<a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a>; <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>). Nine trials received support from a pharmaceutical company or corporation (<a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>; <a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>; <a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>; <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>; <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>; <a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>; <a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>). The posters from two trials were funded by Johnson &amp; Johnson Consumer and Personal Products Worldwide (<a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a>; <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>). One trial received support from two persons with unknown positions (<a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a>). One trial received funding from a university (<a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>), and one trial received support from the National Institute of Health, US Public Health Service and The Detroit General Hospital Research Corporation (<a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>). Only one trial clearly stated that there was no funding or financial source in support of the work (<a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>). </p> </section> </section> <section id="CD011368-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded 55 studies: 18 studies were not RCTs; four studies focused on healthy people or participants with rosacea; 23 presented ineligible interventions or comparisons; and in 10 studies we could not contact authors for clarification of randomisation. See '<a href="./references#CD011368-sec-0369" title="">Characteristics of excluded studies</a>' tables for detailed descriptions of each excluded study. </p> </section> <section id="CD011368-sec-0071"> <h4 class="title">Studies awaiting assessment</h4> <p>We added 12 records to studies awaiting classification (see the '<a href="./references#CD011368-sec-0370" title="">Characteristics of studies awaiting classification</a>' tables). Reasons include: unable to obtain the full text (<a href="./references#CD011368-bbs2-0105" title="BartosovaL , MelicharM , SternberskyJ . External therapy of acne vulgaris in a controlled clinical trial. I. Comparison of the effectiveness of treatment after isolated time intervals of comedo therapy. Cesko-Slovenska Dermatologie1978;53(3):157-63. [PMID: 150310]">Bartosova 1978</a>; <a href="./references#CD011368-bbs2-0106" title="CavicchiniS , CaputoR . National and international experiences with azelaic acid cream in the treatment of papulo-pustular acne [Esperienze cliniche nazionali ed internazionali con una crema a base di acido azelaico nel trattamento dell'acne papulo-pustolosa]. Giornale Italiano di Dermatologia e Venereologia1989;124(10):465-70. [PMID: 2534551]">Cavicchini 1989a</a>; <a href="./references#CD011368-bbs2-0107" title="DraelosZD . Assessing the value of botanical anti-inflammatory agents in an OTC acne treatment regimen. Journal of Drugs in Dermatology2015;14(12):1418-21. [CENTRAL: CN-01200536] ">Draelos 2015</a>; <a href="./references#CD011368-bbs2-0108" title="GiannottiB . National and international clinical experiences with azelaic acid cream in the treatment of comedo acne [Esperienze cliniche nazionali ed internazionali con una crema a base di acido azelaico nel trattamento dell'acne comedonica]. Giornale Italiano di Dermatologia e Venereologia1989;124(10):471-7. [PMID: 2534552]">Giannotti 1989</a>; <a href="./references#CD011368-bbs2-0113" title="PisaniM , GuerreraV , GrimaldiFF . Treatment of acne vulgaris with an ointment containing azelaic acid (12%), L-carnitine (2%), enoxolone (1%): Double-blind study versus placebo. Chronica Dermatologica1991;1(3):339-44. [CENTRAL: CN-00185158] ">Pisani 1991</a>; <a href="./references#CD011368-bbs2-0114" title="PonzioHA , BierRT , BozkoMP . Clinical evaluation of a line of products for the control of acne in teenagers. Anais Brasileiros de Dermatologia1994;69(6):461-5. [CENTRAL: CN-00179147] ">Ponzio 1994</a>, <a href="./references#CD011368-bbs2-0116" title="ZhengY , YinS , XiaY , ChenJ , YeC , ZengQ , et al. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split-face, open-label, single-center study. Cutaneous and ocular toxicology2019;38(1):48-54. [PMID: 30173582]">Zheng 2019</a>), the study was listed as completed on a trial registry but no results could be obtained (<a href="./references#CD011368-bbs2-0109" title="IRCT201010094269N3. Effect of combined topical solution 2% salicylic acid and erythromycin 4% with erythromycin 4% topical solution in the treatment of mild to moderate acne vulgaris. en.irct.ir/trial/4534 (first received 19 October 2011). ">IRCT201010094269N3</a>; <a href="./references#CD011368-bbs2-0111" title="NCT00031096. Comparison of efficacy and safety of azelaic acid 15% gel with its vehicle in subjects with mild to moderate acne. clinicaltrials.gov/ct2/show/study/NCT00031096 (first received 22 February 2002). ">NCT00031096</a>; <a href="./references#CD011368-bbs2-0112" title="NCT02755545. A clinical trial to evaluate the efficacy of two acne treatments. clinicaltrials.gov/ct2/show/study/NCT02755545 (first received 29 April 2016). ">NCT02755545</a>; <a href="./references#CD011368-bbs2-0115" title="TCTR20190118001. A study comparing the efficacy and safety of Jessner's solution and salicylic acid 30% Chemical Peel and in the management of acne vulgaris and post acne hyperpigmentation. www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=4304 (first received 1 January 2019). ">TCTR20190118001</a>), and only a conference abstract was identified and it was not clear if the study met the inclusion criteria of the review (<a href="./references#CD011368-bbs2-0110" title="KernD , NamkoongJ , RiggsM , HollyK , KnaggsH . A novel facial treatment cleansing device improves acne skin. Journal of Investigative Dermatology2019;139(5 Suppl):S166. [EMBASE: 2001808174]">Kern 2019</a>). </p> </section> <section id="CD011368-sec-0072"> <h4 class="title">Ongoing studies</h4> <p>We identified three studies as ongoing and added details to the '<a href="./references#CD011368-sec-0371" title="">Characteristics of ongoing studies</a>' tables. Comparisons included salicylic acid peel versus glycolic acid peel (<a href="./references#CD011368-bbs2-0117" title="ChiCTR1800018343. Comparative study for salicylic acid vs glycolic acid in the treatment of mild-to-moderate acne vulgaris. www.chictr.org.cn/showproj.aspx?proj=19551 (first received 12 September 2018). ">ChiCTR1800018343</a>), 35% glycolic acid peels versus 20% salicylic acid peels (<a href="./references#CD011368-bbs2-0118" title="CTRI/2018/06/014615. Comparison of use of glycolic acid and salicylic acid peel in acne (pimples). www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26734 (first received 26 June 2018). ">CTRI/2018/06/014615</a>), and salicylic acid plus Epiduo 0.1% to 2.5% topical gel versus moisturiser plus Epiduo 0.1% to 2.5% topical gel (<a href="./references#CD011368-bbs2-0119" title="NCT03832647. Anti-acne efficacy of a dermo-cosmetic product associated with the fixed combination adapalene 0.1%/ benzoyl peroxide 2.5% treatment versus this treatment associated with a standard moisturizer in male and female subjects presenting with mild to moderate acne. clinicaltrials.gov/ct2/show/study/nct03832647 (first received 6 February 2019). ">NCT03832647</a>). </p> </section> </section> <section id="CD011368-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to <a href="#CD011368-fig-0002">Figure 2</a> and <a href="#CD011368-fig-0003">Figure 3</a> for a graphical overview of the risk of bias of included studies. See the '<a href="./references#CD011368-sec-0368" title="">Characteristics of included studies</a>' tables for detailed assessment of risk of bias of each included study. </p> <div class="figure" id="CD011368-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011368-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011368-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011368-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011368-sec-0074"> <h4 class="title">Allocation</h4> <section id="CD011368-sec-0075"> <h5 class="title">Random sequence generation</h5> <p>Only eight studies (16.3%) mentioned appropriate randomisation methods and we judged them at low risk of bias. Of this group, the authors performed randomisation using the FORTRAN 77 RANDT program (<a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>), computerized randomisation (<a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>), sealed envelope (<a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>), drawing (<a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>), random number table (<a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>), random permuted block (<a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>), computer‐generated schedule (<a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>), and minimisation method (<a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>). We judged the majority of included studies (41 studies) at unclear risk of bias for randomisation because these studies mentioned randomisation but provided inadequate description of randomisation methods. </p> </section> <section id="CD011368-sec-0076"> <h5 class="title">Allocation concealment</h5> <p>Only one (2%) study reported the method used for allocation concealment and we rated it at low risk of bias (<a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>; <a href="#CD011368-fig-0003">Figure 3</a>). The remaining 48 studies did not address this issue or did not provide sufficient information to permit judgement. </p> </section> </section> <section id="CD011368-sec-0077"> <h4 class="title">Blinding</h4> <p>Of the 49 included studies, 21 had a double‐blind design, 18 had a single‐blind design, and the remaining 10 did not state this issue. Of the 21 studies (42.9%) with a double‐blind design, only two clearly stated their method to ensure blinding of participants and assessors (<a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>; <a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a>). We rated the two studies to be at low risk of bias for both domains. Eleven studies with a 'double‐blind' design did not present sufficient information about method to ensure blinding of participants/personnel and assessors, we therefore judged them at unclear risk of bias for both domains in these studies (<a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>; <a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a>; <a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a>; <a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a>; <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>; <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>; <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>; <a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>; <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a>). We judged the other seven of 21 double‐blinded studies to be at low risk of performance bias and unclear risk of detection bias (<a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>; <a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>; <a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a>; <a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a>; <a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>; <a href="./references#CD011368-bbs2-0046" title="TechapichetvanichT , RajatanavinN , SahawatwongS . The combination of salicylic acid peel with 5% benzoyl peroxide and 1% clindamycin lotion in a treatment of acne vulgaris: a randomized, doubleblind, placebo controlled study. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB13. [CENTRAL: CN-00843979] ">Techapichetvanich 2011</a>). In addition, we judged one of 21 double‐blinded studies to be at unclear risk of performance bias and low risk of detection bias (<a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>). </p> <p>Of the 18 single‐blind studies, eight followed an assessor or observer masked design. Of the eight studies, five did not provide sufficient information on method to ensure blinding of assessors throughout the study, therefore we judged the risk of performance bias as high and detection bias as unclear (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>; <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>; <a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>; <a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>). We judged two of the eight studies to be at unclear risk of performance bias and at low risk of detection bias (<a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>; <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>), as the two studies clearly stated how blinding of assessors was ensured. Moreover, we judged one of the eight studies to be at high risk of performance bias and low risk of detection bias (<a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>), as the participants and personnel were open to interventions. </p> <p>Five of the 18 single‐blind studies were investigator blinded. Of the five studies, three provided sufficient information on method to ensure blinding of investigators, we judged one to be at high risk of performance bias and at low risk of detection bias (<a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>), and one to be at unclear risk of performance bias and at low risk of detection bias (<a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>), and one at high risk of performance bias and unclear risk of detection bias (<a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>). Two out of the five studies did not provide sufficient information on method to ensure blinding of investigators, we judged them to be at unclear risk of performance bias, and one to be at high risk (<a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a>), and the other one to be at low risk of detection bias (<a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>). </p> <p>Two of the 18 single‐blind studies did not provide sufficient information on how blinding was ensured, and we judged them to be at unclear risk of bias for both domains (<a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a>; <a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a>). Another two of the 18 studies were participant‐blinded, we judged them to be at high risk of detection bias, and one to be at unclear risk of performance bias due to the use of identical tubes (<a href="./references#CD011368-bbs2-0007" title="CavicchiniS , CaputoR . Long-term treatment of acne with 20% azelaic acid cream. Acta Dermato-venereologica. Supplementum1989;69(143):40-4. [CENTRAL: CN-00351262] ">Cavicchini 1989</a>), and the other one to be at high risk of performance bias due to probably insufficient blinding of personnel (<a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>). One of the 18 studies was open to assessor, and we judged it to be at unclear risk of performance bias and at high risk of detection bias (<a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>). </p> <p>Ten studies did not mention blinding. For this reason, we judged nine of the 10 studies to be at unclear risk of bias for both domains (<a href="./references#CD011368-bbs2-0002" title="AksakalAB , KoruyucuM , OnderM , OztasMO , GurerMA . A comparative study of metronidazole 1% cream versus azelaic acid 20% cream in the treatment of acne. Gazi Medical Journal1997;8(4):144-7. [CENTRAL: CN-00195442] ">Aksakal 1997</a>; <a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a>; <a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a>; <a href="./references#CD011368-bbs2-0035" title="OzkanM , DurmazG , SabuncuI , SaracogluN , AkgunY , UrerSM . Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative staphylococci. Turkish Journal of Medical Sciences2000;30(5):483-7. [CENTRAL: CN-00424538] ">Ozkan 2000</a>; <a href="./references#CD011368-bbs2-0038" title="PicosseFR , Dos Santos GuadanhimLR , NascimentoLS , PaivaJM , BagatinE . Azelaic acid as an option for maintenance treatment after oral isotretinoin: a comparative and longitudinal study-preliminary results. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB5. [EMBASE: 71894787]">Picosse 2015</a>; <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a>; <a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>; <a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a>; <a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a>). We judged one study to be at unclear risk of performance bias and at high risk of detection bias since the assessor was not blinded (<a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a>). </p> </section> <section id="CD011368-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>We judged a total of 31 studies (63.3%) to be at low risk of attrition bias as they ensured the completeness of outcome data. Of this group, 19 studies had no dropouts, five studies provided data based on intention‐to‐treat (ITT) population, and in seven studies the dropout rate (&lt; 10% per group) was not considered enough to introduce bias. </p> <p>Of the 11 studies (22.4%) that did not provide complete outcome data, we judged at high risk of attrition bias. Of these, 10 studies had a dropout rate of more than 10% per group and one did not state which dropouts belonged to which treatment group (<a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a>). </p> <p>It remained unclear if the outcome data were sufficiently addressed in seven trials (14.3%), we judged them to be at unclear risk of attrition bias. </p> </section> <section id="CD011368-sec-0079"> <h4 class="title">Selective reporting</h4> <p>Twenty‐three studies (46.9%) reported results for all prespecified outcomes mentioned in the study protocol or their methods section (if the protocol was not available), and we judged them to be at low risk of reporting bias. We judged four studies (8.2%) to be at high risk of reporting bias due to no results reported for prespecified outcomes or additionally reported outcomes that were not mentioned in the methods section. In the remaining 22 studies (44.9%), we rated them to be at unclear risk of reporting bias. Of this group, 14 studies did not provide data in a detailed manner and eight studies were published as abstract or poster only. </p> </section> <section id="CD011368-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>In 42 studies (85.7%), we identified no other potential sources of bias and we judged them to be at low risk of bias. </p> <p>We judged three studies (6.1%) to be at high risk of other potential sources of bias. In one trial, there was baseline imbalance in total lesion counts across groups and the author used a Student's t‐test with no post hoc analysis to compare the mean lesions of three treatment groups (<a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>). In one study, there was a suspicion of fraudulent data reporting (<a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a>). In a trial with a cross‐over design, there was no washout period between the first and second phases of the study (<a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>). </p> <p>In four studies (8.2%) it was unclear whether the identified problems would introduce bias. One study reported in the statistical approach that they used non‐inferiority borders of 15% (<a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a>); however, it was not fully clear whether they described an equivalence trial or an inferiority trial. In addition, the total number of participants in table one of the publication was incorrectly reported. In another study (<a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>), the authors reported an advantage for azelaic acid, although the difference was not significant, moreover, the duration of therapy differed between treatment groups. The local adverse events were compared in an indirect fashion and the authors were employees of a pharmaceutical company that marketed azelaic acid in both studies (<a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> and <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>). In another study (<a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>), one author was an employee of GlaxoSmithKline Consumer Healthcare Ltd at the time the study was conducted and the sponsor reviewed the final manuscript before submission. Finally in one trial (<a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>), three authors were employees of GlaxoSmithKline Consumer Healthcare Ltd and held stocks/shares in this company. </p> </section> </section> <section id="CD011368-sec-0081"> <h3 class="title" id="CD011368-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD011368-tbl-0001"><b>Summary of findings 1</b> Azelaic acid compared to adapalene</a>; <a href="./full#CD011368-tbl-0002"><b>Summary of findings 2</b> Azelaic acid compared to benzoyl peroxide</a>; <a href="./full#CD011368-tbl-0003"><b>Summary of findings 3</b> Azelaic acid compared to clindamycin</a>; <a href="./full#CD011368-tbl-0004"><b>Summary of findings 4</b> Azelaic acid compared to tretinoin</a>; <a href="./full#CD011368-tbl-0005"><b>Summary of findings 5</b> Salicylic acid compared to benzoyl peroxide</a>; <a href="./full#CD011368-tbl-0006"><b>Summary of findings 6</b> Salicylic acid compared to pyruvic acid</a>; <a href="./full#CD011368-tbl-0007"><b>Summary of findings 7</b> Salicylic acid compared to tretinoin</a>; <a href="./full#CD011368-tbl-0008"><b>Summary of findings 8</b> Nicotinamide compared to clindamycin</a>; <a href="./full#CD011368-tbl-0009"><b>Summary of findings 9</b> Nicotinamide compared to erythromycin</a>; <a href="./full#CD011368-tbl-0010"><b>Summary of findings 10</b> Glycolic acid (alpha‐hydroxy acid) compared to salicylic‐mandelic acid</a> </p> <p>In this review, we assessed treatment efficacy of all six test interventions (topical azelaic acid, topical salicylic acid, topical nicotinamide, topical sulphur, topical zinc, and topical fruit acid (alpha‐hydroxy acid) by grouping the outcomes into short‐term treatment (less than or equal to 4 weeks), medium‐term treatment (from 5 to 8 weeks) and long‐term treatment (more than 8 weeks). Particularly, we specified the treatment duration for long‐term outcomes. The included studies measured their outcomes at the end of treatment unless otherwise specified. We presented outcome data collected in the post‐treatment follow‐up period in a narrative way. </p> <p>With respect to the outcome, change in lesion counts, 'percentage reduction from baseline' referred to the difference between the mean lesion counts at the beginning and end of treatment divided by the mean lesion counts at the beginning of treatment, and 'number of lesions post‐intervention' referred to the lesion counts after therapy. </p> <section id="CD011368-sec-0082"> <h4 class="title">Comparison 1: topical azelaic acid versus other topical treatments</h4> <section id="CD011368-sec-0083"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p>The single <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> trial compared azelaic acid 15% gel with adapalene 0.1% gel, and the authors assessed participants' global self‐assessment of acne improvement using a one to seven grading system (7 grades between 'very much improved' (1) and 'very much worse' (7)). We found that there were no significant differences between the two groups in 'improved' to 'very much improved' in the medium term (risk ratio (RR) 0.74, 95% confidence interval (CI) 0.52 to 1.06; 1 study, 55 participants) and long term (3 months after start of treatment) (RR 0.89, 95% CI 0.68 to 1.17; 1 study, 55 participants; very low‐quality evidence; <a href="./references#CD011368-fig-0004" title="">Analysis 1.1</a>; <a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>). </p> <p>The single <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> trial compared azelaic acid 15% gel with benzoyl peroxide 5% gel, and the authors assessed the outcome using a four‐point Likert‐type rating scale (very good, good, moderate, poor). Results supported that benzoyl peroxide group had a statistically significant improvement (good or very good improvement) compared to azelaic acid in the long term (4 months after start of treatment) (RR 0.82, 95% CI 0.72 to 0.95; 1 study, 351 participants; moderate‐quality evidence; <a href="./references#CD011368-fig-0004" title="">Analysis 1.1</a>; <a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>). </p> <p>The single <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> trial compared azelaic acid 5% gel with clindamycin 2% gel, and the authors assessed this outcome using a five‐point Likert‐type scale (very satisfied, satisfied, moderately satisfied, unsatisfied, very unsatisfied). We found no significant difference in moderately to very satisfied improvement in the long term (3 months after start of treatment) (RR 0.95, 95% CI 0.81 to 1.12; 1 study, 100 participants; <a href="./references#CD011368-fig-0004" title="">Analysis 1.1</a>). Another single trial, <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>, compared azelaic acid 15% gel with clindamycin 1% gel, and the authors assessed the outcome using a four‐point Likert‐type rating scale (very good, good, moderate, poor). We found that there was no significant difference in good or very good improvement in the long term (4 months after start of treatment) (RR 1.13, 95% CI 0.92 to 1.38; 1 study, 229 participants; low‐quality evidence; <a href="./references#CD011368-fig-0004" title="">Analysis 1.1</a>; <a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>). </p> <p>The single <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> trial compared azelaic acid 20% gel with erythromycin 2% gel, and the authors assessed this outcome using a five‐point Likert‐type scale (very satisfied, satisfied, moderately satisfied, unsatisfied, very unsatisfied). We found no significant difference in moderately to very satisfied improvement in the long term (3 months after start of treatment) (RR 1.06, 95% CI 0.85 to 1.32; 1 study, 66 participants; <a href="./references#CD011368-fig-0004" title="">Analysis 1.1</a>). </p> <p>The single <a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> trial compared 20% azelaic acid cream with 0.05% tretinoin cream, and the authors reported the outcome using a four‐point Likert‐type rating scale (excellent, good, moderate, poor). Results showed that there was no significant difference in good to excellent improvement in the long term (6 months after start of treatment) (RR 0.94, 95% CI 0.78 to 1.14; 1 study, 289 participants; moderate‐quality evidence; <a href="./references#CD011368-fig-0004" title="">Analysis 1.1</a>; <a href="./full#CD011368-tbl-0004">summary of findings Table 4</a>). </p> <p>The single <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> trial compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel, and the authors reported this outcome using a 7‐point scale (0 = very much improved, 1 = much improved, 2 = minimally improved, 3 = no change, 4 = minimally worse, 5 = much worse, 6 = very much worse) at all terms (4, 8, and 12 weeks after start of treatment). The study authors compared the proportion of participants with ratings of 'much improved/very much improved' and there was a clear difference between groups in favour of benzoyl peroxide 3% + clindamycin 1% gel in the medium and long term. Short term: RR 0.74 (95% CI 0.54 to 1.02; 1 study, 221 participants); medium term: RR 0.72 (95% CI 0.55 to 0.95; 1 study, 221 participants); and long term: RR 0.75 (95% CI 0.57 to 0.99; 1 study, 221 participants) (<a href="./references#CD011368-fig-0004" title="">Analysis 1.1</a>). The quality of evidence was low (<a href="#CD011368-tbl-0014">Table 4</a>). </p> <div class="table" id="CD011368-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Azelaic acid compared to benzoyl peroxide/clindamycin</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to benzoyl peroxide/clindamycin for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> 11 study centres in Germany<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical benzoyl peroxide/clindamycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide/clindamycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> <br/><i>Much to very much improved</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>559 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b><br/>(318 to 553) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b> <br/>(0.57 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.15</p> <p>(0.43 to 3.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>559 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>693 per 1000</b><br/>(564 to 849) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> <br/>(1.01 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The common application site reactions include pruritus, pain, erythema and dryness.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>CDLQI</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The authors reported that a greater mean (SD) change in CDLQI was noted with benzoyl peroxide 3% + clindamycin 1% gel (‐60.5% ± 70.6, n = 107) versus azelaic acid 20% cream (‐36.8% ± 74.8, n = 108). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDLQI</b> : Children's Dermatology Life Quality Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and with unclear risk of allocation concealment and other bias. One level for imprecision: optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and with unclear allocation concealment and other bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of allocation concealment and other bias. One level for imprecision: total population size is less than 400 and wide CI.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> <p>We rated the findings measured in the long term as very low‐ to moderate‐quality evidence due to risk of bias and/or imprecision (<a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>; <a href="#CD011368-tbl-0014">Table 4</a>; <a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011368-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD011368-sec-0084"> <h5 class="title">Withdrawal for any reason</h5> <p>For this outcome, two studies compared azelaic acid with adapalene (<a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a>; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>), and there was no clear difference in the short term (RR 0.80, 95% CI 0.05 to 12.01; 1 study, 45 participants) and long term (12 weeks after start of treatment) (RR 2.64, 95% CI 0.33 to 20.99; 1 study, 55 participants) (<a href="./references#CD011368-fig-0005" title="">Analysis 1.2</a>). The quality of evidence was very low (<a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>). When azelaic acid was compared with benzoyl peroxide (<a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a>; <a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a>), there was also no clear difference in the short term (RR 0.40, 95% CI 0.04 to 4.10; 1 study, 45 participants) and long term (16 weeks after start of treatment) (RR 0.88, 95% CI 0.60 to 1.29; 1 study, 351 participants) (<a href="./references#CD011368-fig-0005" title="">Analysis 1.2</a>). The quality of evidence was low (<a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>). When azelaic acid was compared with clindamycin, one study reported no withdrawals in the medium term (<a href="./references#CD011368-bbs2-0035" title="OzkanM , DurmazG , SabuncuI , SaracogluN , AkgunY , UrerSM . Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative staphylococci. Turkish Journal of Medical Sciences2000;30(5):483-7. [CENTRAL: CN-00424538] ">Ozkan 2000</a>). Another two studies compared azelaic acid with clindamycin in the long term (treatment duration over 12 weeks) (<a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a>; <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>), there was no clear difference (RR 1.30, 95% CI 0.48 to 3.56; 2 studies, 329 participants; low‐quality evidence; <a href="./references#CD011368-fig-0005" title="">Analysis 1.2</a>; <a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>). When azelaic acid was compared with metronidazole, one study reported no withdrawals in the long term (12 weeks after start of treatment) (<a href="./references#CD011368-fig-0005" title="">Analysis 1.2</a>). When 20% azelaic acid cream was compared with 0.05% tretinoin cream (<a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a>; <a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a>), there was no statistically significant difference in the long term (treatment duration over 12 weeks) (RR 0.66, 95% CI 0.29 to 1.47; 2 studies, 309 participants; low‐quality evidence; <a href="./references#CD011368-fig-0005" title="">Analysis 1.2</a>; <a href="./full#CD011368-tbl-0004">summary of findings Table 4</a>). When azelaic acid 20% cream was compared with benzoyl peroxide 3% + clindamycin 1% gel (<a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>), there was also no clear difference in the long term (12 weeks after start of treatment) (RR 1.15, 95% CI 0.43 to 3.07; 1 study, 221 participants; low‐quality evidence; <a href="./references#CD011368-fig-0005" title="">Analysis 1.2</a>; <a href="#CD011368-tbl-0014">Table 4</a>). </p> <p>We rated the findings measured in the long term as very low‐ to low‐quality of evidence due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>; <a href="#CD011368-tbl-0014">Table 4</a>; <a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011368-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD011368-sec-0085"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0086"> <h6 class="title">Total (percentage reduction from baseline)</h6> <p>One study comparing azelaic acid 5% gel with clindamycin 2% gel contributed data for this outcome (<a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>). Clindamycin had an advantage over azelaic acid in reducing total lesion counts in the short term (mean difference (MD) ‐12.03, 95% CI ‐13.01 to ‐11.05; 1 study, 100 participants; <a href="./references#CD011368-fig-0006" title="">Analysis 1.3</a>), medium term (MD ‐14.41, 95% CI ‐15.47 to ‐13.35; 1 study, 96 participants; <a href="./references#CD011368-fig-0006" title="">Analysis 1.3</a>), and long term (12 weeks after start of treatment) (MD ‐11.95, 95% CI ‐13.28 to ‐10.62; 1 study, 88 participants; <a href="./references#CD011368-fig-0006" title="">Analysis 1.3</a>). The differences were statistically significant. </p> <p>Another trial compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel (<a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>). There was a clear difference for all treatment terms (4, 8 and 12 weeks after start of treatment) in favour of benzoyl peroxide 3% + clindamycin 1% gel. Short term: MD ‐13.00 (95% CI ‐19.23 to ‐6.77; 1 study, 212 participants); medium term: MD ‐15.10 (95% CI ‐23.01 to ‐7.19; 1 study, 206 participants); and long term: MD ‐18.50 (95% CI ‐26.46 to ‐10.54; 1 study, 211 participants) (<a href="./references#CD011368-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD011368-sec-0087"> <h6 class="title">Total</h6> <p>Only <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> compared azelaic acid 15% gel with adapalene 0.1% gel reported the data in the long term (3 months after start of treatment); however, the data were skewed and we could therefore not present the data in a forest plot and instead presented it in a table (see table in <a href="./references#CD011368-fig-0007" title="">Analysis 1.4</a>). There was no statistically significant difference between the azelaic acid and adapalene group in percentage reduction from baseline (P = 0.396). </p> <p>In one study with no usable outcome data (<a href="./references#CD011368-bbs2-0035" title="OzkanM , DurmazG , SabuncuI , SaracogluN , AkgunY , UrerSM . Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative staphylococci. Turkish Journal of Medical Sciences2000;30(5):483-7. [CENTRAL: CN-00424538] ">Ozkan 2000</a>), the authors stated that azelaic acid (form and concentration unknown) was more effective in reducing acne grade, assessed using the Leeds' technique, when compared to clindamycin phosphate (concentration unknown). </p> </section> <section id="CD011368-sec-0088"> <h6 class="title">Inflamed (percentage reduction from baseline)</h6> <p>The single <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> trial compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel. There was a clear difference between groups at all treatment terms (4, 8 and 12 weeks after start of treatment) in favour of benzoyl peroxide 3% + clindamycin 1% gel. Short term: MD ‐14.10 (95% CI ‐22.02 to ‐6.16; 1 study, 212 participants); medium term: MD ‐15.90 (95% CI ‐23.74 to ‐8.06; 1 study, 2016 participants); and long term: MD ‐17.30 (95% CI ‐24.73 to ‐9.87; 1 study, 211 participants) (<a href="./references#CD011368-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD011368-sec-0089"> <h6 class="title">Inflamed (number of lesions post‐intervention)</h6> <p>The single <a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> trial compared azelaic acid (form and concentration unknown) with adapalene and benzoyl peroxide. There was no clear difference between azelaic acid and adapalene (MD 0.00, 95% CI ‐2.47 to 2.47; 1 study, 43 participants; <a href="./references#CD011368-fig-0009" title="">Analysis 1.6</a>) or benzoyl peroxide (MD ‐0.10, 95% CI ‐2.54 to 2.34; 1 study, 42 participants; <a href="./references#CD011368-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD011368-sec-0090"> <h6 class="title">Inflamed</h6> <p>Five studies reported data for this outcome; however, the data were not available for meta‐analysis, so we presented the data in <a href="./references#CD011368-fig-0010" title="">Analysis 1.7</a>. <a href="./references#CD011368-bbs2-0002" title="AksakalAB , KoruyucuM , OnderM , OztasMO , GurerMA . A comparative study of metronidazole 1% cream versus azelaic acid 20% cream in the treatment of acne. Gazi Medical Journal1997;8(4):144-7. [CENTRAL: CN-00195442] ">Aksakal 1997</a> only reported the P value; the authors reported that azelaic acid 20% cream was more effective in reducing inflamed lesions when compared to metronidazole 1% cream (P &lt; 0.001). Results from <a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a> demonstrated the significant advantage of 3% erythromycin/5% benzoyl peroxide over 20% azelaic acid in reducing inflammatory lesions. The authors from <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> reported that the median percentage reduction of inflamed lesions was 70% in the azelaic acid 15% gel group and 77% in the benzoyl peroxide 5% gel group (P &gt; 0.05). Authors from <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> reported that the median percentage reduction of inflamed lesions was 71% in the azelaic acid 15% gel group and 63% in the clindamycin 1% gel group (P &gt; 0.05). Data from <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> were skewed and the authors compared azelaic acid 15% gel with adapalene 0.1% gel; there was no significant difference between groups in percentage change of inflamed lesions in the long term (3 months after start of treatment) (P = 0.816). </p> </section> <section id="CD011368-sec-0091"> <h6 class="title">Papules (percentage reduction from baseline)</h6> <p>Only one study that compared azelaic acid 5% gel with clindamycin 2% gel contributed data for this outcome (<a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>). Clindamycin 2% gel had an advantage over azelaic acid 5% gel in reducing the papular lesion count in the short term (MD ‐23.74, 95% CI ‐24.54 to ‐22.94; 1 study, 100 participants; <a href="./references#CD011368-fig-0011" title="">Analysis 1.8</a>), medium term (MD ‐34.25, 95% CI ‐35.51 to ‐32.99; 1 study, 96 participants; <a href="./references#CD011368-fig-0011" title="">Analysis 1.8</a>) and long term (12 weeks after start of treatment) (MD ‐25.03, 95% CI ‐26.38 to ‐23.68; 1 study, 88 participants; <a href="./references#CD011368-fig-0011" title="">Analysis 1.8</a>). The differences were statistically significant. </p> </section> <section id="CD011368-sec-0092"> <h6 class="title">Papules (number of lesions post‐intervention)</h6> <p>Only one study that compared azelaic acid 20% gel with erythromycin 2% gel contributed data for this outcome (<a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>). Participants in the erythromycin 2% gel group had less papules post‐intervention than those in the azelaic acid 20% gel group in the short term (MD 3.40, 95% CI 2.99 to 3.81; 1 study, 66 participants; <a href="./references#CD011368-fig-0012" title="">Analysis 1.9</a>), and medium term (MD 2.05, 95% CI 1.60 to 2.50; 1 study, 66 participants; <a href="./references#CD011368-fig-0012" title="">Analysis 1.9</a>). The difference was statistically significant. There was no clear difference between topical azelaic acid 20% gel and erythromycin 2% gel in the long term (12 weeks after start of treatment) (MD ‐0.17, 95% CI ‐0.36 to 0.02; 1 study, 66 participants; <a href="./references#CD011368-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD011368-sec-0093"> <h6 class="title">Pustules (percentage reduction from baseline)</h6> <p>Only one study that compared azelaic acid 5% gel with clindamycin 2% gel contributed data for this outcome (<a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>). Clindamycin 2% gel was better than azelaic acid 5% gel in reducing the pustular lesion count in the short term (MD ‐6.53, 95% CI ‐7.45 to ‐5.61; 1 study, 100 participants; <a href="./references#CD011368-fig-0013" title="">Analysis 1.10</a>), medium term (MD ‐9.07, 95% CI ‐10.42 to ‐7.72; 1 study, 96 participants; <a href="./references#CD011368-fig-0013" title="">Analysis 1.10</a>), and long term (12 weeks after start of treatment) (MD ‐9.71, 95% CI ‐11.33 to ‐8.09; 1 study, 88 participants; <a href="./references#CD011368-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD011368-sec-0094"> <h6 class="title">Pustules (number of lesions post‐intervention)</h6> <p>Only one study that compared azelaic acid 20% gel with erythromycin 2% gel contributed data for this outcome (<a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>). There was a difference between topical azelaic acid 20% gel and erythromycin 2% gel in the short term (MD ‐2.31, 95% CI ‐2.64 to ‐1.98; 1 study, 66 participants; <a href="./references#CD011368-fig-0014" title="">Analysis 1.11</a>), medium term (MD ‐2.95, 95% CI ‐3.24 to ‐2.66; 1 study, 66 participants; <a href="./references#CD011368-fig-0014" title="">Analysis 1.11</a>), and long term (12 weeks after start of treatment) (MD ‐1.80, 95% CI ‐1.97 to ‐1.63; 1 study, 66 participants; <a href="./references#CD011368-fig-0014" title="">Analysis 1.11</a>), which were all in favour of azelaic acid 20% gel. </p> </section> <section id="CD011368-sec-0095"> <h6 class="title">Non‐inflamed</h6> <p>We found five relevant trials that collected data for this outcome; however, the data were not available for meta‐analysis, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0015" title="">Analysis 1.12</a>). <a href="./references#CD011368-bbs2-0002" title="AksakalAB , KoruyucuM , OnderM , OztasMO , GurerMA . A comparative study of metronidazole 1% cream versus azelaic acid 20% cream in the treatment of acne. Gazi Medical Journal1997;8(4):144-7. [CENTRAL: CN-00195442] ">Aksakal 1997</a> only reported the P value; the authors reported that azelaic acid 20% cream was more effective in reducing non‐inflamed lesions when compared to metronidazole 1% cream (P &lt; 0.001). <a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a> compared 20% azelaic acid cream with 0.05% retinoic acid cream; the authors did not report the P value and MDs. Results from <a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a> demonstrated significant advantage of 3% erythromycin/5% benzoyl peroxide over 20% azelaic acid in reducing comedones. The authors from <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> reported that the median percentage reduction of non‐inflamed lesions was 60% in the azelaic acid 15% gel group and 71% in the benzoyl peroxide 5% gel group (P &gt; 0.05). Authors from <a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> reported that the median percentage reduction of non‐inflamed lesions was 57% in the azelaic acid 15% gel group and 45% in the clindamycin 1% gel group (P &lt; 0.05). Data from <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> were skewed and results also showed that there was no significant difference in percentage reduction of non‐inflamed lesions (P = 0.063) or microcomedones (P = 0.25) in the long term (3 months after start of treatment) between azelaic acid 15% gel and adapalene 0.1% gel. </p> </section> <section id="CD011368-sec-0096"> <h6 class="title">Non‐inflamed (percentage reduction from baseline)</h6> <p>One study that compared azelaic acid 5% gel with clindamycin 2% gel contributed data for this outcome (<a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a>). Clindamycin 2% gel was better than azelaic acid 5% gel in reducing the non‐inflamed lesion (comedones) count in the short term (MD ‐5.81, 95% CI ‐6.80 to ‐4.82; 1 study, 100 participants; <a href="./references#CD011368-fig-0016" title="">Analysis 1.13</a>); however, this clear advantage was not observed in the medium term (MD 0.11, 95% CI ‐1.24 to 1.46; 1 study, 96 participants; <a href="./references#CD011368-fig-0016" title="">Analysis 1.13</a>) and long term (12 weeks after start of treatment) (MD ‐1.11, 95% CI ‐2.91 to 0.69; 1 study, 88 participants; <a href="./references#CD011368-fig-0016" title="">Analysis 1.13</a>). </p> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel. There was a clear difference between groups for all treatment terms (4, 8 and 12 weeks after start of treatment) in favour of benzoyl peroxide 3% + clindamycin 1% gel. Short term: MD ‐11.10 (95% CI ‐18.64 to ‐3.56; 1 study, 212 participants); medium term: MD ‐13.00 (95% CI ‐22.76 to ‐3.24; 1 study, 206 participants); and long term: MD ‐18.50 (95% CI ‐28.33 to ‐8.67; 1 study, 211 participants) (<a href="./references#CD011368-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD011368-sec-0097"> <h6 class="title">Non‐inflamed (number of lesions post‐intervention)</h6> <p>One study compared azelaic acid 20% gel with erythromycin 2% gel (<a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>). There was a difference between topical azelaic acid 20% gel and erythromycin 2% gel in the short term (MD ‐2.68, 95% CI ‐2.89 to ‐2.47; 1 study, 66 participants; <a href="./references#CD011368-fig-0017" title="">Analysis 1.14</a>), medium term (MD ‐1.80, 95% CI ‐2.10 to ‐1.50; 1 study, 66 participants; <a href="./references#CD011368-fig-0017" title="">Analysis 1.14</a>) and long term (12 weeks after start of treatment) (MD ‐2.07, 95% CI ‐2.25 to ‐1.89; 1 study, 66 participants; <a href="./references#CD011368-fig-0017" title="">Analysis 1.14</a>), which were all in favour of azelaic acid 20% gel. </p> <p>Another study compared azelaic acid (form and concentration unknown) with benzoyl peroxide and adapalene (<a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a>). There was no clear difference between azelaic acid and adapalene in the medium term (MD ‐3.00, 95% CI ‐8.07 to 2.07; 1 study, 43 participants; <a href="./references#CD011368-fig-0017" title="">Analysis 1.14</a>). In addition, there was also no clear difference between azelaic acid and benzoyl peroxide in the medium term (MD ‐4.40, 95% CI ‐10.77 to 1.97; 1 study, 42 participants; <a href="./references#CD011368-fig-0017" title="">Analysis 1.14</a>). </p> </section> </section> <section id="CD011368-sec-0098"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p>For this outcome, no data reported in the short and medium term. <a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> assessed the outcome using a four‐point Likert‐type rating scale (very good, good, moderate, poor). Study authors compared azelaic acid 15% gel with benzoyl peroxide 5% gel, and the benzoyl peroxide group demonstrated a statistically significant good or very good improvement in the long term (4 months after start of treatment) (RR 0.84, 95% CI 0.74 to 0.96; 1 study, 351 participants; <a href="./references#CD011368-fig-0018" title="">Analysis 1.15</a>). </p> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> assessed the outcome using a four‐point Likert‐type rating scale (very good, good, moderate, poor). Study authors compared azelaic acid 15% gel with clindamycin 1% gel in good or very good improvement in the long term (4 months after start of treatment), and there was no significant difference (RR 0.92, 95% CI 0.78 to 1.10; 1 study, 229 participants; <a href="./references#CD011368-fig-0018" title="">Analysis 1.15</a>). Only <a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> compared azelaic acid 20% cream with tretinoin 0.05% cream in good to excellent improvement in the long term (6 months after start of treatment), and there was no significant difference (RR 0.94, 95% CI 0.80 to 1.11; 1 study, 289 participants; <a href="./references#CD011368-fig-0018" title="">Analysis 1.15</a>). </p> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel and the authors reported this outcome using a six‐point scale (6 points from clear (0) to very clear (5)) for all treatment terms (4, 8 and 12 weeks after start of treatment). There was a clear significant difference in the medium term (RR 0.54, 95% CI 0.31 to 0.95; 1 study, 221 participants) and long term (RR 0.53, 95% CI 0.33 to 0.87; 1 study, 221 participants), which was in favour of benzoyl peroxide 3% + clindamycin 1% gel group. But there was no clear difference in the short term (RR 0.58, 95% CI 0.29 to 1.17; 1 study, 221 participants) (<a href="./references#CD011368-fig-0018" title="">Analysis 1.15</a>). </p> <p><a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a> had no usable outcome data and the authors stated that azelaic acid 20% cream was less effective in physician global evaluation when compared to 3% erythromycin/5% benzoyl peroxide gel. The authors also stated that azelaic acid 20% cream was inferior to 3% erythromycin/5% benzoyl peroxide gel in overall acne condition improvement and reduction of inflammatory lesions and comedones. </p> </section> <section id="CD011368-sec-0099"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0100"> <h6 class="title">Total events ‐ azelaic acid versus adapalene</h6> <p><a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> reported no "significant difference" between topical azelaic acid 15% gel and adapalene 1% gel (RR 1.16, 95% CI 0.47 to 2.85; 1 study, 55 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). We rated this finding as very low‐quality evidence due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD011368-sec-0101"> <h6 class="title">Total events ‐ azelaic acid versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0007" title="CavicchiniS , CaputoR . Long-term treatment of acne with 20% azelaic acid cream. Acta Dermato-venereologica. Supplementum1989;69(143):40-4. [CENTRAL: CN-00351262] ">Cavicchini 1989</a> reported that one out of 15 people in the azelaic acid 20% cream group versus two out of 15 people in the benzoyl peroxide 5% gel group experienced minor adverse events (P = 1.00, Fisher's Exact test). There was no clear difference between topical azelaic acid 20% cream and benzoyl peroxide 5% gel (RR 0.50, 95% CI 0.05 to 4.94; 1 study, 30 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). We rated this finding as very low‐quality evidence due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD011368-sec-0102"> <h6 class="title">Total events ‐ azelaic acid versus benzoyl + clindamycin</h6> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel. The participants who received benzoyl peroxide 3% + clindamycin 1% gel experienced fewer total number of events, though there was no clear significant difference (RR 1.24, 95% CI 1.01 to 1.52; 1 study, 221 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). We rated this finding as low‐quality evidence due to risk of bias and imprecision (<a href="#CD011368-tbl-0014">Table 4</a>). </p> </section> <section id="CD011368-sec-0103"> <h6 class="title">Total events ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> compared azelaic acid 5% gel with clindamycin 2% gel. There was no clear difference between treatment groups (RR 1.50, 95% CI 0.67 to 3.35; 1 study, 100 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). We rated this finding as low‐quality evidence due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD011368-sec-0104"> <h6 class="title">Total events ‐ azelaic acid versus erythromycin</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that 16 out of 35 people in the azelaic acid 20% gel group versus 17 out of 31 people in the erythromycin 2% gel group experienced total events. There was no significant difference between topical azelaic acid 20% gel and erythromycin 2% gel (RR 0.83, 95% CI 0.51 to 1.35; 1 study, 66 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0105"> <h6 class="title">Application site pain ‐ azelaic acid versus benzoyl + clindamycin</h6> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel. There was a significant difference between groups showing azelaic acid caused more application site pain (RR 3.17, 95% CI 1.41 to 7.12; 1 study, 221 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0106"> <h6 class="title">Burning ‐ azelaic acid versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> showed there was no significant difference between topical azelaic acid 15% gel and benzoyl peroxide 5% gel (RR 1.10, 95% CI 0.61 to 1.97; 1 study, 351 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0107"> <h6 class="title">Burning ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> reported burning in 12/114 participants in the azelaic acid 15% gel treatment group compared to 0/115 participants in the clindamycin 1% gel group. There was a significant difference between groups, showing azelaic acid caused more burning (RR 25.22, 95% CI 1.51 to 420.92; 1 study, 229 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>), but the confidence interval was very wide. </p> </section> <section id="CD011368-sec-0108"> <h6 class="title">Burning ‐ azelaic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> reported no significant difference between topical azelaic acid 20% cream and tretinoin 0.05% cream (RR 0.80, 95% CI 0.38 to 1.71; 1 study, 289 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0109"> <h6 class="title">Scaling ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that four out of 50 people in the azelaic acid 5% gel group versus six out of 50 people in the clindamycin 2% gel group experienced scaling (P = 0.741, Fisher's Exact test). There was no significant difference between topical azelaic acid 5% gel and clindamycin 2% gel (RR 0.67, 95% CI 0.20 to 2.22; 1 study, 100 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0110"> <h6 class="title">Scaling ‐ azelaic acid versus erythromycin</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that four out of 35 people in the azelaic acid 20% gel group versus two out of 31 people in the erythromycin 2% gel group experienced scaling (P = 0.68, Fisher's Exact test). There was no significant difference between topical azelaic acid 20% gel and erythromycin 2% gel (RR 1.77, 95% CI 0.35 to 9.01; 1 study, 66 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0111"> <h6 class="title">Scaling ‐ azelaic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> reported that topical azelaic acid 20% cream had lower risk of scaling than tretinoin 0.05% cream (RR 0.58, 95% CI 0.37 to 0.91; 1 study, 289 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). This difference was statistically different. </p> </section> <section id="CD011368-sec-0112"> <h6 class="title">Erythema ‐ azelaic acid versus adapalene</h6> <p><a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> reported no significant difference between topical azelaic acid (form and concentration unknown) and adapalene (RR 0.80, 95% CI 0.30 to 2.10; 1 study, 45 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0113"> <h6 class="title">Erythema ‐ azelaic acid versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> reported no significant difference between topical azelaic acid (form and concentration unknown) and benzoyl peroxide (RR 0.48, 95% CI 0.21 to 1.09; 1 study, 45 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0114"> <h6 class="title">Erythema ‐ azelaic acid versus benzoyl peroxide/clindamycin</h6> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> reported no significant difference between topical azelaic acid 20% cream and benzoyl peroxide 3% + clindamycin 1% gel (RR 1.68, 95% CI 0.41 to 6.87; 1 study, 221 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0115"> <h6 class="title">Erythema ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that three out of 50 people in the azelaic acid 5% gel group versus four out of 50 people in the clindamycin 2% gel group experienced erythema (P = 1.00, Fisher's Exact test). There was no significant difference between topical azelaic acid 5% gel and clindamycin 2% gel (RR 0.75, 95% CI 0.18 to 3.18; 1 study, 100 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0116"> <h6 class="title">Erythema ‐ azelaic acid versus erythromycin</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that three out of 35 people in the azelaic acid 20% gel group versus four out of 31 people in the erythromycin 2% gel group experienced erythema (P = 0.70, Fisher's Exact test). There was no significant difference between topical azelaic acid 20% gel and erythromycin 2% gel (RR 0.66, 95% CI 0.16 to 2.74; 1 study, 66 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0117"> <h6 class="title">Erythema ‐ azelaic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> reported that topical azelaic acid 20% cream had lower risk of erythema than tretinoin 0.05% cream (RR 0.64, 95% CI 0.41 to 0.99; 1 study, 289 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>), and this difference was statistically significant. </p> </section> <section id="CD011368-sec-0118"> <h6 class="title">Dryness ‐ azelaic acid versus adapalene</h6> <p><a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> reported no significant difference between topical azelaic acid (form and concentration unknown) and adapalene (RR 0.80, 95% CI 0.51 to 1.26; 1 study, 45 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0119"> <h6 class="title">Dryness ‐ azelaic acid versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> and <a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> reported no significant difference between topical azelaic acid and benzoyl peroxide (RR 0.56, 95% CI 0.27 to 1.16; 2 studies, 396 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0120"> <h6 class="title">Dryness ‐ azelaic acid versus benzoyl peroxide/clindamycin</h6> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> reported no significant difference between topical azelaic acid 20% cream and benzoyl peroxide 3% + clindamycin 1% gel (RR 1.51, 95% CI 0.26 to 8.88; 1 study, 221 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0121"> <h6 class="title">Dryness ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported no significant difference between topical azelaic acid and clindamycin (RR 2.44, 95% CI 0.96 to 6.19; 2 studies, 329 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0122"> <h6 class="title">Dryness ‐ azelaic acid versus erythromycin</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that two out of 35 people in the azelaic acid 20% gel group versus four out of 31 people in the erythromycin 2% gel group experienced dryness (P = 0.41, Fisher's Exact test). There was no significant difference between topical azelaic acid 20% gel and erythromycin 2% gel (RR 0.44, 95% CI 0.09 to 2.25; 1 study, 66 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0123"> <h6 class="title">Oiliness ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that five out of 50 people in the azelaic acid 5% gel group versus four out of 50 people in the clindamycin 2% gel group experienced oiliness (P = 1.00, Fisher's Exact test). There was no significant difference between topical azelaic acid 5% gel and clindamycin 2% gel (RR 1.25, 95% CI 0.36 to 4.38; 1 study, 100 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0124"> <h6 class="title">Oiliness ‐ azelaic acid versus erythromycin</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that three out of 35 people in the azelaic acid 20% gel group versus three out of 31 people in the erythromycin 2% gel group experienced oiliness (P = 1.00, Fisher's Exact test). There was no significant difference between topical azelaic acid 20% gel and erythromycin 2% gel (RR 0.89, 95% CI 0.19 to 4.07; 1 study, 66 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0125"> <h6 class="title">Itching ‐ azelaic acid versus adapalene</h6> <p><a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> reported no significant difference between topical azelaic acid (form and concentration unknown) and adapalene (RR 1.23, 95% CI 0.84 to 1.79; 1 study, 45 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0126"> <h6 class="title">Itching ‐ azelaic acid versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> and <a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> reported itching was higher in the azelaic acid group compared with the benzoyl peroxide group, but the RR was uncertain due to the wide CI spanning 1 (RR 3.29, 95% CI 0.24 to 45.29; 2 studies, 396 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0127"> <h6 class="title">Itching ‐ azelaic acid versus benzoyl peroxide/clindamycin</h6> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> reported a significant difference between groups, showing azelaic acid 20% cream caused more itching compared with benzoyl peroxide 3% + clindamycin 1% gel (RR 3.15, 95% CI 1.49 to 6.68; 1 study, 221 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0128"> <h6 class="title">Itching ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported more itching in the azelaic acid group compared with the clindamycin group, but the RR was uncertain due to the wide CI spanning 1 (RR 2.56, 95% CI 0.68 to 9.57; 2 studies, 329 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0129"> <h6 class="title">Itching ‐ azelaic acid versus erythromycin</h6> <p>Some studies, for example <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a>, reported this outcome as 'pruritus'. We contacted authors to confirm whether 'pruritus' was equal to 'itching'; authors from <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> replied they were the same thing. Therefore, we considered 'pruritus' and 'itching' to be the same thing and we used 'itching' throughout the text. </p> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that four out of 35 people in the azelaic acid 20% gel group versus three out of 31 people in the erythromycin 2% gel group experienced itching (P = 1.00, Fisher's Exact test). There was no significant difference between topical azelaic acid 20% gel and erythromycin 2% gel (RR 1.18, 95% CI 0.29 to 4.87; 1 study, 66 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0130"> <h6 class="title">Red skin ‐ azelaic acid versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> reported no significant difference between topical azelaic acid 15% gel and benzoyl peroxide 5% gel (RR 0.68, 95% CI 0.36 to 1.26; 1 study, 351 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011368-sec-0131"> <h6 class="title">Red skin ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> reported that topical azelaic acid 15% gel had a higher risk of red skin than clindamycin 1% gel (RR 6.05, 95% CI 1.39 to 26.44; 1 study, 229 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>), and the difference was statistically significant. </p> </section> <section id="CD011368-sec-0132"> <h6 class="title">Desquamation ‐ azelaic acid versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> reported a statistically significant difference between topical azelaic acid 15% gel and benzoyl peroxide 5% gel (RR 0.25, 95% CI 0.08 to 0.73; 1 study, 351 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>), which indicated a lower risk of desquamation after using azelaic acid. </p> </section> <section id="CD011368-sec-0133"> <h6 class="title">Eczema ‐ azelaic acid versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> reported that zero out of 114 people in the azelaic acid 15% gel group versus four out of 115 people in the clindamycin 1% gel group experienced eczema (P = 0.12, Fisher's Exact test). There was no clear difference between topical azelaic acid 15% gel and clindamycin 1% gel (RR 0.11, 95% CI 0.01 to 2.06; 1 study, 229 participants; <a href="./references#CD011368-fig-0019" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD011368-sec-0134"> <h5 class="title">Quality of life</h5> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> compared azelaic acid 20% cream with benzoyl peroxide 3% + clindamycin 1% gel (12 weeks after start of treatment) using the 10‐question Children's Dermatology Life Quality Index (CDLQI; 0 = not at all, 1 = a little, 2 = a lot, 3 = very much, low = well) to assess how much the skin disease affected participants' lives. The percentage change from baseline (skewed data) was in favour of benzoyl peroxide 3% + clindamycin 1% gel (‐36.8% ± 74.8 in azelaic acid group versus ‐60.5% ± 70.6 in benzoyl peroxide + clindamycin group). The quality of evidence was low (<a href="#CD011368-tbl-0014">Table 4</a>). </p> <p><a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> compared azelaic acid 15% gel with adapalene 0.1% gel; we were unable to present the skewed data from this study in a forest plot, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0020" title="">Analysis 1.17</a>). There was no "statistically significant" difference (P = 0.549) in absolute change of Dermatology Life Quality Index in the long term (3 months after start of treatment) between azelaic acid and adapalene (‐1.88 ± 3.35 and ‐2.74 ± 2.90 in azelaic acid group versus ‐2.58 ± 4.68 in adapalene group). The quality of evidence was very low (<a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> <section id="CD011368-sec-0135"> <h4 class="title">Comparison 2: topical azelaic acid versus placebo</h4> <section id="CD011368-sec-0136"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p>No study collected data for this outcome.</p> </section> <section id="CD011368-sec-0137"> <h5 class="title">Withdrawal for any reason</h5> <p>One trial compared azelaic acid 20% gel with placebo (<a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a>), neither treatment group experienced withdrawals in the medium term (<a href="./references#CD011368-fig-0021" title="">Analysis 2.1</a>). Three relevant trials reported data in the long term (<a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a>; <a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>; <a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a>). There was no clear difference between topical azelaic acid 20% cream and placebo cream in the long term (treatment duration more than 8 weeks) (RR 1.60, 95% CI 0.55 to 4.66; 3 studies, 152 participants; low‐quality evidence; <a href="./references#CD011368-fig-0021" title="">Analysis 2.1</a>; <a href="#CD011368-tbl-0015">Table 5</a>), and two of the three studies reporting zero events. </p> <div class="table" id="CD011368-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Azelaic acid compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to placebo for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described (4 studies)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/>(35 to 295) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.60</b> <br/>(0.55 to 4.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 19.00</b><br/>(1.16 to 312.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/30 versus 0/30 experienced minor adverse events. In the other studies in this comparison, events such as scaling, dry skin, erythema, oiliness, and pruritus were reported, but the number of participants with these events were low and similar across groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: three studies included, two with unclear risk of selection bias and one with unclear risk of allocation concealment, one study with high risk of reporting bias and one with high risk of attrition bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, and study with unclear random sequence generation and allocation concealment. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> </section> <section id="CD011368-sec-0138"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0139"> <h6 class="title">&gt; 50% inflamed reduction</h6> <p>For this outcome, we only found one relevant trial that reported data in the long term (3 months after start of treatment) (<a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>). The study stated that 10 participants using azelaic acid 20% cream demonstrated a reduction of at least 50% in inflamed lesions, compared to only one participant using placebo cream by the end of study (RR 10.00, 95% CI 1.41 to 70.99; 1 study, 40 participants; <a href="./references#CD011368-fig-0022" title="">Analysis 2.2</a>). However, the result had serious imprecision due to a very small sample size. </p> </section> <section id="CD011368-sec-0140"> <h6 class="title">Inflamed (percentage reduction from baseline)</h6> <p>Three studies reported data for this outcome in the short, medium and long term (<a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>; <a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>; <a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a>). <a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a> and <a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> were parallel trials and <a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a> was a split‐face trial. As there were no means ± standard deviations (SDs) or SDs presented, we described the data in a table (see table in <a href="./references#CD011368-fig-0023" title="">Analysis 2.3</a>). All three studies concluded that compared to placebo, azelaic acid showed a greater percentage reduction in inflamed lesions in the short, medium, and long term (3 months after start of treatment). </p> </section> <section id="CD011368-sec-0141"> <h6 class="title">&gt; 50% non‐inflamed reduction</h6> <p>We only found one relevant trial and it reported data in the long term (3 months after start of treatment) (<a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>). By the end of study, a higher rate of &gt; 50% non‐inflamed reduction was observed in the azelaic acid group 20% cream (11/20) than in the placebo cream group (4/20) (RR 2.75, 95% CI 1.05 to 7.20; 1 study, 40 participants; <a href="./references#CD011368-fig-0024" title="">Analysis 2.4</a>). However, the result had serious imprecision due to a very small sample size. </p> </section> <section id="CD011368-sec-0142"> <h6 class="title">Non‐inflamed (percentage reduction from baseline)</h6> <p><a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a> reported data over the medium and long term (3 months after start of treatment); however, the authors only reported the P value with no means and SDs, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0025" title="">Analysis 2.5</a>). When compared to placebo cream, the azelaic acid 20% cream showed a greater percentage reduction in non‐inflamed lesions in the medium (P &lt; 0.027) and long term (P &lt; 0.027). The other split‐face study only reported the percentage reduction with no SDs and P value (<a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>; <a href="./references#CD011368-fig-0025" title="">Analysis 2.5</a>). </p> </section> <section id="CD011368-sec-0143"> <h6 class="title">Various types of acne (percentage reduction from baseline)</h6> <p>Three studies reported data for medium and long term outcomes (<a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>; <a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a>; <a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a>); however, as the SDs were missing, we presented the data in a table (see table in <a href="./references#CD011368-fig-0026" title="">Analysis 2.6</a>). Apart from pustule number (the percentage reduction was greater in the azelaic acid group, P = 0.08), azelaic acid 20% gel showed a better effect in percentage reduction of total lesion numbers (P = 0.002), comedone numbers (P = 0.001), papule numbers (P = 0.003), and acne severity index (P = 0.001), when compared to placebo in the medium term (<a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a>). There was also a significant difference between azelaic acid 20% cream and placebo cream in comedone percentage reduction in the long term (3 months after start of treatment) (55.6% for azelaic acid, 0% for placebo) in favour of azelaic acid 20% cream (no exact P value reported) (<a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a>). Another split‐face study (<a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a>), also suggested the advantage of topical azelaic acid 20% cream over placebo in total lesion reduction in the long term (12 weeks after start of treatment) (P &lt; 0.001). </p> </section> <section id="CD011368-sec-0144"> <h6 class="title">Various types of acne (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported short‐term data. However, the number of participants in the azelaic acid group was missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0027" title="">Analysis 2.7</a>). The azelaic acid 20% gel group showed lower papule numbers (P &lt; 0.001), pustule numbers (P &lt; 0.001), and comedone numbers (P &lt; 0.001) when compared with placebo after treatment. </p> </section> <section id="CD011368-sec-0145"> <h6 class="title">Comedones (reduction in number of lesions post‐intervention)</h6> <p>Only <a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a> reported data for this outcome and SDs were missing. The azelaic acid 20% cream reduced more lesion counts than placebo treatment in the long term (4 months after start of treatment); however, the authors did not test whether the difference was significant (<a href="./references#CD011368-fig-0028" title="">Analysis 2.8</a>). In addition, azelaic acid 20% cream showed better effect in reducing comedones (measured by scanning electron microscopy) than placebo in the long term (4 months after start of treatment) (<a href="./references#CD011368-fig-0028" title="">Analysis 2.8</a>). </p> </section> </section> <section id="CD011368-sec-0146"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> reported data in the long term (3 months after start of treatment). The authors assessed this outcome using a four‐point system (75% to 100% reduction of the initial total lesion count: excellent; 50% to 75% reduction: good; 25% to 50% reduction: moderate; less than 25%: poor response). There was a statistically significant difference between topical azelaic acid 20% cream and placebo cream in good to excellent improvement (RR 1.64, 95% CI 1.00 to 2.67; 1 study, 92 participants; <a href="./references#CD011368-fig-0029" title="">Analysis 2.9</a>), which was in favour of azelaic acid 20% cream. However, the estimated result was fairly imprecise due to the small sample size. </p> </section> <section id="CD011368-sec-0147"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0148"> <h6 class="title">Burning</h6> <p><a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> reported that four out of 43 people in the azelaic acid 20% cream group versus one out of 49 people in the placebo cream group experienced burning (P = 0.18, Fisher's Exact test). Burning was reported more in the topical azelaic acid 20% cream group compared with the placebo cream but the RR was imprecise due to the uncertainty from the wide CI (RR 4.56, 95% CI 0.53 to 39.24; 1 study, 92 participants; <a href="./references#CD011368-fig-0030" title="">Analysis 2.10</a>). </p> </section> <section id="CD011368-sec-0149"> <h6 class="title">Scaling</h6> <p><a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> and <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that five out of 78 people in the azelaic acid group versus two out of 69 people in the placebo group experienced scaling (P = 0.448, Fisher's Exact test). There was no clear difference between topical azelaic acid and placebo due to the wide CIs surrounding the effect size (RR 1.49, 95% CI 0.16 to 13.48; 2 studies, 147 participants; <a href="./references#CD011368-fig-0030" title="">Analysis 2.10</a>). </p> </section> <section id="CD011368-sec-0150"> <h6 class="title">Erythema</h6> <p><a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> and <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that five out of 78 people in the azelaic acid group versus two out of 69 people in the placebo group experienced erythema (P = 0.448, Fisher's Exact test). There was no clear difference between topical azelaic acid and placebo (RR 1.96, 95% CI 0.39 to 9.78; 2 studies, 147 participants; <a href="./references#CD011368-fig-0030" title="">Analysis 2.10</a>). </p> </section> <section id="CD011368-sec-0151"> <h6 class="title">Dryness</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that two out of 35 people in the azelaic acid 20% gel group versus zero out of 20 people in the placebo group experienced dryness (P = 0.529, Fisher's Exact test). There was no significant difference between treatment groups (RR 2.92, 95% CI 0.15 to 57.90; 1 study, 55 participants; <a href="./references#CD011368-fig-0030" title="">Analysis 2.10</a>) </p> </section> <section id="CD011368-sec-0152"> <h6 class="title">Oiliness</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that three out of 35 people in the azelaic acid 20% gel group versus zero out of 20 people in the placebo group experienced oiliness (P = 0.293, Fisher's Exact test). There was no difference between treatment groups (RR 4.08, 95% CI 0.22 to 75.25; 1 study, 55 participants; <a href="./references#CD011368-fig-0030" title="">Analysis 2.10</a>) </p> </section> <section id="CD011368-sec-0153"> <h6 class="title">Itching</h6> <p><a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> and <a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported that six out of 78 people in the azelaic acid group versus zero out of 69 people in the placebo group experienced itching (P = 0.03, Fisher's Exact test). There was no clear difference between treatment groups (RR 5.45, 95% CI 0.68 to 43.53; 2 studies, 147 participants; <a href="./references#CD011368-fig-0030" title="">Analysis 2.10</a>). </p> </section> <section id="CD011368-sec-0154"> <h6 class="title">Total events</h6> <p><a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a> reported that nine out of 30 people in the azelaic acid 20% gel group versus zero out of 30 people in the placebo group experienced minor adverse events (P = 0.002, Fisher's Exact test). Result of meta‐analysis showed that topical azelaic acid 20% gel had a higher rate of adverse events than placebo (RR 19.00, 95% CI 1.16 to 312.42; 1 study, 60 participants; <a href="./references#CD011368-fig-0030" title="">Analysis 2.10</a>). However, the result was imprecise as the estimated CI was very wide. We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0015">Table 5</a>). </p> </section> </section> <section id="CD011368-sec-0155"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0156"> <h4 class="title">Comparison 3: topical azelaic acid versus no treatment (including studies with a co‐intervention in both arms) </h4> <section id="CD011368-sec-0157"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> assessed this outcome using a five‐point Likert‐type scale (very satisfied, satisfied, moderately satisfied, unsatisfied, very unsatisfied). We found no significant difference in moderately to very satisfied improvement between treatment groups in the long term (3 months after start of treatment) (RR 1.08, 95% CI 0.94 to 1.24; 2 studies, 171 participants; <a href="./references#CD011368-fig-0031" title="">Analysis 3.1</a>). </p> </section> <section id="CD011368-sec-0158"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> and <a href="./references#CD011368-bbs2-0038" title="PicosseFR , Dos Santos GuadanhimLR , NascimentoLS , PaivaJM , BagatinE . Azelaic acid as an option for maintenance treatment after oral isotretinoin: a comparative and longitudinal study-preliminary results. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB5. [EMBASE: 71894787]">Picosse 2015</a> found no statistically significant difference between topical azelaic acid and no treatment in the long term (treatment duration over 8 weeks) (RR 0.67, 95% CI 0.37 to 1.22; 2 studies, 150 participants; <a href="./references#CD011368-fig-0032" title="">Analysis 3.2</a>). </p> </section> <section id="CD011368-sec-0159"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0160"> <h6 class="title">Total (percentage reduction from baseline)</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> compared azelaic acid 5% and clindamycin 2% combination gel with clindamycin 2% gel alone. Results showed that the combination gel was superior to clindamycin 2% gel alone in percentage reduction of total lesions. There was a clear difference between treatment groups in the short term (MD 7.62, 95% CI 6.24 to 9.00; 1 study, 100 participants; <a href="./references#CD011368-fig-0033" title="">Analysis 3.3</a>), medium term (MD 12.48, 95% CI 11.12 to 13.84; 1 study, 97 participants; <a href="./references#CD011368-fig-0033" title="">Analysis 3.3</a>), and long term (3 months after start of treatment) (MD 16.08, 95% CI 14.56 to 17.60; 1 study, 87 participants; <a href="./references#CD011368-fig-0033" title="">Analysis 3.3</a>). </p> </section> <section id="CD011368-sec-0161"> <h6 class="title">Non‐inflamed (percentage reduction from baseline)</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> compared azelaic acid 5% and clindamycin 2% combination gel with clindamycin 2% gel alone. Results showed that the combination gel was superior to clindamycin 2% gel alone in percentage reduction of non‐inflamed lesions. There was a clear difference between treatment groups in the short term (MD 4.30, 95% CI 3.05 to 5.55; 1 study, 100 participants; <a href="./references#CD011368-fig-0034" title="">Analysis 3.4</a>), medium term (MD 14.63, 95% CI 12.89 to 16.37; 1 study, 97 participants; <a href="./references#CD011368-fig-0034" title="">Analysis 3.4</a>), and long term (3 months after start of treatment) (MD 13.67, 95% CI 11.59 to 15.75; 1 study, 87 participants; <a href="./references#CD011368-fig-0034" title="">Analysis 3.4</a>). </p> </section> <section id="CD011368-sec-0162"> <h6 class="title">Papules (percentage reduction from baseline)</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> compared azelaic acid 5% and clindamycin 2% combination gel with clindamycin 2% gel alone. Results showed that the combination gel was superior to clindamycin 2% gel alone in percentage reduction of papules. There was a clear difference between treatment groups in the short term (MD 6.59, 95% CI 5.40 to 7.78; 1 study, 100 participants; <a href="./references#CD011368-fig-0035" title="">Analysis 3.5</a>), medium term (MD 8.08, 95% CI 6.71 to 9.45; 1 study, 97 participants; <a href="./references#CD011368-fig-0035" title="">Analysis 3.5</a>), and long term (3 months after start of treatment) (MD 14.51, 95% CI 12.95 to 16.07; 1 study, 87 participants; <a href="./references#CD011368-fig-0035" title="">Analysis 3.5</a>). </p> </section> <section id="CD011368-sec-0163"> <h6 class="title">Pustules (percentage reduction from baseline)</h6> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> compared azelaic acid 5% and clindamycin 2% combination gel with clindamycin 2% gel alone. Results showed that the combination gel was superior to clindamycin 2% gel alone in percentage reduction of pustules. There was a clear difference between treatment groups in the short term (MD 9.89, 95% CI 8.66 to 11.12; 1 study, 100 participants; <a href="./references#CD011368-fig-0036" title="">Analysis 3.6</a>), medium term (MD 14.73, 95% CI 13.03 to 16.43; 1 study, 97 participants; <a href="./references#CD011368-fig-0036" title="">Analysis 3.6</a>), and long term (3 months after start of treatment) (MD 20.05, 95% CI 17.96 to 22.14; 1 study, 87 participants; <a href="./references#CD011368-fig-0036" title="">Analysis 3.6</a>). </p> </section> <section id="CD011368-sec-0164"> <h6 class="title">Inflamed (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported data for this outcome, but the number of participants was missing. When compared to erythromycin 2% gel alone, the azelaic acid 5% and erythromycin 2% combination gel group showed lower papule numbers and pustule numbers after treatment in the short, medium, and long term (3 months after start of treatment) (P &lt; 0.01) (<a href="./references#CD011368-fig-0037" title="">Analysis 3.7</a>). </p> </section> <section id="CD011368-sec-0165"> <h6 class="title">Comedones (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> reported data for this outcome, but the number of participants was missing. When compared to erythromycin 2% gel alone, the azelaic acid 5% and erythromycin 2% combination gel group showed lower comedone numbers after treatment in the short, medium, and long term (3 months after start of treatment) (P &lt; 0.01) (<a href="./references#CD011368-fig-0038" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD011368-sec-0166"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p>No study collected data for this outcome.</p> </section> <section id="CD011368-sec-0167"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0168"> <h6 class="title">Scaling</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that four out of 90 people in the azelaic acid group versus eight out of 81 people in the no treatment group experienced scaling. There was no clear difference between topical azelaic acid and no treatment (RR 0.47, 95% CI 0.15 to 1.50; 2 studies, 171 participants; <a href="./references#CD011368-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD011368-sec-0169"> <h6 class="title">Erythema</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that four out of 90 people in the azelaic acid group versus nine out of 81 people in the no treatment group experienced erythema. There was no clear difference between topical azelaic acid and no treatment (RR 0.39, 95% CI 0.12 to 1.21; 2 studies, 171 participants; <a href="./references#CD011368-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD011368-sec-0170"> <h6 class="title">Dryness</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that five out of 90 people in the azelaic acid group versus seven out of 81 people in the no treatment group experienced dryness. There was no clear difference between topical azelaic acid and no treatment (RR 0.61, 95% CI 0.20 to 1.85; 2 studies, 171 participants; <a href="./references#CD011368-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD011368-sec-0171"> <h6 class="title">Oiliness</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that six out of 90 people in the azelaic acid group versus seven out of 81 people in the no treatment group experienced oiliness. There was no clear difference between topical azelaic acid and no treatment (RR 0.78, 95% CI 0.27 to 2.24; 2 studies, 171 participants; <a href="./references#CD011368-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD011368-sec-0172"> <h6 class="title">Itching</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that five out of 90 people in the azelaic acid group versus six out of 81 people in the no treatment group experienced itching (RR 0.73, 95% CI 0.23 to 2.29; 2 studies, 171 participants; <a href="./references#CD011368-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD011368-sec-0173"> <h6 class="title">Total events</h6> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> and <a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> reported that 18 out of 90 people in the azelaic acid group versus 25 out of 81 people in the no treatment group experienced total events (RR 0.59, 95% CI 0.36 to 0.97; 2 studies, 171 participants; <a href="./references#CD011368-fig-0039" title="">Analysis 3.9</a>). </p> </section> </section> <section id="CD011368-sec-0174"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0175"> <h4 class="title">Comparison 4: topical salicylic acid versus other topical treatments</h4> <section id="CD011368-sec-0176"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion (n = 46) and the authors assessed this outcome using a five‐point scale (0: worsening or unchanged, 1: mild improvement, 2: moderate improvement, 3: good improvement and 4: excellent improvement). Both treatments demonstrated significant moderate to excellent improvement, and there was no difference between groups in the long term (12 weeks after start of treatment) (RR 1.00, 95% CI 0.92 to 1.09; 1 study, 46 participants; <a href="./references#CD011368-fig-0040" title="">Analysis 4.1</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). </p> <p><a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> compared salicylic acid 30% peels with pyruvic acid 50% peels and the authors assessed this outcome using a four‐point scale (excellent, good, fair, poor) in the medium term (8 weeks after start of treatment). Both treatments demonstrated significant good to excellent improvement, and there was no clear difference between groups (RR 1.12, 95% CI 0.68 to 1.84; 1 study, 86 participants; <a href="./references#CD011368-fig-0040" title="">Analysis 4.1</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0006">summary of findings Table 6</a>). </p> <section id="CD011368-sec-0177"> <h6 class="title">Participants' global self‐assessment of acne improvement (%) ‐ split‐face designs</h6> <p><a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a> and <a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>, using a split‐face design, reported data for this outcome; however, the means and SDs or SDs alone were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0041" title="">Analysis 4.2</a>). <a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a> assessed this outcome using a four‐point scale (3 = good improvement, 2 = moderate improvement, 1 = mild improvement, 0 = no improvement or worsening) showed that the percentage of participants with good to mild improvement in the short term was 92.3% in the 30% salicylic acid group and 84.6% in Jessner's solution group. Another study used patient self‐questionnaires to assess this outcome at two months post‐treatment (treatment duration of 10 weeks, measured at the post‐treatment follow‐up period) (<a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>). The percentage of participants with 'more improved' was 35% in the 30% salicylic acid peel group and 41% in the 30% glycolic acid peel group. </p> </section> </section> <section id="CD011368-sec-0178"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> compared salicylic acid 30% peels with pyruvic acid 50% peels in the medium term, and there was no clear difference between groups (RR 0.89, 95% CI 0.53 to 1.50; 1 study, 86 participants; <a href="./references#CD011368-fig-0042" title="">Analysis 4.3</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0006">summary of findings Table 6</a>). </p> <p>When salicylic acid was compared with benzoyl peroxide, two trials reported no withdrawals in the short term (<a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>; <a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>), and <a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a> also reported no withdrawals in the medium term (<a href="./references#CD011368-fig-0042" title="">Analysis 4.3</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0005">summary of findings Table 5</a>). </p> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> and <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a> compared salicylic acid with tretinoin; neither treatment group had any withdrawals in the long term (12 weeks after start of treatment) (<a href="./references#CD011368-fig-0042" title="">Analysis 4.3</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). </p> <p>One trial compared salicylic acid 30% peels with Jessner's solution (<a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>); neither treatment group had any withdrawals in the long term (12 weeks after start of treatment) (<a href="./references#CD011368-fig-0042" title="">Analysis 4.3</a>). </p> </section> <section id="CD011368-sec-0179"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0180"> <h6 class="title">Total lesion (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. the tretinoin group had a lower total lesion count than topical salicylic acid after intervention. The difference was significant in the short term (MD 7.70, 95% CI 1.89 to 13.51; 1 study, 46 participants; <a href="./references#CD011368-fig-0043" title="">Analysis 4.4</a>). However, the estimated RR had a very wide 95% CI which led to an imprecise result. The difference between topical salicylic acid and tretinoin in the medium term was uncertain due to the wide CI (MD 2.80, 95% CI ‐3.31 to 8.91; 1 study, 46 participants; <a href="./references#CD011368-fig-0043" title="">Analysis 4.4</a>), but showed greater certainty in the long term (12 weeks after start of treatment) (MD 3.60, 95% CI ‐0.06 to 7.26; 1 study, 46 participants; <a href="./references#CD011368-fig-0043" title="">Analysis 4.4</a>). </p> <p><a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a> had no usable outcome data; the authors compared the short‐term efficacy of salicylic acid 2% gel, benzoyl peroxide 3% gel and vehicle gel. The authors demonstrated the overall improvement in target lesion parameters of swelling, diameter and erythema from baseline, but there was no significant difference among these groups. In <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a> (also with no usable outcome data), the authors stated that 0.5% salicylic acid in mild foaming cleaner formulations could significantly inhibit emerging acne lesions when compared to its vehicle. In <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a> (again with no usable outcome data), the authors showed that salicylic acid in a microgel complex was superior to its vehicle in reducing total lesion counts and global acne severity. </p> </section> <section id="CD011368-sec-0181"> <h6 class="title">Inflamed (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. The tretinoin group had a lower inflamed lesion count than topical salicylic acid after intervention. The difference was significant in the short term (MD 4.30, 95% CI 0.50 to 8.10; 1 study, 46 participants; <a href="./references#CD011368-fig-0044" title="">Analysis 4.5</a>). There was no clear difference between topical salicylic acid and tretinoin in the medium term (MD 2.70, 95% CI ‐0.47 to 5.87; 1 study, 46 participants; <a href="./references#CD011368-fig-0044" title="">Analysis 4.5</a>), and long term (12 weeks after start of treatment) (MD 1.10, 95% CI ‐1.03 to 3.23; 1 study, 46 participants; <a href="./references#CD011368-fig-0044" title="">Analysis 4.5</a>). </p> </section> <section id="CD011368-sec-0182"> <h6 class="title">Inflamed (mean counts or %)</h6> <p>Three studies reported data for this outcome; however, the SDs were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0045" title="">Analysis 4.6</a>). <a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> reported the percentage reduction of inflamed lesions in the long term (12 weeks after start of treatment) was 77.6% in the salicylic acid 3% lotion group and 81.5% in the tretinoin 0.05 cream group; however, this difference was not significant. In one trial with a split‐face design (<a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a>), the author reported no difference in reduction of inflamed lesions between the salicylic acid 30% peel group and Jessner's solution group. Another split‐face trial reported there no difference in mean inflamed lesion counts post‐intervention in the long term (12 weeks after start of treatment) between the salicylic acid 20% or 30% peel group and the lipohydroxy acid 5% or 10% peel group (P = 0.111) (<a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>). <a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a>, with no usable outcome data, compared a proprietary 2% salicylic acid microgel with 10% benzoyl peroxide cream, and the authors found that the clinical resolution of target inflammatory lesions was more rapid with the novel 2% salicylic acid microgel than 10% benzoyl peroxide cream. </p> </section> <section id="CD011368-sec-0183"> <h6 class="title">Papules (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> reported no clear difference between salicylic acid 30% peels and pyruvic acid 50% peels in the short and medium term (<a href="./references#CD011368-fig-0046" title="">Analysis 4.7</a>). Short term: MD 0.87 (95% CI ‐2.48 to 4.22; 1 study, 52 participants) and medium term: MD 1.12 (95% CI ‐1.55 to 3.79; 1 study, 52 participants). </p> </section> <section id="CD011368-sec-0184"> <h6 class="title">Pustules (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> reported no clear difference between salicylic acid 30% peels and pyruvic acid 50% peels in the short and medium term (<a href="./references#CD011368-fig-0047" title="">Analysis 4.8</a>). Short term: MD ‐0.08 (95% CI ‐0.85 to 0.69; 1 study, 52 participants) and medium term: MD 0.31 (95% CI ‐0.53 to 1.15; 1 study, 52 participants). </p> </section> <section id="CD011368-sec-0185"> <h6 class="title">Non‐inflamed (number of lesions post‐intervention)</h6> <p>Only one study that compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion contributed data for this outcome (<a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a>). There was no statistically significant difference between topical salicylic acid and tretinoin in the short term (MD 3.90, 95% CI ‐0.03 to 7.83; 1 study, 46 participants; <a href="./references#CD011368-fig-0048" title="">Analysis 4.9</a>) and medium term (MD 0.30, 95% CI ‐3.55 to 4.15; 1 study, 46 participants; <a href="./references#CD011368-fig-0048" title="">Analysis 4.9</a>). However, there was a clear difference between topical salicylic acid and tretinoin in the long term (12 weeks after start of treatment) (MD 2.50, 95% CI 0.11 to 4.89; 1 study, 46 participants; <a href="./references#CD011368-fig-0048" title="">Analysis 4.9</a>), with less non‐inflamed lesion counts in the tretinoin group. </p> <p><a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> compared salicylic acid 30% peels with pyruvic acid 50% peels; participants receiving pyruvic acid 50% peels had fewer non‐inflamed lesions, though there was no clear difference between groups in the short (MD 19.89, 95% CI ‐7.65 to 47.43; 1 study, 52 participants) and medium terms (MD 17.48, 95% CI ‐6.45 to 41.41; 1 study, 52 participants) (<a href="./references#CD011368-fig-0048" title="">Analysis 4.9</a>). </p> </section> <section id="CD011368-sec-0186"> <h6 class="title">Non‐inflamed (counts or percentage)</h6> <p>Three studies reported data for this outcome; however, the SDs were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0049" title="">Analysis 4.10</a>). <a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> reported no difference in the long term (12 weeks after start of treatment) between the salicylic acid 3% lotion group and tretinoin 0.05% cream group (81.5% versus 87.2%). The split‐face design trial of <a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a> reported a medium‐term significant number reduction of non‐inflamed lesion counts in the salicylic acid 30% peel group compared to the Jessner's solution group (average number reduction of non‐inflamed counts 8 versus 4.3). In another split‐face trial (<a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>), there was no difference in percentage reduction of non‐inflamed lesion counts in the long term (12 weeks after start of treatment) between the salicylic acid 20% or 30% peel group and the lipohydroxy acid 5% or 10% peel group (P = 0.878). </p> </section> <section id="CD011368-sec-0187"> <h6 class="title">Various types of acne lesions (counts or percentage)</h6> <p>Four studies reported data for this outcome; however, the SDs were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0050" title="">Analysis 4.11</a>). In a parallel trial (<a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>), 2% salicylic acid plus 1% clindamycin lotion showed a greater percentage reduction in closed comedones (P = 0.011), papules (P = 0.031), and total lesions (P = 0.039) in the long term (12 weeks after start of treatment) when compared to 0.025% tretinoin plus 1% clindamycin lotion. In a split‐face trial that compared salicylic acid 30% peel with glycolic acid 30% peel (<a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>), there was no statistically significant difference between groups in percentage reduction of total lesions at one month post‐treatment (P &gt; 0.05) (treatment duration of 10 weeks, measured at the post‐treatment follow‐up period). In <a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a>, with a cross‐over design that compared salicylic acid 2% cleaner with 10% benzoyl peroxide wash, there was no statistically significant difference between groups in number of comedones post‐intervention. </p> </section> </section> <section id="CD011368-sec-0188"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared salicylic acid 3% gel with tretinoin 0.05% cream and reported long term data (12 weeks after start of treatment) (n = 46) and the authors assessed this outcome using a five‐point scale (0: worsening or unchanged, 1: mild improvement, 2: moderate improvement, 3: good improvement and 4: excellent improvement). There was no difference between topical salicylic acid and tretinoin in moderate to excellent improvement (RR 1.00, 95% CI 0.92 to 1.09; 1 study, 46 participants; <a href="./references#CD011368-fig-0051" title="">Analysis 4.12</a>). <a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a> reported data collected in the long term (12 weeks after start of treatment) (n = 40) and the authors assessed this outcome using percentage decrease in Michaelsson acne scores (MAS) (good improvement: &gt; 50% decrease in MAS; fair improvement: 21% to 50% decrease in MAS; poor improvement: 11% to 20% decrease in MAS; no change: 0% to 10% decrease in MAS), and there was no clear difference between 30% salicylic acid peels and Jessner's solution peels (RR 1.11, 95% CI 0.93 to 1.31; 1 study, 40 participants; <a href="./references#CD011368-fig-0051" title="">Analysis 4.12</a>). <a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> compared salicylic acid 30% peels with pyruvic acid 50% peels and the authors assessed this outcome using percentage decrease of acne severity index (ASI) (excellent = improved more than 75%, good = improved 50% to 75%, moderate = improved 25% to 50%, poor = improved &lt; 25%), and there was no clear difference between salicylic acid 30% peels and pyruvic acid 50% peels (RR 1.20, 95% CI 0.70 to 2.06; 1 study, 86 participants; <a href="./references#CD011368-fig-0051" title="">Analysis 4.12</a>). </p> <section id="CD011368-sec-0189"> <h6 class="title">Physicians' global evaluation of acne improvement ‐ split‐face trials</h6> <p>In one split‐face trial (<a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>), the authors assessed this outcome using a five‐point system (good: more than 50% improvement, fair: 21% to 50% improvement, poor: 10% to 20% improvement, no change, or worse) but did not report whether there was a statistical difference between the salicylic acid 30% peel group and glycolic acid 30% peel group at two months post‐treatment (treatment duration of 10 weeks, measured at the post‐treatment follow‐up period). The SDs were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0052" title="">Analysis 4.13</a>). </p> <p>In another study with a split‐face design that included a total of 20 participants suffering from comedonal acne (<a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a>), each participant received salicylic acid peels (20% or 30%) on one side of the face and lipohydroxy acid peels (5% or 10%) on the other side of the face. The authors assessed this outcome using a three‐point scoring system (1 = worse, 2 = stable, 3 = improved). There was a significant difference between groups in the short term (MD ‐0.40, 95% CI ‐0.67 to ‐0.13; 1 study; <a href="./references#CD011368-fig-0053" title="">Analysis 4.14</a>), which was in favour of lipohydroxy acid (5% or 10%) peel. However, there was no significant difference between groups in the medium term (MD 0.10, 95% CI ‐0.17 to 0.37; 1 study; <a href="./references#CD011368-fig-0053" title="">Analysis 4.14</a>) and long term (12 weeks after start of treatment) (MD 0.00, 95% CI ‐0.24 to 0.24; 1 study; <a href="./references#CD011368-fig-0053" title="">Analysis 4.14</a>). </p> </section> </section> <section id="CD011368-sec-0190"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0191"> <h6 class="title">Dryness ‐ salicylic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. There was no significant difference between topical salicylic acid and tretinoin (RR 1.17, 95% CI 0.70 to 1.94; 1 study, 46 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0192"> <h6 class="title">Peeling ‐ salicylic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. There was no significant difference between topical salicylic acid and tretinoin (RR 0.71, 95% CI 0.40 to 1.26; 1 study, 46 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0193"> <h6 class="title">Erythema ‐ salicylic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. There was no significant difference between topical salicylic acid and tretinoin (RR 0.88, 95% CI 0.38 to 2.01; 1 study, 46 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0194"> <h6 class="title">Burning ‐ salicylic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. There was no significant difference between topical salicylic acid and tretinoin (RR 1.14, 95% CI 0.50 to 2.63; 1 study, 46 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0195"> <h6 class="title">Itching ‐ salicylic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. The authors reported that three out of 23 people in the 3% alcohol‐based salicylic acid plus clindamycin 1% lotion group versus five out of 23 people in the tretinoin 0.05% cream plus clindamycin 1% lotion group experienced itching (P = 0.70, Fisher's Exact test). There was no significant difference between treatment groups (RR 0.60, 95% CI 0.16 to 2.22; 1 study, 46 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0196"> <h6 class="title">Postpeel burning and stinging ‐ salicylic acid versus Jessner's solution</h6> <p><a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a> compared salicylic acid 30% peel with Jessner's solution peel, and we found no clear difference between salicylic acid and Jessner's solution (RR 1.44, 95% CI 0.81 to 2.58; 1 study, 40 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0197"> <h6 class="title">Postpeel erythema ‐ salicylic acid versus Jessner's solution</h6> <p><a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a> compared salicylic acid 30% peel with Jessner's solution peel, and we found no clear difference between salicylic acid and Jessner's solution (RR 1.50, 95% CI 0.50 to 4.52; 1 study, 40 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0198"> <h6 class="title">Postpeel hyperpigmentation ‐ salicylic acid versus Jessner's solution</h6> <p><a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a> compared salicylic acid 30% peel with Jessner's solution peel. The authors reported that one out of 20 people in the salicylic acid 30% peel group versus three out of 20 people in the Jessner's solution peel group experienced postpeel hyperpigmentation (P = 0.61, Fisher's Exact test). There was no clear difference between salicylic acid and Jessner's solution (RR 0.33, 95% CI 0.04 to 2.94; 1 study, 40 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> </section> <section id="CD011368-sec-0199"> <h6 class="title">Total events ‐ salicylic acid versus benzoyl peroxide</h6> <p>In one study with 90 people (<a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>), the author compared the short‐term efficacy of salicylic acid 2% gel, benzoyl peroxide 3% gel and vehicle gel. They reported that no adverse events were observed during this five‐day study (30 participants in each treatment group) (<a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). </p> <p><a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a> reported this outcome in the medium term. The authors reported that zero out of 20 people in the 2% salicylic acid microgel group versus two out of 21 people in the benzoyl peroxide 10% cream group experienced minor adverse events (P = 0.49, Fisher's Exact test). There was no clear difference between the 2% salicylic acid microgel group and benzoyl peroxide 10% cream group due to the wide CI (RR 0.21, 95% CI 0.01 to 4.11; 1 study, 41 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD011368-sec-0200"> <h6 class="title">Total events ‐ salicylic acid versus tretinoin</h6> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion and <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a> compared 2% salicylic acid plus 1% clindamycin lotion with 0.025% tretinoin plus 1% clindamycin lotion. There was no clear difference between treatment groups due to the wide CI (RR 1.37, 95% CI 0.66 to 2.87; 2 studies, 74 participants; <a href="./references#CD011368-fig-0054" title="">Analysis 4.15</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD011368-sec-0201"> <h6 class="title">Total events ‐ salicylic acid versus lipohydroxy acid</h6> <p><a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a> was a split‐face design that compared salicylic acid peel (20% or 30% ) with lipohydroxy acid peel (5% or 10%), the authors did not report total number of participants who experienced at least one minor adverse event but evaluated minor adverse events using a 10 cm visual analogue scale. There was no difference for itching (P = 0.412), tightness (P = 0.108), and erythema (P = 0.103). Salicylic acid peels induced more desquamation (P = 0.007) and dryness (P &lt; 0.05) but less stinging (P = 0.017) and burning (P = 0.021) when compared to lipohydroxy acid peels. </p> </section> </section> <section id="CD011368-sec-0202"> <h5 class="title">Quality of life ‐ AQOL (score, post‐intervention)</h5> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> compared 3% alcohol‐based salicylic acid plus clindamycin 1% lotion with tretinoin 0.05% cream plus clindamycin 1% lotion. The study reported no statistically difference between groups for this outcome in the long term (12 weeks after start of treatment); however, the data were skewed, so we therefore could only present the data in a table (see table in <a href="./references#CD011368-fig-0055" title="">Analysis 4.16</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). <a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a> did not provide means ± SDs, and the study compared salicylic acid 2% microgel with 10% benzoyl peroxide cream and found a significant improvement in quality of life with salicylic acid 2% microgel (<a href="./references#CD011368-fig-0055" title="">Analysis 4.16</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0005">summary of findings Table 5</a>). </p> </section> </section> <section id="CD011368-sec-0203"> <h4 class="title">Comparison 5: topical salicylic acid versus placebo</h4> <section id="CD011368-sec-0204"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <section id="CD011368-sec-0205"> <h6 class="title">Participants' global self‐assessment of acne improvement (score, high = well)</h6> <p>Only one study contributed data for this outcome assessed by a seven‐point interval rating scale (<a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a>). There was no significant difference between topical salicylic acid 2% lotion and placebo lotion in the short term (MD 0.30, 95% CI ‐0.12 to 0.72; 1 study, 106 participants; <a href="./references#CD011368-fig-0056" title="">Analysis 5.1</a>) or long term (12 weeks after start of treatment) (MD 0.40, 95% CI ‐0.05 to 0.85; 1 study, 99 participants; <a href="./references#CD011368-fig-0056" title="">Analysis 5.1</a>). However, in the medium term, participants in the salicylic acid group recorded a higher score for acne improvement than those in the placebo group, the difference was clearly significant (MD 0.50, 95% CI 0.23 to 0.77; 1 study, 102 participants; <a href="./references#CD011368-fig-0056" title="">Analysis 5.1</a>). </p> </section> </section> <section id="CD011368-sec-0206"> <h5 class="title">Withdrawal for any reason</h5> <p>One trial compared salicylic acid 2% gel with vehicle gel (<a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>), and neither treatment group had any withdrawals in the short term (<a href="./references#CD011368-fig-0057" title="">Analysis 5.2</a>). Another two trials reported data in the long term (12 weeks after start of treatment) (<a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a>; <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a>), and there was no clear difference between salicylic acid and placebo due to the wide CI (RR 2.07, 95% CI 0.76 to 5.68; 2 studies, 163 participants; <a href="./references#CD011368-fig-0057" title="">Analysis 5.2</a>), but one study reported no events. </p> </section> <section id="CD011368-sec-0207"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0208"> <h6 class="title">Mean counts or percentage reduction</h6> <p>Three studies reported data for this outcome; however, the authors did not provide mean and/or SDs. <a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a> only reported the P values, and results showed that salicylic acid 2% lotion treatment had better efficacy in whitehead (long term, P &lt; 0.002), papules (long term, P = 0.022), and total lesion (medium term, P &lt; 0.043; and long term, P &lt; 0.001) number reduction when compared to placebo. In <a href="./references#CD011368-bbs2-0046" title="TechapichetvanichT , RajatanavinN , SahawatwongS . The combination of salicylic acid peel with 5% benzoyl peroxide and 1% clindamycin lotion in a treatment of acne vulgaris: a randomized, doubleblind, placebo controlled study. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB13. [CENTRAL: CN-00843979] ">Techapichetvanich 2011</a>, the percentage reduction of non‐inflamed lesions in the long term (10 weeks after start of treatment) was 84.0% for the salicylic acid (20% or 30%) peel group and 36.0% for the vehicle peel group (P = 0.001), and the percentage reduction of total lesions in the long term was 84.0% for the salicylic acid (20% or 30%) peel group and 26.0% for the vehicle peel group (P = 0.001), suggesting the benefits of salicylic acid treatment. The <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a> study also suggested the advantage of salicylic acid 0.5% solution over placebo in percentage reduction in total lesions in the long term, although the author did not state whether the difference was of statistical significant (<a href="./references#CD011368-fig-0058" title="">Analysis 5.3</a>). </p> </section> <section id="CD011368-sec-0209"> <h6 class="title">Inflamed (counts or percentage)</h6> <p>Two studies reported data for this outcome; however, the authors did not provide mean and/or SDs, so we presented the data in a table (<a href="./references#CD011368-fig-0059" title="">Analysis 5.4</a>). <a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a> showed a statistically significant difference between topical salicylic acid 2% lotion and placebo lotion in the long term (12 weeks after start of treatment) (P &lt; 0.022) in favour of salicylic acid, but no difference in the short and medium term for reduction in number of inflamed lesions. <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a> did not report the P value, but the data suggested the advantage of salicylic acid 0.5% solution over placebo for percentage reduction of inflamed lesions in the long term (12 weeks after start of treatment). </p> </section> <section id="CD011368-sec-0210"> <h6 class="title">Non‐inflamed (counts or percentage)</h6> <p>Two studies reported data for this outcome; however, the authors did not provide mean and/or SDs (<a href="./references#CD011368-fig-0060" title="">Analysis 5.5</a>). <a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a> showed that topical salicylic acid 2% lotion demonstrated a significant reduction in number of non‐inflamed lesions in the medium (P = 0.047) and long term (12 weeks after start of treatment) (P &lt; 0.001) compared to placebo lotion, but no difference in the short term (no exact P value reported). <a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a> showed no significant difference between groups for percentage reduction of closed comedones in the long term (12 weeks after start of treatment) (no exact P value reported); however, the percentage reduction of open comedones was significant in the salicylic acid 0.5% solution group compared to placebo (no exact P value reported). </p> </section> </section> <section id="CD011368-sec-0211"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a> compared salicylic acid 0.5% solution with placebo and reported long term data (12 weeks after start of treatment) (n = 49). The authors assessed this outcome using a four‐point Likert‐type scale (excellent, good, fair, poor). There were more participants rated as good or excellent improvement in the salicylic acid 0.5% solution group than participants in the placebo group (RR 2.16, 95% CI 1.17 to 4.0; 1 study, 49 participants; <a href="./references#CD011368-fig-0061" title="">Analysis 5.6</a>). </p> </section> <section id="CD011368-sec-0212"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0213"> <h6 class="title">Total adverse events</h6> <p><a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a> included 90 participants and compared the short‐term efficacy of salicylic acid 2% gel, benzoyl peroxide 3% gel and vehicle gel. They reported that no adverse events were observed during this five‐day study (30 participants in each treatment group) (<a href="./references#CD011368-fig-0062" title="">Analysis 5.7</a>). </p> <p><a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a> included 49 participants and compared 0.5% salicylic acid solution with placebo solution in the long term. However, there were no adverse events reported in either treatment group (<a href="./references#CD011368-fig-0062" title="">Analysis 5.7</a>); the authors only stated that side effects were minimal. </p> </section> </section> <section id="CD011368-sec-0214"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0215"> <h4 class="title">Comparison 6: topical salicylic acid versus no treatment (including studies with a co‐intervention in both arms) </h4> <section id="CD011368-sec-0216"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p>For this outcome, there were no data reported in the short and medium term. <a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> reported data in the long term (12 weeks after start of treatment) and the authors assessed this outcome using a five‐point scale (0 = worsening or unchanged, 1 = mild improvement, 2 = moderate improvement, 3 = good improvement, 4 = excellent improvement). This trial compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel in moderate to excellent improvement. There was no significant difference between treatment groups (RR 0.96, 95% CI 0.86 to 1.07; 1 study, 50 participants; <a href="./references#CD011368-fig-0063" title="">Analysis 6.1</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0016">Table 6</a>). </p> <div class="table" id="CD011368-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Salicylic acid compared to no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to no treatment for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Skin Disease and Leishmaniasis Research Center and Isfahan University of Medical Sciences clinics (1 study); a tertiary care hospital of Eastern India (1 study); not described (1 study)<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> <br/><i>Moderate to excellent improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>960 per 1000</b><br/>(860 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/>(0.86 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin/benzoyl peroxide was a co‐intervention given in both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.0</b> <br/>(0.13 to 70.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies had no withdrawals.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> <p>(61 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.43</b> <br/>(0.14 to 82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All side effects reported in the study were of mild to moderate intensity and transient.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>AQOL</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The authors reported no "significant differences" in AQOL between treatment groups (salicylic acid/clindamycin/benzoyl peroxide group versus clindamycin/benzoyl peroxide group) at baseline and the end of the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median and 95% CI reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AQOL</b> : acne quality of life; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: optimal sample size not met.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: three studies included and all with unclear risk of allocation concealment and high risk of performance bias, two studies with unclear risk of random sequence generation. Two levels for imprecision: very wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: two studies included and both with unclear risk of selection and high risk of performance bias, one with unclear risk of reporting bias. Two levels for imprecision: very wide CI and optimal sample size not met.<br/><sup>d</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: very small total sample size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> </section> <section id="CD011368-sec-0217"> <h5 class="title">Withdrawal for any reason</h5> <p>Three relevant trials reported data for this outcome in the long term (treatment duration over 12 weeks) (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>; <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>). Two trials had no withdrawals during treatment (<a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>; <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>). There was no clear difference between treatment groups due to the wide CI (RR 3.00, 95% CI 0.13 to 70.30; 3 studies, 138 participants, two of which reported no events, <a href="./references#CD011368-fig-0064" title="">Analysis 6.2</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0016">Table 6</a>). </p> </section> <section id="CD011368-sec-0218"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0219"> <h6 class="title">Total (percentage reduction from baseline)</h6> <p>Three studies reported data for this outcome (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>; <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>; however, the authors did not provide mean and/or SDs. Two studies reported higher percentage reduction of lesion counts in the salicylic acid group than that in the no treatment group (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>; <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>), and authors stated the difference was statistically significant in the long term (12 weeks after start of treatment). <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a> also reported higher percentage reduction of total lesion counts in the salicylic acid group in the long term (16 weeks after start of treatment), although the authors did not state whether the difference was statistically significant. (<a href="./references#CD011368-fig-0065" title="">Analysis 6.3</a>). </p> </section> <section id="CD011368-sec-0220"> <h6 class="title">Inflamed (percentage reduction from baseline)</h6> <p>Two studies reported data for this outcome; however, the authors did not provide mean and/or SDs, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0066" title="">Analysis 6.4</a>). Study authors compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel. The study reported higher percentage reduction of lesion counts in the salicylic acid group than in the no treatment group (98.2% versus 73.8%); the authors stated the difference was statistically significant in the long term (12 weeks after start of treatment) (<a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a>). Another study also reported higher percentage reduction of papules and pustules in the salicylic acid group in the long term (12 weeks after start of treatment) (<a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a>). </p> </section> <section id="CD011368-sec-0221"> <h6 class="title">Non‐inflamed (percentage reduction from baseline)</h6> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel; however, the authors did not provide SDs. In <a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> the percentage reduction of non‐inflamed lesions in the long term (12 weeks after start of treatment) was significantly greater in participants receiving salicylic acid treatment (94.7%) than no treatment (81.1%), although the P value was unclear. Authors <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a> compared 2% salicylic acid + 1% clindamycin lotion with 1% clindamycin lotion and results showed higher percentage reduction of comedones in the salicylic acid group (<a href="./references#CD011368-fig-0067" title="">Analysis 6.5</a>). </p> </section> </section> <section id="CD011368-sec-0222"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> reported data collected in the long term (12 weeks after start of treatment). This trial compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel and assessed this outcome using a 5‐point scale (0 = worsening or unchanged, 1 = mild improvement, 2 = moderate improvement, 3 = good improvement, 4 = excellent improvement). There was no significant difference between treatment groups in the moderate to excellent improvement categories (RR 0.96, 95% CI 0.86 to 1.07; 1 study, 50 participants; <a href="./references#CD011368-fig-0068" title="">Analysis 6.6</a>). </p> </section> <section id="CD011368-sec-0223"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0224"> <h6 class="title">Dryness</h6> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel. Results showed a higher risk of dryness in the salicylic acid/clindamycin/benzoyl peroxide group than control (16/25 versus 6/25). The difference was significant (RR 2.67, 95% CI 1.25 to 5.68; 1 study, 50 participants; <a href="./references#CD011368-fig-0069" title="">Analysis 6.7</a>). </p> </section> <section id="CD011368-sec-0225"> <h6 class="title">Peeling</h6> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel. There was no clear difference between treatment groups (RR 1.50, 95% CI 0.74 to 3.03; 1 study, 50 participants; <a href="./references#CD011368-fig-0069" title="">Analysis 6.7</a>). </p> </section> <section id="CD011368-sec-0226"> <h6 class="title">Erythema</h6> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel. The estimated RR had a very wide 95% CI resulting in imprecision (RR 4.00, 95% CI 0.94 to 17.00; 1 study, 50 participants; <a href="./references#CD011368-fig-0069" title="">Analysis 6.7</a>), </p> </section> <section id="CD011368-sec-0227"> <h6 class="title">Burning</h6> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel. There was no clear difference between treatment groups (RR 1.67, 95% CI 0.71 to 3.89; 1 study, 50 participants; <a href="./references#CD011368-fig-0069" title="">Analysis 6.7</a>). </p> </section> <section id="CD011368-sec-0228"> <h6 class="title">Itching</h6> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel. The authors reported that five out of 25 people in the salicylic acid/clindamycin/benzoyl peroxide group versus three out of 25 people in the clindamycin/benzoyl peroxide group experienced itching (P = 0.70, Fisher's Exact test). There was no significant difference between treatment groups (RR 1.67, 95% CI 0.45 to 6.24; 1 study, 50 participants; <a href="./references#CD011368-fig-0069" title="">Analysis 6.7</a>). </p> </section> <section id="CD011368-sec-0229"> <h6 class="title">Total events</h6> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> and <a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a> compared salicylic acid with no treatment in the long term (12 weeks after start of treatment). There was no clear difference between treatment groups due to a wide CI (RR 3.43, 95% CI 0.14 to 82.00; 2 studies, 78 participants; <a href="./references#CD011368-fig-0069" title="">Analysis 6.7</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0016">Table 6</a>). </p> </section> </section> <section id="CD011368-sec-0230"> <h5 class="title">Quality of life ‐ AQOL (score, post‐intervention)</h5> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> compared 3% salicylic acid to 1% clindamycin lotion and 5% benzoyl peroxide gel with 1% clindamycin lotion and 5% benzoyl peroxide gel in the long term (12 weeks after start of treatment); however, the data were not available for meta‐analysis (<a href="./references#CD011368-fig-0070" title="">Analysis 6.8</a>). At the end of the study, the median and 95% CI of the AQOL score was 0.5 (0.6 to 2.1) in the salicylic acid/clindamycin/benzoyl peroxide treatment group and 1 (1.5 to 4.3) in the clindamycin/benzoyl peroxide group, the study authors may have reported the wrong data as the median was not included in the 95% CI. The authors reported no "statistically significant" difference between treatment groups. We assessed the evidence as very low quality (<a href="#CD011368-tbl-0016">Table 6</a>). </p> </section> </section> <section id="CD011368-sec-0231"> <h4 class="title">Comparison 7: topical nicotinamide versus other topical treatments</h4> <section id="CD011368-sec-0232"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p>No study collected data for this outcome.</p> </section> <section id="CD011368-sec-0233"> <h5 class="title">Withdrawal for any reason</h5> <p>We found three trials that compared nicotinamide with clindamycin (<a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>; <a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>), and there was no significant difference between the treatment groups in the medium term, two of which reported zero events, (RR 1.13, 95% CI 0.49 to 2.60; 3 studies, 216 participants; <a href="./references#CD011368-fig-0071" title="">Analysis 7.1</a>). We rated this as low‐quality evidence due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0008">summary of findings Table 8</a>). </p> <p>Only <a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> compared topical nicotinamide 4% gel with erythromycin 4% gel, and there was no significant difference between the treatment groups (RR 1.40, 95% CI 0.46 to 4.22; 1 study, 158 participants; <a href="./references#CD011368-fig-0071" title="">Analysis 7.1</a>). We rated this as low‐quality evidence due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0009">summary of findings Table 9</a>). </p> </section> <section id="CD011368-sec-0234"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0235"> <h6 class="title">Inflamed (number of lesions post‐intervention)</h6> <p>There were no long term data for this outcome. <a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> reported short and medium term data (n = 80). There was no clear difference between topical nicotinamide 4% gel and clindamycin 1% gel in the short term (MD 0.97, 95% CI ‐0.92 to 2.86; 1 study, 80 participants; <a href="./references#CD011368-fig-0072" title="">Analysis 7.2</a>), or the medium term (MD 0.92, 95% CI ‐1.25 to 3.09; 1 study, 80 participants; <a href="./references#CD011368-fig-0072" title="">Analysis 7.2</a>). </p> </section> <section id="CD011368-sec-0236"> <h6 class="title">Inflamed counts (counts or percentage)</h6> <p>Two studies reported data for this outcome; however, the data were not available for meta‐analysis; they are presented in a table (see table in <a href="./references#CD011368-fig-0073" title="">Analysis 7.3</a>). <a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a> compared nicotinamide 4% gel with clindamycin 1% gel, there was no difference in percentage reduction of inflamed lesions in the short (P = 0.06, no means ± SDs provided) and medium term (P = 0.17, skewed data). <a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> compared nicotinamide 4% gel with erythromycin 4% gel, but the study authors did not report the P value and the data were skewed. </p> </section> <section id="CD011368-sec-0237"> <h6 class="title">Comedones (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> reported data collected in the medium term (n = 158). There was no clear difference between topical nicotinamide 4% gel and erythromycin 4% gel (MD ‐1.00, 95% CI ‐2.10 to 0.10; 1 study, 158 participants; <a href="./references#CD011368-fig-0074" title="">Analysis 7.4</a>). </p> </section> </section> <section id="CD011368-sec-0238"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a> reported data collected in the short and medium term. The authors assessed this outcome using a 5‐point scoring system (+3 = much better, +2 = moderately better, +1 = slightly better, 0 = no change, ‐1 = worse). There was no significant difference between topical nicotinamide 4% gel and clindamycin 1% gel in the moderately better or much better categories in the short term (RR 0.93, 95% CI 0.53 to 1.66; 1 study, 76 participants) or medium term (RR 0.95, 95% CI 0.60 to 1.50; 1 study, 76 participants; <a href="./references#CD011368-fig-0075" title="">Analysis 7.5</a>). </p> <p><a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a> also reported the P value for this outcome (<a href="./references#CD011368-fig-0076" title="">Analysis 7.6</a>). There was no statistically significant difference between topical nicotinamide 4% gel and clindamycin 1% gel in the percentage of participants in the moderately better or much better categories in the short term (P = 0.36) or medium term (P = 0.19) for physicians' global evaluation of acne improvement. </p> </section> <section id="CD011368-sec-0239"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0240"> <h6 class="title">Itching ‐ nicotinamide versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> reported that four out of 40 people in the nicotinamide 4% gel group versus three out of 40 people in the clindamycin 1% gel group experienced itching (P = 1.00, Fisher's Exact test). There was no significant difference between topical nicotinamide 4% gel and clindamycin 1% gel (RR 1.33, 95% CI 0.32 to 5.58; 1 study, 80 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> <section id="CD011368-sec-0241"> <h6 class="title">Burning ‐ nicotinamide versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> reported that seven out of 40 people in the nicotinamide 4% gel group versus two out of 40 people in the clindamycin 1% gel group experienced burning (P = 0.15, Fisher's Exact test). There was no clear difference between topical nicotinamide 4% gel and clindamycin 1% gel as the CI was wide (RR 3.50, 95% CI 0.77 to 15.83; 1 study, 80 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> <section id="CD011368-sec-0242"> <h6 class="title">Crusting ‐ nicotinamide versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> reported that two out of 40 people in the nicotinamide 4% gel group versus three out of 40 people in the clindamycin 1% gel group experienced crusting (P = 1.00, Fisher's Exact test). There was no significant difference between nicotinamide 4% gel and clindamycin 1% gel (RR 0.67, 95% CI 0.12 to 3.78; 1 study, 80 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> <section id="CD011368-sec-0243"> <h6 class="title">Greasy skin ‐ nicotinamide versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> reported that zero out of 40 people in the nicotinamide 4% gel group versus three out of 40 people in the clindamycin 1% gel group experienced greasy skin (P = 0.24, Fisher's Exact test). There was no clear difference between nicotinamide 4% gel and clindamycin 1% gel (RR 0.14, 95% CI 0.01 to 2.68; 1 study, 80 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> <section id="CD011368-sec-0244"> <h6 class="title">Dermatitis ‐ nicotinamide versus clindamycin</h6> <p><a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> reported that one out of 40 people in the nicotinamide 4% gel group versus zero out of 40 people in the clindamycin 1% gel group experienced dermatitis (P = 1.00, Fisher's Exact test). There was no clear difference between nicotinamide 4% gel and clindamycin 1% gel (RR 3.00, 95% CI 0.13 to 71.51; 1 study, 80 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>), as the estimated RR had a very wide 95% CI resulting in imprecision. </p> </section> <section id="CD011368-sec-0245"> <h6 class="title">Total events ‐ nicotinamide versus clindamycin</h6> <p>Three trials compared nicotinamide with clindamycin (<a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a>; <a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a>; <a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a>). There was no significant difference between topical nicotinamide and clindamycin (RR 1.20, 95% CI 0.73 to 1.99; 3 studies, 216 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). We rated this as low‐quality evidence due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0008">summary of findings Table 8</a>). </p> </section> <section id="CD011368-sec-0246"> <h6 class="title">Pertinent clinical signs ‐ nicotinamide versus erythromycin (short term)</h6> <p><a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> found "no significant difference" between topical nicotinamide 4% gel and erythromycin 4% gel (RR 1.33, 95% CI 0.60 to 2.99; 1 study, 158 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> <section id="CD011368-sec-0247"> <h6 class="title">Pertinent clinical signs ‐ nicotinamide versus erythromycin (medium term)</h6> <p><a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> found "no significant difference" between topical nicotinamide 4% gel and erythromycin 4% gel (RR 1.10, 95% CI 0.50 to 2.44; 1 study, 158 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> <section id="CD011368-sec-0248"> <h6 class="title">Funtional or physical signs ‐ nicotinamide versus erythromycin (short term)</h6> <p><a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> found "no significant difference" between topical nicotinamide 4% gel and erythromycin 4% gel (RR 1.05, 95% CI 0.61 to 1.82; 1 study, 158 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> <section id="CD011368-sec-0249"> <h6 class="title">Funtional or physical signs ‐ nicotinamide versus erythromycin (medium term)</h6> <p><a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> found "no significant difference" between topical nicotinamide 4% gel and erythromycin 4% gel (RR 0.75, 95% CI 0.38 to 1.48; 1 study, 158 participants; <a href="./references#CD011368-fig-0077" title="">Analysis 7.7</a>). </p> </section> </section> <section id="CD011368-sec-0250"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0251"> <h4 class="title">Comparison 8: topical sulphur versus other topical treatments</h4> <section id="CD011368-sec-0252"> <h5 class="title">Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high = well) </h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> assessed this outcome using a numerical point scoring system (greatly improved +2, somewhat improved +1, no change 0, worse ‐1); however, the SDs were missing (<a href="./references#CD011368-fig-0078" title="">Analysis 8.1</a>). The study authors compared topical sulphur 2% lotion to topical benzoyl peroxide 5% lotion, the average score (high = well) was 0.75 in the sulphur group and 0.66 in the benzoyl peroxide group. The authors did not state whether the difference was statistically significant. We assessed the evidence as very low‐quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0017">Table 7</a>). </p> <div class="table" id="CD011368-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sulphur compared to benzoyl peroxide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulphur compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Wayne State University Health Service<br/><b>Intervention:</b> topical sulphur<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical sulphur</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Numerical point system defined by investigator, high = well</i> <br/>(medium term: treatment duration from 5 to 8 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The score (high = well) was 0.75 in sulphur group and 0.66 in benzoyl peroxide group.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SDs were missing.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>334 per 1000</b><br/>(78 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.67</b> <br/>(0.62 to 11.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. But the authors reported that five patients in the benzoyl peroxide group (5/16) versus zero in sulphur group (0/18) developed erythema and drying. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by four levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: very small sample size.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> </section> <section id="CD011368-sec-0253"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> reported that six out of 18 people in the topical sulphur 2% lotion group versus two out of 16 people in the benzoyl peroxide 5% lotion group withdrew from the trial (P = 0.23, Fisher's Exact test). There was no clear difference between the topical sulphur 2% lotion group and the topical benzoyl peroxide 5% lotion group in the medium term (RR 2.67, 95% CI 0.62 to 11.39; 1 study, 34 participants; <a href="./references#CD011368-fig-0079" title="">Analysis 8.2</a>). We assessed the evidence as very low‐quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0017">Table 7</a>). </p> </section> <section id="CD011368-sec-0254"> <h5 class="title">Change in lesion counts (scores, high = well)</h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared topical sulphur 2% lotion with topical benzoyl peroxide 5% lotion; however, the SDs were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0080" title="">Analysis 8.3</a>). The average scores (high = well) of comedone‐pustule and papule‐cyst in participants receiving sulphur treatment were lower than in the benzoyl peroxide group. The authors did not state whether the difference was statistically significant. </p> </section> <section id="CD011368-sec-0255"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared topical sulphur 2% lotion with topical benzoyl peroxide 5% lotion. Trial authors assessed this outcome by using a scoring system defined by investigators (unchanged or worse: ‐4 to 0, minimal improvement: 0.1 to 3.99, moderate improvement: 4 to 5.99, good improvement: 6 to 8). There was no significant difference between treatment groups in the moderate to good improvement categories in the medium term (RR 1.24, 95% CI 0.49 to 3.15; 1 study, 34 participants; <a href="./references#CD011368-fig-0081" title="">Analysis 8.4</a>). </p> </section> <section id="CD011368-sec-0256"> <h5 class="title">Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) </h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared topical sulphur 2% lotion with topical benzoyl peroxide 5% lotion; however, the SDs were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0082" title="">Analysis 8.5</a>). Trial authors assessed this outcome using a numerical point scoring system (complete improvement +3, moderate improvement +2, slight improvement +1, questionable 0, no change 0, worse ‐1). The average score (high = well) was 0.50 in the sulphur treatment group and 1.07 in the benzoyl peroxide group. However, the authors did not state whether the difference was statistically significant. </p> </section> <section id="CD011368-sec-0257"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0258"> <h6 class="title">Erythema and drying ‐ sulphur versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> reported that zero out of 18 people in the topical sulphur 2% lotion group versus five out of 16 people in the benzoyl peroxide 5% lotion group experienced erythema and drying (P = 0.02, Fisher's Exact test). We did not present the RR and 95% CI because the presence of zero events in one arm led to discordant results (<a href="./references#CD011368-fig-0083" title="">Analysis 8.6</a>). </p> </section> </section> <section id="CD011368-sec-0259"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0260"> <h4 class="title">Comparison 9: topical sulphur versus placebo</h4> <section id="CD011368-sec-0261"> <h5 class="title">Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high = well) </h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared sulphur 2% lotion with placebo lotion using a numerical point scoring system (greatly improved +2, somewhat improved +1, no change 0, worse ‐1); however, the SDs were missing (<a href="./references#CD011368-fig-0084" title="">Analysis 9.1</a>). The average score (high = well) was 0.75 in participants receiving sulphur treatment and 0.53 in the placebo group. The authors did not state whether the difference was statistically significant. We assessed the evidence as very low‐quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0018">Table 8</a>). </p> <div class="table" id="CD011368-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Sulphur compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulphur compared to placebo for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Wayne State University Health Service<br/><b>Intervention:</b> topical sulphur<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical sulphur</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Numerical point system defined by investigator, high = well</i> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The score (high = well) was 0.75 in participants receiving sulphur treatment and 0.53 in placebo group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SDs were missing.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b><br/>(112 to 989) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.58</b> <br/>(0.53 to 4.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. Two participants in the placebo group (2/19) versus zero in sulphur group (0/18) developed erythema and drying. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by four levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, and reporting bias. Two levels for imprecision: very small sample size.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> </section> <section id="CD011368-sec-0262"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> reported that six out of 18 people in the topical sulphur 2% lotion group versus four out of 19 people in the placebo group withdrew from the trial. There was no clear difference between topical sulphur 2% lotion and placebo in the medium term (RR 1.58, 95% CI 0.53 to 4.70; 1 study, 37 participants; <a href="./references#CD011368-fig-0085" title="">Analysis 9.2</a>). We assessed the evidence as very low‐quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0018">Table 8</a>). </p> </section> <section id="CD011368-sec-0263"> <h5 class="title">Change in lesion counts (scores, high=well)</h5> <p>Only one study reported data for this outcome; however, the SDs were missing (<a href="./references#CD011368-fig-0086" title="">Analysis 9.3</a>). <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared sulphur 2% lotion with placebo lotion, the score (high = well) of comedone‐pustule was ‐ 0.70 in participants receiving sulphur treatment and 0.00 in the placebo group; the authors did not state whether this difference was statistically significant. In addition, the score (high = well) of papule‐cyst was 0.30 in participants receiving sulphur treatment and 0.53 in the placebo group; the authors did not state whether this difference was statistically significant. </p> </section> <section id="CD011368-sec-0264"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared topical sulphur 2% lotion with placebo using a scoring system defined by investigators (unchanged or worse: ‐4 to 0, minimal improvement: 0.1 to 3.99, moderate improvement: 4 to 5.99, good improvement: 6 to 8). There was no significant difference between treatment groups in the moderate to good improvement categories in the medium term (RR 1.48, 95% CI 0.57 to 3.82; 1 study, 37 participants; <a href="./references#CD011368-fig-0087" title="">Analysis 9.4</a>). </p> </section> <section id="CD011368-sec-0265"> <h5 class="title">Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) </h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared sulphur 2% lotion with placebo lotion; however, the SDs were missing (<a href="./references#CD011368-fig-0088" title="">Analysis 9.5</a>). Trial authors assessed this outcome using a numerical point scoring system (complete improvement +3, moderate improvement +2, slight improvement +1, questionable 0, no change 0, worse ‐1). The average score (high = well) was 0.50 in participants receiving sulphur treatment and 0.94 in the placebo group. The authors did not state whether this difference was statistically significant. </p> </section> <section id="CD011368-sec-0266"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0267"> <h6 class="title">Erythema and drying</h6> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared sulphur 2% lotion with placebo lotion. The authors reported that zero out of 18 people in the topical sulphur 2% lotion group versus two out of 19 people experienced erythema and drying (P = 0.49, Fisher's Exact test). There was no clear difference between treatment groups (RR 0.21, 95% CI 0.01 to 4.11; 1 study, 37 participants; <a href="./references#CD011368-fig-0089" title="">Analysis 9.6</a>). </p> </section> </section> <section id="CD011368-sec-0268"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0269"> <h4 class="title">Comparison 10: topical sulphur versus no treatment (including studies with a co‐intervention in both arms) </h4> <section id="CD011368-sec-0270"> <h5 class="title">Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high = well) </h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared sulphur 2% + benzoyl peroxide 5% lotion with benzoyl peroxide 5% lotion using a numerical point scoring system (greatly improved +2, somewhat improved +1, no change 0, worse ‐1); however, the SDs were missing (<a href="./references#CD011368-fig-0090" title="">Analysis 10.1</a>). The average score (high = well) was 1.15 in participants receiving sulphur + benzoyl peroxide treatment and 0.66 in the benzoyl peroxide group. The authors did not state whether the difference was statistically significant. </p> </section> <section id="CD011368-sec-0271"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> reported that six out of 19 people in the topical sulphur 2% + benzoyl peroxide 5% lotion group versus two out of 16 people in the benzoyl peroxide 5% lotion group withdrew from the trial (P = 0.24, Fisher's Exact test). There was no clear difference between topical sulphur 2% + benzoyl peroxide 5% lotion and benzoyl peroxide 5% lotion in the medium term (RR 2.53, 95% CI 0.59 to 10.83; 1 study, 35 participants; <a href="./references#CD011368-fig-0091" title="">Analysis 10.2</a>). </p> </section> <section id="CD011368-sec-0272"> <h5 class="title">Change in lesion counts (scores, high = well)</h5> <p>Only one study reported data for this outcome; however, the SDs were missing (<a href="./references#CD011368-fig-0092" title="">Analysis 10.3</a>). <a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared sulphur 2% + benzoyl peroxide 5% lotion with benzoyl peroxide 5% lotion, the score (high = well) of comedone‐pustule was 0.81 in participants receiving sulphur 2% + benzoyl peroxide 5% lotion and 0.55 in the benzoyl peroxide 5% lotion group, the score (high = well) of papule‐cyst was 0.91 in participants receiving sulphur 2% + benzoyl peroxide 5% lotion treatment and 0.69 in the benzoyl peroxide 5% lotion group. The authors did not state whether this difference was statistically significant. </p> </section> <section id="CD011368-sec-0273"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared topical sulphur 2% + benzoyl peroxide 5% lotion with benzoyl peroxide 5% lotion using a scoring system defined by investigators (unchanged or worse: ‐4 to 0, minimal improvement: 0.1 to 3.99, moderate improvement: 4 to 5.99, good improvement: 6 to 8). There was no significant difference between treatment groups in the moderate to good improvement categories in the medium term (RR 1.52, 95% CI 0.64 to 3.61; 1 study, 35 participants; <a href="./references#CD011368-fig-0093" title="">Analysis 10.4</a>). </p> </section> <section id="CD011368-sec-0274"> <h5 class="title">Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) </h5> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> compared topical sulphur 2% + benzoyl peroxide 5% lotion with benzoyl peroxide 5% lotion; however, the SDs were missing (<a href="./references#CD011368-fig-0094" title="">Analysis 10.5</a>). Trial authors assessed this outcome by using a numerical point scoring system (complete improvement +3, moderate improvement +2, slight improvement +1, questionable 0, no change 0, worse ‐1). The average score (high = well) was 1.53 in participants receiving sulphur 2% + benzoyl peroxide 5% treatment and 1.07 in the benzoyl peroxide 5% group. The authors did not state whether this difference was statistically significant. </p> </section> <section id="CD011368-sec-0275"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0276"> <h6 class="title">Erythema and drying</h6> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> reported that four out of 19 people in the topical sulphur 2% + benzoyl peroxide 5% lotion group versus five out of 16 people in the benzoyl peroxide 5% lotion group experienced erythema and drying (P = 0.70, Fisher's Exact test). There was no clear difference between treatment groups (RR 0.22, 95% CI 0.22 to 2.09; 1 study, 35 participants; <a href="./references#CD011368-fig-0095" title="">Analysis 10.6</a>). </p> </section> </section> <section id="CD011368-sec-0277"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0278"> <h4 class="title">Comparison 11: topical zinc versus other topical treatments</h4> <section id="CD011368-sec-0279"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p>No study collected data for this outcome.</p> </section> <section id="CD011368-sec-0280"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a> reported that three out of 23 people in the 5% zinc sulphate solution group versus four out of 24 people in the 2% tea lotion group withdrew from the trial (P = 1.00, Fisher's Exact test). There was no significant difference between the 5% zinc sulphate solution group and the 2% tea lotion group in the medium term (RR 0.78, 95% CI 0.20 to 3.12; 1 study, 47 participants; <a href="./references#CD011368-fig-0096" title="">Analysis 11.1</a>). We rated the quality of evidence as very low due to risk of bias and imprecision (<a href="#CD011368-tbl-0019">Table 9</a>). </p> <div class="table" id="CD011368-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Zinc compared to tea</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc compared to tea for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Department of Dermatology and Venereology, Baghdad Teaching Hospital, Baghdad, Iraq<br/><b>Intervention:</b> topical zinc<br/><b>Comparison:</b> topical tea </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical tea</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical zinc</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(33 to 520) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/>(0.20 to 3.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>304 per 1000</b><br/>(113 to 823) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/>(0.54 to 3.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Five people experienced burning and two experienced itching in the zinc sulphate treatment group, in contrast, five people had mild itching in the tea lotion treatment group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by four levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition bias and with unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> </section> <section id="CD011368-sec-0281"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0282"> <h6 class="title">Papules (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a> reported data collected in the medium term. There was no clear difference between 5% zinc sulphate solution and 2% tea lotion (MD ‐2.44, 95% CI ‐7.80 to 2.92; 1 study, 40 participants; <a href="./references#CD011368-fig-0097" title="">Analysis 11.2</a>). </p> </section> <section id="CD011368-sec-0283"> <h6 class="title">Pustules (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a> reported data collected in the medium term. There was no significant difference between 5% zinc sulphate solution and 2% tea lotion (MD ‐0.70, 95% CI ‐6.97 to 5.57; 1 study, 40 participants; <a href="./references#CD011368-fig-0098" title="">Analysis 11.3</a>). </p> </section> </section> <section id="CD011368-sec-0284"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p>For this outcome, there were no data reported in the short and long term; <a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a> reported data collected in the medium term and assessed this outcome using a three‐point system defined by the trial authors (reduction of more than 50% inflamed lesion count: good; 10% to 50% reduction: moderate; less than 10% reduction: no response). There was no significant difference between 5% zinc sulphate solution and 2% tea lotion in the good or moderate response categories (RR 0.80, 95% CI 0.51 to 1.24; 1 study, 47 participants; <a href="./references#CD011368-fig-0099" title="">Analysis 11.4</a>). </p> </section> <section id="CD011368-sec-0285"> <h5 class="title">Minor adverse events ‐ total events</h5> <section id="CD011368-sec-0286"> <h6 class="title">Zinc versus tea</h6> <p><a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a> reported no significant difference between 5% zinc sulphate solution and 2% tea lotion (RR 1.46, 95% CI 0.54 to 3.95; 1 study, 47 participants; <a href="./references#CD011368-fig-0100" title="">Analysis 11.5</a>). We rated the quality of evidence as very low due to risk of bias and imprecision (<a href="#CD011368-tbl-0019">Table 9</a>). </p> </section> </section> <section id="CD011368-sec-0287"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0288"> <h4 class="title">Comparison 12: topical zinc versus no treatment (including studies with a co‐intervention in both arms) </h4> <section id="CD011368-sec-0289"> <h5 class="title">Participants' global self‐assessment of acne improvement (visual analogue scale)</h5> <p>Only one study that compared zinc/clindamycin 1% gel with clindamycin 1% gel reported data for this outcome (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>); however, the data were not available for meta‐analysis due to no reporting of means ± SDs (<a href="./references#CD011368-fig-0101" title="">Analysis 12.1</a>). The study authors only reported that there was no significant difference between treatment groups for this outcome in the long term (16 weeks after start of treatment) but they did not report the visual analogue scale or P values. We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0020">Table 10</a>). </p> <div class="table" id="CD011368-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Zinc compared to no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc compared to no treatment for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> eight centres in the UK, one in France and one in Germany<br/><b>Intervention:</b> topical zinc plus clindamycin 1% gel<br/><b>Comparison:</b> no treatment plus clindamycin 1% gel </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical zinc</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Visual analogue scale</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The study authors only reported no significant difference between treatment groups.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin 1% gel was a co‐intervention given in both arms. No numerical data provided.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b><br/>(31 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/>(0.43 to 3.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin 1% gel was a co‐intervention given in both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin 1% gel was a co‐intervention given in both arms.</p> <p>The authors only report number of adverse events, not number of participants ‐ 91 adverse events in 80 zinc/clindamycin participants and 117 adverse events in 83 clindamycin participants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: small sample size.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: small sample size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> </section> <section id="CD011368-sec-0290"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a> compared zinc/clindamycin 1% gel with clindamycin 1% gel. There was no significant difference between treatment groups in the long term (16 weeks after start of treatment) (RR 1.21, 95% CI 0.43 to 3.45; 1 study, 163 participants; <a href="./references#CD011368-fig-0102" title="">Analysis 12.2</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0020">Table 10</a>). </p> </section> <section id="CD011368-sec-0291"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0292"> <h6 class="title">Total (lesion counts reduction)</h6> <p>Only one study that compared zinc/clindamycin 1% gel with clindamycin 1% gel reported data for this outcome (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>); however, the data were not available for meta‐analysis due to no reporting of means and SDs; instead we presented the data in a table (see table in <a href="./references#CD011368-fig-0103" title="">Analysis 12.3</a>). There was no significant difference between treatment groups in the medium and long term (16 weeks after start of treatment) (P = 0.707), but the authors did not report the data in each group. </p> </section> <section id="CD011368-sec-0293"> <h6 class="title">Inflamed (lesion counts reduction)</h6> <p>Two studies reported data for this outcome; however, the data were not available for meta‐analysis due to no reporting of means and SDs <a href="./references#CD011368-fig-0104" title="">Analysis 12.4</a>. <a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a> compared 1.2% zinc/4% erythromycin with 4% erythromycin in the long term (12 weeks after start of treatment) and reported an improvement in both groups after intervention; however, they did not state whether there was a difference between groups. In another trial that compared zinc/clindamycin 1% gel with clindamycin 1% gel (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>), the results demonstrated no difference in the long term (16 weeks after start of treatment) between groups (P = 0.626); the authors also did not report the values of reduction in inflamed lesion counts. </p> </section> <section id="CD011368-sec-0294"> <h6 class="title">Non‐inflamed (lesion count reduction)</h6> <p>Two studies reported data for this outcome; however, the data were not available for meta‐analysis due to no reporting of means and SDs; we presented the data in a table instead (see table in <a href="./references#CD011368-fig-0105" title="">Analysis 12.5</a>). <a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a> compared 1.2% zinc/4% erythromycin with 4% erythromycin in the long term (12 weeks after start of treatment), the study authors did not report the values of reduction in non‐inflamed lesion counts or the P value. In another trial that compared zinc/clindamycin 1% gel with clindamycin 1% gel (<a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a>), the results demonstrated no difference in the medium and long term (16 weeks after start of treatment) between groups (P = 0.769); the authors also did not report the values of reduction in non‐inflamed lesion counts. </p> </section> </section> <section id="CD011368-sec-0295"> <h5 class="title">Physicians' global evaluation of acne improvement (visual analogue scale)</h5> <p><a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a> compared zinc/clindamycin 1% gel with clindamycin 1% gel; however, the data were not available for meta‐analysis due to no reporting of means or SDs; we presented the data in a table (see table in <a href="./references#CD011368-fig-0106" title="">Analysis 12.6</a>). There was no significant difference between groups in the long term (16 weeks after start of treatment) but the study authors did not report the visual analogue scale or P values. </p> </section> <section id="CD011368-sec-0296"> <h5 class="title">Minor adverse events</h5> <p>We did not find any studies that reported total number of participants experiencing at least one minor adverse event. <a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a> compared zinc/clindamycin 1% gel with clindamycin 1% gel, but the study authors did not report the P value and showed results as count data (<a href="./references#CD011368-fig-0107" title="">Analysis 12.7</a>). The total number of adverse events was 91 in 80 participants receiving zinc/clindamycin 1% gel and 117 in 83 participants receiving clindamycin 1% gel. We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0020">Table 10</a>). </p> </section> <section id="CD011368-sec-0297"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0298"> <h4 class="title">Comparison 13: topical alpha‐hydroxy acid versus other topical treatments</h4> <section id="CD011368-sec-0299"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> and <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels. <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> used a visual analogue scale (poor &lt; 30% improvement; fair 30% to 60% improvement; and good &gt; 60% improvement); <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> also used a visual analogue scale (good &gt; 60%; fair 31% to 60%; poor &lt; 30%; no change, worse). Both treatments demonstrated significant fair to good improvement, and there was no clear difference between groups in the long term (12 weeks after start of treatment) (RR 1.06, 95% CI 0.88 to 1.26; 1 study, 40 participants; <a href="./references#CD011368-fig-0108" title="">Analysis 13.1</a>). We assessed the evidence as low quality due to imprecision (<a href="./full#CD011368-tbl-0010">summary of findings Table 10</a>). In <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a>, the authors collected data in the post‐treatment follow‐up period and reported that 20 out of 22 people in the 35% glycolic acid peel group versus 20 out of 22 people in the 20% salicylic ‐ 10% mandelic acid peel group demonstrated fair to good improvement at three months post‐treatment (treatment duration of 12 weeks, measured in the post‐treatment follow‐up period). </p> </section> <section id="CD011368-sec-0300"> <h5 class="title">Withdrawal for any reason</h5> <p><a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> compared topical alpha‐hydroxy acid (gluconolactone 14% in solution) and benzoyl peroxide 5% lotion. There was no significant difference between treatment groups in the long term (12 weeks after start of treatment) (RR 0.83, 95% CI 0.27 to 2.55; 1 study, 100 participants; <a href="./references#CD011368-fig-0109" title="">Analysis 13.2</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0021">Table 11</a>). </p> <div class="table" id="CD011368-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Gluconolactone (alpha‐hydroxy acid) compared to benzoyl peroxide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gluconolactone (alpha‐hydroxy acid) compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described<br/><b>Intervention:</b> topical gluconolactone (alpha‐hydroxy acid)<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical gluconolactone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(32 to 306) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/>(0.27 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(135 to 425) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> <br/>(0.27 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dryness was the most commonly reported problem in treatment groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias, and with unclear risk of selection bias and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias and unclear risk of selection and reporting bias. One level for imprecision: optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> and <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels; neither treatment group had any withdrawals in the long term (12 weeks after start of treatment) (<a href="./references#CD011368-fig-0109" title="">Analysis 13.2</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0010">summary of findings Table 10</a>). </p> </section> <section id="CD011368-sec-0301"> <h5 class="title">Change in lesion counts</h5> <section id="CD011368-sec-0302"> <h6 class="title">Non‐inflamed (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels in the short and medium term; there was a clear significant difference between groups at both treatment terms in favour of 20% salicylic ‐ 10% mandelic acid peels. Short term: MD 10.00 (95% CI 4.41 to 15.59; 1 study, 40 participants) and medium term: MD 11.90 (95% CI 7.17 to 16.63; 1 study, 40 participants) (<a href="./references#CD011368-fig-0110" title="">Analysis 13.3</a>). The authors also reported data collected at two months post‐treatment (treatment duration of 12 weeks, measured at the post‐treatment follow‐up period); the 20% salicylic ‐ 10% mandelic acid peels was favoured (1.8 ± 1.99 in 20% salicylic ‐ 10% mandelic acid peels group versus 14.3 ± 10.03 in the 35% glycolic acid peels group). </p> </section> <section id="CD011368-sec-0303"> <h6 class="title">Papules (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels in the long term; there was a clear significant difference between groups in favour of 20% salicylic ‐ 10% mandelic acid peels (MD 1.25, 95% CI 0.36 to 2.14; 1 study, 40 participants) (<a href="./references#CD011368-fig-0111" title="">Analysis 13.4</a>). The authors also reported data collected at two months post‐treatment (treatment duration of 12 weeks, measured at the post‐treatment follow‐up period); the 20% salicylic ‐ 10% mandelic acid peels group was favoured (2.45 ± 1.28 in 20% salicylic ‐ 10% mandelic acid peels group versus 3.4 ± 1.57 in the 35% glycolic acid peels group). </p> </section> <section id="CD011368-sec-0304"> <h6 class="title">Pustules (number of lesions post‐intervention)</h6> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels in the long term; there was a clear significant difference between groups in favour of 20% salicylic ‐ 10% mandelic acid peels (MD 1.20, 95% CI 0.44 to 1.96; 1 study, 40 participants) (<a href="./references#CD011368-fig-0112" title="">Analysis 13.5</a>). The authors also reported data collected at two months post‐treatment (treatment duration of 12 weeks, measured at the post‐treatment follow‐up period); the 20% salicylic ‐ 10% mandelic acid peels group was favoured (2.2 ± 1.47 in 20% salicylic ‐ 10% mandelic acid peels group versus 3.75 ± 1.997 in the 35% glycolic acid peels group). </p> </section> <section id="CD011368-sec-0305"> <h6 class="title">Total (counts or percentage)</h6> <p><a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a>, a parallel study, reported data for this outcome; however, the data were not available for meta‐analysis due to no reporting of means and SDs (<a href="./references#CD011368-fig-0113" title="">Analysis 13.6</a>). The study authors only stated there was no significant difference in total lesion count reduction between alpha‐hydroxy acid (gluconolactone 14% in solution) and benzoyl peroxide 5% lotion in the short, medium, and long term (12 weeks after start of treatment), but they did not report data in each group. </p> <p><a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>, a split‐face design, also reported data for this outcome. The study authors compared 30% glycolic acid peels with 30% salicylic acid peels; there was no statistically significant difference between groups in percentage reduction of total lesions at one month post‐treatment (P &gt; 0.05) (treatment duration of 10 weeks, measured at the post‐treatment follow‐up period) (<a href="./references#CD011368-fig-0113" title="">Analysis 13.6</a>). </p> </section> <section id="CD011368-sec-0306"> <h6 class="title">Inflamed (counts)</h6> <p>Two studies reported data for this outcome. <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> did not provide means and SDs, and in <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>, data were skewed, so we could only present the data in a table (see table in <a href="./references#CD011368-fig-0114" title="">Analysis 13.7</a>). In the parallel <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> trail that compared alpha‐hydroxy acid (gluconolactone 14% in solution) with benzoyl peroxide 5% lotion, there was significant difference in the medium (P &lt; 0.05) and long term (12 weeks after start of treatment) (P &lt; 0.05), indicating that benzoyl peroxide can lead to a greater reduction in lesion counts, but no difference was observed in the short term. In the split‐face <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a> trial that compared alpha‐hydroxy acid (glycolic acid) 20% to 70% peels with amino fruit acid 20% to 60% peels, there was no significant difference between groups in number of inflamed lesions in the short, medium, and long term (6 months after start of treatment) (P &gt; 0.05). The mean number of inflamed lesions post‐intervention in the alpha‐hydroxy acid (glycolic acid) peel group was close to that in the amino fruit acid peels group for the same time period, but the data were skewed (e.g. mean ± SD: 10.08 ± 5.72 in the alpha‐hydroxy acid group; 8.67 ± 4.48 in the amino fruit acid peels group). </p> </section> <section id="CD011368-sec-0307"> <h6 class="title">Non‐inflamed (counts)</h6> <p>Two studies reported data for this outcome; however, <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> did not provide means and SDs and in <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>, data were skewed (<a href="./references#CD011368-fig-0115" title="">Analysis 13.8</a>). In the parallel <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> trial that compared alpha‐hydroxy acid (gluconolactone 14% in solution) with benzoyl peroxide 5% lotion, there was no significant difference between groups in lesion count reduction in the short, medium, and long term (12 weeks after start of treatment) (no exact P value reported). In the split‐face <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a> trial that compared alpha‐hydroxy acid (glycolic acid) 20% to 70% peels with amino fruit acid 20% to 60% peels, there was no significant difference between groups in number of non‐inflamed lesions in the short, medium, and long term (6 months after start of treatment) (P &gt; 0.05). The mean number of non‐inflamed lesions post‐intervention in the alpha‐hydroxy acid (glycolic acid) peel group was close to that in the amino fruit acid peels group for the same time period, but the data were skewed (e.g. mean ± SD: 36.29 ± 37.37 in the alpha‐hydroxy acid group; 36.00 ± 40.42 in the amino fruit acid peels group). </p> </section> </section> <section id="CD011368-sec-0308"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> and <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels using the same five‐point visual analogue scale (worse; no change; poor: &lt; 30% improvement; fair: 31% to 60% improvement; good: &gt; 60% improvement). <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> reported that two out of 20 people in the 35% glycolic acid peels group versus five out of 20 people in the 20% salicylic ‐ 10% mandelic acid peels group demonstrated fair to good improvement in the short term (P = 0.41, Fisher's Exact test). The 35% glycolic acid peels group showed fewer numbers of participants with fair to good improvement for all treatment terms; the difference was statistically significant in the medium (RR 0.29, 95% CI 0.11 to 0.72; 1 study, 40 participants) but not in the short term (RR 0.40, 95% CI 0.09 to 1.83; 1 study, 40 participants) or long term (RR 0.95, 95% CI 0.79 to 1.13; 1 study, 40 participants) (<a href="./references#CD011368-fig-0116" title="">Analysis 13.9</a>). In <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>, the authors also collected data at the post‐treatment follow‐up period and reported that 16 out of 20 people in the 35% glycolic acid peels group versus 19 out of 20 people in the 20% salicylic ‐ 10% mandelic acid peels group demonstrated fair to good improvement at two months post‐treatment (treatment duration of 12 weeks, measured at the post‐treatment follow‐up period). <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> reported that 20 out of 22 people in the 35% glycolic acid peels group versus 21 out of 22 people in the 20% salicylic ‐ 10% mandelic acid peels group demonstrated fair to good improvement at three months post‐treatment (treatment duration of 12 weeks, measured at the post‐treatment follow‐up period). </p> <section id="CD011368-sec-0309"> <h6 class="title">Physicians' global evaluation of acne improvement (percentage) ‐ split‐face design</h6> <p>Only one study reported data for this outcome at two months post‐treatment (treatment duration of 10 weeks, measured at the post‐treatment follow‐up period); however, the SDs were missing, so we presented the data in a table (see table in <a href="./references#CD011368-fig-0117" title="">Analysis 13.10</a>). The trial authors assessed this outcome using a five‐point system (good: more than 50% improvement; fair: 21% to 50% improvement; poor: 10% to 20% improvement; no change; or worse). In this split‐face trial (<a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a>), the authors did not report whether there was a difference between the alpha‐hydroxy acid (glycolic acid 30% peel) group and the salicylic acid 30% peel group. </p> </section> </section> <section id="CD011368-sec-0310"> <h5 class="title">Minor adverse events</h5> <section id="CD011368-sec-0311"> <h6 class="title">Total events ‐ gluconolactone (alpha‐hydroxy acid) versus benzoyl peroxide</h6> <p><a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> compared alpha‐hydroxy acid (gluconolactone 14% in solution) with benzoyl peroxide 5% lotion and showed that alpha‐hydroxy acid had a lower risk of minor adverse events than benzoyl peroxide (12/50 versus 25/50). There was a significant difference (RR 0.48, 95% CI 0.27 to 0.85; 1 study, 100 participants; <a href="./references#CD011368-fig-0118" title="">Analysis 13.11</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0021">Table 11</a>). </p> </section> <section id="CD011368-sec-0312"> <h6 class="title">Total events ‐ glycolic acid versus salicylic ‐ mandelic acid</h6> <p><a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels; there was no difference between groups (RR 1.80, 95% CI 0.72 to 4.52; 1 study, 44 participants; <a href="./references#CD011368-fig-0118" title="">Analysis 13.11</a>). We assessed the evidence as very low quality due to risk of bias and imprecision (<a href="./full#CD011368-tbl-0010">summary of findings Table 10</a>). </p> <p>In one split‐face study with no usable outcome data (<a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>), the authors compared 70% glycolic acid peels with Jessner's solution peels. The authors demonstrated the equal treatment effect and lesser degree of exfoliation in the glycolic acid arm. </p> </section> <section id="CD011368-sec-0313"> <h6 class="title">Burning or sensation</h6> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> reported that two out of 20 people in the 35% glycolic acid peels group versus four out of 20 people in the 20% salicylic ‐ 10% mandelic acid peels group experienced burning or sensation (P = 0.66, Fisher's Exact test). There was no difference between groups (RR 0.50, 95% CI 0.10 to 2.43; 1 study, 40 participants; <a href="./references#CD011368-fig-0118" title="">Analysis 13.11</a>). </p> </section> <section id="CD011368-sec-0314"> <h6 class="title">Desquamation</h6> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> and <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> compared 35% glycolic acid peels with 20% salicylic ‐ 10% mandelic acid peels; there was no difference between groups (RR 1.03, 95% CI 0.11 to 9.60; 2 studies, 84 participants; <a href="./references#CD011368-fig-0118" title="">Analysis 13.11</a>). </p> </section> <section id="CD011368-sec-0315"> <h6 class="title">Dryness</h6> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> reported that two out of 20 people in the 35% glycolic acid peels group versus three out of 20 people in the 20% salicylic ‐ 10% mandelic acid peels group experienced dryness (P = 1.00, Fisher's Exact test); there was no difference between groups (RR 0.67, 95% CI 0.12 to 3.57; 1 study, 40 participants; <a href="./references#CD011368-fig-0118" title="">Analysis 13.11</a>). </p> <p><a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> compared alpha‐hydroxy acid (gluconolactone 14% in solution) with benzoyl peroxide 5% lotion but with no numerical data. The authors only reported that the number of participants who experienced dryness in the benzoyl peroxide group was significantly greater than that in the alpha‐hydroxy acid (gluconolactone 14% in solution) group (P &lt; 0.02). </p> </section> <section id="CD011368-sec-0316"> <h6 class="title">Acne flare</h6> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> and <a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> reported that three out of 42 people in the 35% glycolic acid peels group versus three out of 42 people in the 20% salicylic ‐ 10% mandelic acid peels group experienced acne flare (P = 1.00, Fisher's Exact test); there was no difference between groups (RR 1.00, 95% CI 0.22 to 4.63; 2 studies, 84 participants; <a href="./references#CD011368-fig-0118" title="">Analysis 13.11</a>). </p> </section> </section> <section id="CD011368-sec-0317"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0318"> <h4 class="title">Comparison 14: topical alpha‐hydroxy acid versus placebo</h4> <section id="CD011368-sec-0319"> <h5 class="title">Participants' global self‐assessment of acne improvement</h5> <p>No study collected data for this outcome.</p> </section> <section id="CD011368-sec-0320"> <h5 class="title">Withdrawal for any reason</h5> <p>For this outcome, we only found one relevant trial that compared alpha‐hydroxy acid (gluconolactone 14% in solution) with placebo. <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> reported data in the long term (12 weeks after start of treatment). The authors reported that five out of 50 people in the gluconolactone 14% solution group versus four out of 50 people in the placebo group withdrew from the trial (P = 1.00, Fisher's Exact test). There was no significant difference between topical alpha‐hydroxy acid and placebo (RR 1.25, 95% CI 0.36 to 4.38; 1 study, 100 participants; <a href="./references#CD011368-fig-0119" title="">Analysis 14.1</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0022">Table 12</a>). </p> <div class="table" id="CD011368-tbl-0022"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Gluconolactone (alpha‐hydroxy acid) compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gluconolactone (alpha‐hydroxy acid) compared to placebo for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described<br/><b>Intervention:</b> topical gluconolactone (alpha‐hydroxy acid)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical gluconolactone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(29 to 350) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> <br/>(0.36 to 4.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(91 to 631) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.40</b> <br/>(0.91 to 6.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in gluconolactone group reported more erythema, burning and stinging, pruritus and scaling than those in the placebo group, but these differences were not "significant". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias and unclear risk of selection and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias and unclear risk of selection and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </div> </section> <section id="CD011368-sec-0321"> <h5 class="title">Change in lesion counts</h5> <p>No study collected data for this outcome.</p> </section> <section id="CD011368-sec-0322"> <h5 class="title">Physicians' global evaluation of acne improvement</h5> <p>No study collected data for this outcome.</p> </section> <section id="CD011368-sec-0323"> <h5 class="title">Minor adverse events ‐ total events</h5> <p>For this outcome, there were no data reported in the short term and medium term. We only found one relevant trial that compared alpha‐hydroxy acid (gluconolactone 14% in solution) with its placebo. <a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> reported data collected in the long term (12 weeks after start of treatment). There was no "significant" difference between topical alpha‐hydroxy acid and placebo (RR 2.40, 95% CI 0.91 to 6.31; 1 study, 100 participants; <a href="./references#CD011368-fig-0120" title="">Analysis 14.2</a>). We assessed the evidence as low quality due to risk of bias and imprecision (<a href="#CD011368-tbl-0022">Table 12</a>). </p> </section> <section id="CD011368-sec-0324"> <h5 class="title">Quality of life</h5> <p>No study collected data for this outcome.</p> </section> </section> <section id="CD011368-sec-0325"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not conduct funnel plots for primary outcomes, as the number of included studies in each forest plot was fewer than 10. </p> </section> <section id="CD011368-sec-0326"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to perform sensitivity analyses due to the small numbers of studies.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011368-sec-0327" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011368-sec-0327"></div> <section id="CD011368-sec-0328"> <h3 class="title" id="CD011368-sec-0328">Summary of main results</h3> <p>We evaluated six test interventions in this review (topical azelaic acid, topical salicylic acid, topical nicotinamide, topical sulphur, topical zinc, and topical fruit acid (alpha‐hydroxy acid). The most‐assessed treatments were salicylic acid and azelaic acid (assessed by 73.5% of the included studies). The least assessed treatment was sulphur (1 study). With regard to the primary outcomes, 38.8% of the studies measured 'participants global self‐assessment of acne improvement', and 85.7% measured 'withdrawal for any reason'. Minor side effects were well‐reported, but the total number was not always reported in each study; some studies only reported the number of individual side effects. Quality of life was least reported, with only 12.2% of the studies measuring this outcome. </p> <p>Although certain outcomes and interventions were well‐assessed, evidence quality ranged from very low to moderate, with most of the evidence deemed very low or low quality, meaning we cannot draw definitive conclusions about the treatments in question. </p> <p>The following results were measured at the end of treatment, which was long‐term (except for 2 studies where it was medium‐term) for the outcome 'participants' global self‐assessment of acne improvement’ and mixed length (medium‐term mainly) for minor adverse events. We assessed minor adverse events as total number of participants who experienced at least one minor adverse event. </p> <section id="CD011368-sec-0329"> <h4 class="title">Azelaic acid</h4> <p>For participants' global self‐assessment of acne improvement, there is probably little or no difference between treatments when azelaic acid is compared to tretinoin (moderate‐quality evidence; <a href="./full#CD011368-tbl-0004">summary of findings Table 4</a>), and there may be little or no difference between treatments when azelaic acid is compared to clindamycin (low‐quality evidence; <a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>). We are uncertain if there is a difference between azelaic acid and adapalene (very low‐quality evidence; <a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>). Azelaic acid is probably less effective than benzoyl peroxide (moderate‐quality evidence; <a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>). </p> <p>When assessing our other primary outcome, withdrawal (for any reason), low‐quality evidence showed there may be no difference between azelaic acid versus benzoyl peroxide, clindamycin, or tretinoin (<a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011368-tbl-0004">summary of findings Table 4</a>). When comparing azelaic acid to adapalene, we are uncertain of the effect on number of withdrawals due to very low‐quality evidence (<a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>). </p> <p>Most adverse events reported were mild in nature and were limited to the application sites. Based on results of single small studies, we are not certain of total minor adverse events when comparing azelaic acid with adapalene or benzoyl peroxide (very low‐quality evidence; <a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011368-tbl-0002">summary of findings Table 2</a>). There may be no difference between groups in total minor adverse events when comparing azelaic acid to clindamycin (low‐quality evidence; <a href="./full#CD011368-tbl-0003">summary of findings Table 3</a>). In the studies comparing azelaic acid to tretinoin, the total number of minor adverse events were not reported, but the study authors did report individual application site reactions, such as scaling (<a href="./full#CD011368-tbl-0004">summary of findings Table 4</a>). </p> <p>Quality of life was not well‐assessed by the studies evaluating azelaic acid, and we are uncertain of the effect of azelaic acid compared to adapalene due to very low‐quality evidence (<a href="./full#CD011368-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD011368-sec-0330"> <h4 class="title">Salicylic acid</h4> <p>For participants' global self‐assessment of acne improvement, results may be similar with salicylic acid compared to pyruvic acid tretinoin (low‐quality evidence; <a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). We are not certain of the effect of salicylic acid compared to pyruvic acid (very low‐quality evidence; <a href="./full#CD011368-tbl-0006">summary of findings Table 6</a>). This outcome was not assessed in the study comparing salicylic acid to benzoyl peroxide (<a href="./full#CD011368-tbl-0005">summary of findings Table 5</a>). </p> <p>When comparing salicylic acid to benzoyl peroxide, we are uncertain of the effect on number of withdrawals due to very low‐quality evidence (<a href="./full#CD011368-tbl-0005">summary of findings Table 5</a>). There may be no difference between groups in the number of withdrawals when comparing salicylic acid and pyruvic acid (low‐quality evidence; <a href="./full#CD011368-tbl-0006">summary of findings Table 6</a>). There were no withdrawals when salicylic acid was compared to tretinoin (low‐quality evidence; <a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). </p> <p>All side effects reported were of mild to moderate intensity and transient. The incidence of total minor adverse events when comparing salicylic acid with benzoyl peroxide or tretinoin was uncertain due to very low‐quality evidence (<a href="./full#CD011368-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). Total minor adverse events were not reported in the trial comparing salicylic acid to pyruvic acid (<a href="./full#CD011368-tbl-0006">summary of findings Table 6</a>), but individual application site reactions were reported, such as scaling and redness. </p> <p>Quality of life was not well‐assessed by the studies evaluating salicylic acid, and we are uncertain of the effect of salicylic acid compared to benzoyl peroxide or tretinoin due to very low‐quality evidence (<a href="./full#CD011368-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD011368-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD011368-sec-0331"> <h4 class="title">Nicotinamide</h4> <p>Out of the four studies which assessed nicotinamide against clindamycin or erythromycin, none reported data for participants' global self‐assessment of acne improvement. There may be no differences in rate of withdrawals when comparing nicotinamide to clindamycin or erythromycin, based on low‐quality evidence (<a href="./full#CD011368-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD011368-tbl-0009">summary of findings Table 9</a>). Most adverse events reported were local application site reactions. Based on the results of three studies, there may be no difference in the incidence of total minor adverse events when comparing nicotinamide with clindamycin (low‐quality evidence; <a href="./full#CD011368-tbl-0008">summary of findings Table 8</a>). The total number of minor adverse events was not reported for nicotinamide versus erythromycin. No studies collected data for quality of life. </p> </section> <section id="CD011368-sec-0332"> <h4 class="title">Alpha‐hydroxy (fruit) acid</h4> <p>Glycolic acid peels may make no difference to participants' global self‐assessment of acne improvement when compared with salicylic‐mandelic acid peels, and there were no withdrawals in this comparison (both low‐quality evidence; <a href="./full#CD011368-tbl-0010">summary of findings Table 10</a>). We are uncertain if there is a difference between the two groups in total minor adverse events due to very low‐quality evidence (<a href="./full#CD011368-tbl-0010">summary of findings Table 10</a>). Adverse events associated with alpha‐hydroxy acid treatment were always mild in nature. This comparison did not assess quality of life. </p> </section> </section> <section id="CD011368-sec-0333"> <h3 class="title" id="CD011368-sec-0333">Overall completeness and applicability of evidence</h3> <p>The eligible evidence included in this review is not sufficient to address all of our prespecified objectives. The limited number of randomised controlled trials (RCTs) concerning the use of the review's topical treatments of interest make it hard to evaluate their efficacy, and combining study results for meta‐analysis was challenging due to the variability in conducting and reporting of trials. </p> <p>Of the 49 included studies, 47 studies had a total of 3880 participants, and two studies did not report the sample size (<a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>). All eligible trials investigated participants with different forms or severity of acne vulgaris. Of the total included participants in this review, 75.7% (2939 participants from 33 trials) had mild to moderate acne, 10.3% (399 participants from 5 trials) probably also had mild to moderate acne, 4.8% (188 participants from 3 trials) had unknown acne severity, and only a part of the remaining 9.1% (354 participants from 6 trials) had a severe form of acne. </p> <p>The age of participants from 41 studies ranged from 10 years old to 45 years old; the other eight studies did not report these data. Based on what the trials reported, most participants were aged 12 to 30 years, and there were more female than male participants, which is reflective of the age group and sex in which acne is most prevalent. </p> <p>Treatment was overwhelmingly of medium‐ to long‐term duration. Medium‐term treatment was classed as treatment applied for four to eight weeks, and long‐term treatment was deemed as any intervention applied for more than eight weeks. The length of treatment duration in some studies (e.g. a 5‐day treatment duration in <a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a>) could have been too short to detect a significant difference between treatment groups. </p> <p>We identified RCTs for all of the six test interventions. Most studies assessed salicylic acid and azelaic acid; four studies investigated nicotinamide; three studies tested the efficacy and safety of zinc; and six studies investigated the efficacy and safety of alpha‐hydroxy acid. Sulphur was the least‐assessed intervention, with only one study testing its efficacy and safety. However, the least‐assessed treatments (sulphur, zinc, and gluconolactone) are no longer used in common current clinical practice. Thirty‐one studies compared the above interventions with active treatments, such as clindamycin, erythromycin, tretinoin, and benzoyl peroxide. Fourteen studies compared the interventions with placebo control or no treatment. Four studies compared the interventions with both active treatments and placebo. This means that for some of the core comparisons we found no evidence. For example, we did not identify any studies comparing azelaic acid with placebo that assessed the outcome of participants' global self‐assessment of acne improvement; neither did we identify any studies comparing nicotinamide with placebo or no treatment that assessed any of the outcomes. </p> <p>Less than half of the trials assessed the primary outcome 'participants' global self‐assessment of acne improvement' (19/49). In terms of safety, 42/50 trials measured 'withdrawal for any reason', and although the total number of minor adverse events was not always reported, individual side effects were. The least‐reported outcome was quality of life, which was measured by six studies. </p> </section> <section id="CD011368-sec-0334"> <h3 class="title" id="CD011368-sec-0334">Quality of the evidence</h3> <section id="CD011368-sec-0335"> <h4 class="title">Limitations in study design and implementation</h4> <p>Our assessments of risk of bias revealed considerable variations in study design and implementation among the included studies. Only eight studies clearly addressed how the randomisation was performed (<a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a>; <a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>; <a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>; <a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a>; <a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a>; <a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a>; <a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a>; <a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a>), and only one study author stated how to conceal the allocation (<a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a>). Thirty‐nine studies had a double‐ or single‐blind design, but more than half of the studies did not report sufficient information about their methods to confirm blinding of participants/personnel and assessors. The remaining 10 studies did not mention blinding information. We rated 11 of the included trials to be at high risk of attrition bias. It should be noted that a significant proportion of the outcome data were of skewed distribution, and we presented them in additional tables in the <a href="./references#CD011368-sec-0346" title="">Data and analyses</a> section. In addition, the study authors frequently did not report SDs and the continuous data could not be analysed in meta‐analysis in such instances. For most of the comparisons, it was only possible to get pooled estimates with limited number of trials. Therefore, we downgraded all of the outcomes assessed via GRADE by at least one level for study limitations due to high/unclear risk of bias (we downgraded a small minority of outcomes by two levels for very serious study limitations). </p> </section> <section id="CD011368-sec-0336"> <h4 class="title">Indirectness of the evidence</h4> <p>The included studies in our review assessed representative populations, though no studies included participants with neonatal and infantile acne. In our review, we included both active‐ and placebo‐controlled trials, rendering it applicable to assess the efficacy of most of the interventions. However, we failed to include some trials that compared nicotinamide to placebo/no treatment. The evidence provided by the included head‐to‐head trials was both relevant and direct. We did not downgrade the 'indirectness' domain in all GRADE assessments. </p> </section> <section id="CD011368-sec-0337"> <h4 class="title">Inconsistency of the results</h4> <p>We failed to find high levels of heterogeneity in all cases, mainly because the evidence for many comparisons/outcomes was based on a single study. Therefore, we did not downgrade for 'inconsistency' in any of our GRADE assessments. </p> </section> <section id="CD011368-sec-0338"> <h4 class="title">Imprecision of the results</h4> <p>The very limited number of included studies examining six test interventions did not allow us to substantively evaluate the degree of precision of the effect estimates. In most instances, there was only a single study in each comparison, and wide confidence intervals (CIs), small sample sizes (optimal sample size is not met) or total number of events (&lt; 300) were responsible for the imprecision. Therefore, we downgraded the majority of outcomes assessed via GRADE by one level for serious imprecision. </p> </section> <section id="CD011368-sec-0339"> <h4 class="title">Publication bias</h4> <p>We were unable to assess publication bias because none of the comparisons had more than 10 studies. Therefore, it is meaningless to create funnel plots. We did not downgrade the 'Publication bias' domain in any GRADE assessments. </p> </section> </section> <section id="CD011368-sec-0340"> <h3 class="title" id="CD011368-sec-0340">Potential biases in the review process</h3> <p>As shown in <a href="#CD011368-sec-0031">Electronic searches</a>, we conducted a systematic electronic search of databases. In addition, we also checked the bibliographies of included studies for further references to relevant trials. However, the fact that 15 potentially eligible studies have not yet been incorporated may be a source of potential bias. We were unable to contact some study authors for further data due to the lack of a correspondence email address. We contacted study authors in order to obtain additional data, but only a few replied and not all provided us with the requested data. </p> <p>Although there were some departures from the protocol (see <a href="#CD011368-sec-0366">Differences between protocol and review</a>), these changes are unlikely to be a potential source of bias. We did not make any a posteriori decisions about the analysis or investigation of heterogeneity after seeing the data. </p> <p>Our inclusion of studies investigating a synergistic salicylic acid microgel complex could be questioned (<a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a>; <a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a>; <a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a>; <a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a>). These four studies were published as abstracts with no contact emails; thus, based on this insufficient information, we did not know the components and the drug delivery system of the intervention. </p> </section> <section id="CD011368-sec-0341"> <h3 class="title" id="CD011368-sec-0341">Agreements and disagreements with other studies or reviews</h3> <p>There have been no reviews published which evaluated these topical treatments in a systematic way. Our review substantially updates and improves the previous work in this area. The findings of this review generally agree with the findings in previous summary reviews (<a href="./references#CD011368-bbs2-0152" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence-based review. American Journal of Clinical Dermatology2012;13(3):141-52. [MEDLINE: 22268388]">Gamble 2012</a>; <a href="./references#CD011368-bbs2-0159" title="HaiderA , ShawJC . Treatment of acne vulgaris. JAMA2004;292(6):726-35. [MEDLINE: 15304471]">Haider 2004</a>; <a href="./references#CD011368-bbs2-0183" title="PurdyS , deBerkerD . Acne vulgaris. Clinical Evidence2011;2011:1714. [MEDLINE: 21477388]">Purdy 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011368-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011368-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011368-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011368-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 1: Participants' global self‐assessment of acne improvement" data-id="CD011368-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 1: Participants' global self‐assessment of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 2: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 3: Change in lesion counts ‐ total (percentage reduction from baseline)" data-id="CD011368-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 3: Change in lesion counts ‐ total (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0007"> <p> <div class="table" id="CD011368-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ total</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other topical treatments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Thielitz 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment (percent reduction of total lesions) (n, mean ± SD) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AzA9M: n =17, 33.54 ± 39.96</p> <p>AzA3M: n = 19, 38.75 ± 29.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adapalene: n = 19, 48.87 ± 26.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.396 (AzA9M + AzA3M versus Adapalene)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 4: Change in lesion counts ‐ total </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0007">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 5: Change in lesion counts ‐ inflamed (percentage reduction from baseline)" data-id="CD011368-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 5: Change in lesion counts ‐ inflamed (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 6: Change in lesion counts ‐ inflamed (number of lesions post‐intervention)" data-id="CD011368-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 6: Change in lesion counts ‐ inflamed (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0010"> <p> <div class="table" id="CD011368-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments (Comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aksakal 1997</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported (metronidazole)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001 (statistical method not reported), Quote: "The results of this study showed that the AZA cream is more effective than the metronidazole cream in reducing counts of inflamed and non‐inflamed lesions of acne" </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dunlap 1997</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium term (number of lesion)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported (3% erythromycin/5% benzoyl peroxide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported. Quote: <i>"The result of the study demonstrated significant differences favoring 3% erythromycin/5% benzoyl peroxide over 20% azelaic acid for the following parameters: 1) reduction in inflammatory lesion..."</i> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gollnick 2004a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: four months after start of treatment (Median of percent reduction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77% (benzoyl peroxide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &gt; 0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gollnick 2004b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: four months after start of treatment (Median of percent reduction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% (clindamycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &gt; 0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Thielitz 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment (percent change) (n, mean ± SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AzA3M: n = 19, ‐32.31 ± 38.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 19, ‐37.99 ± 37.63 (Adapalene)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.816</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 7: Change in lesion counts ‐ inflamed </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0010">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 8: Change in lesion counts ‐ papules (percentage reduction from baseline)" data-id="CD011368-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 8: Change in lesion counts ‐ papules (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 9: Change in lesion counts ‐ papules (number of lesions post‐intervention)" data-id="CD011368-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 9: Change in lesion counts ‐ papules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 10: Change in lesion counts ‐ pustules (percentage reduction from baseline)" data-id="CD011368-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 10: Change in lesion counts ‐ pustules (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 11: Change in lesion counts ‐ pustules (number of lesions post‐intervention)" data-id="CD011368-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 11: Change in lesion counts ‐ pustules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0015"> <p> <div class="table" id="CD011368-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ non‐inflamed</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aksakal 1997</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear (number of lesions post intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More counts (metronidazole)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Barbareschi 1991</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: four months after start of treatment, reduction in number of lesions (mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (Retinoic acid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, the author did not test the difference between groups.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dunlap 1997</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium term: reduction in number of comedones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported (3% erythromycin/5% benzoyl peroxide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported. Quote: " The result of the study demonstrated significant differences favoring 3% erythromycin/5% benzoyl peroxide over 20% azelaic acid for the following parameters: 2) reduction in comedones..." </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gollnick 2004a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: four months after start of treatment (Median of percent reduction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71% (benzoyl peroxide)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &gt; 0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gollnick 2004b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: four months after start of treatment (Median of percent reduction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45% (clindamycin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Thielitz 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment (percent reduction of non‐inflamed lesions) (n, mean ± SD) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AzA9M: n =17, 26.36 ± 57.64</p> <p>AzA3M: n = 19, 41.25 ± 32.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adapalene: n = 19, 55.21 ± 29.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.063 (AzA9M + AzA3M versus Adapalene)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Thielitz 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment, percent reduction of microcomedones (n, mean ± SD) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AzA9M: n =17, 10.61 ± 44.32</p> <p>AzA3M: n = 19, 18.63 ± 54.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adapalene: n = 19, 27.06 ± 50.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.25 (AzA9M + AzA3M versus Adapalene)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 12: Change in lesion counts ‐ non‐inflamed </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0015">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 13: Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline)" data-id="CD011368-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 13: Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 14: Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention)" data-id="CD011368-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 14: Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 15: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 15: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 16: Minor adverse events" data-id="CD011368-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 16: Minor adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0020"> <p> <div class="table" id="CD011368-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Quality of life</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Schaller 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment ‐ Children's Dermatology Life Quality Index<br/>(percent change, mean ± SD) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐36.8% ± 74.8, n = 108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐60.5% ± 70.6, n = 107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Thielitz 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment ‐ Dermatology Life Quality Index questionnaire<br/>(absolute change, n mean ± SD) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AzA9M: n =17, ‐1.88 ± 3.35</p> <p>AzA3M: n = 19, ‐2.74 ± 2.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adapalene: n = 19, ‐2.58 ± 4.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.549 (adapalene vs AzA9M + 3M)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Topical azelaic acid versus other topical treatments, Outcome 17: Quality of life </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical azelaic acid versus placebo, Outcome 1: Withdrawal for any reason" data-id="CD011368-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 1: Withdrawal for any reason</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical azelaic acid versus placebo, Outcome 2: Change in lesion counts ‐ &gt; 50% inflamed reduction" data-id="CD011368-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 2: Change in lesion counts ‐ &gt; 50% inflamed reduction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0023"> <p> <div class="table" id="CD011368-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed (percentage reduction from baseline)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azelaic acid (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 1989</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001, the results demonstrated significant difference favouring azelaic acid over placebo cream. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 1989</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.0025, the results demonstrated significant difference favouring azelaic acid over placebo cream. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Katsambas 1989a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.05, the results demonstrated significant difference favouring azelaic acid over placebo cream. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 1989</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment, unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001, the results demonstrated significant difference favouring azelaic acid over placebo cream. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Katsambas 1989a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment, 72%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.05, the results demonstrated significant difference favouring azelaic acid over placebo cream. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term (split‐face trials)</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hayashi 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment, 68.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear, not reported</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 3: Change in lesion counts ‐ inflamed (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical azelaic acid versus placebo, Outcome 4: Change in lesion counts ‐ &gt; 50% non‐inflamed reduction" data-id="CD011368-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 4: Change in lesion counts ‐ &gt; 50% non‐inflamed reduction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0025"> <p> <div class="table" id="CD011368-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azelaic acid (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 1989</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.027, the results demonstrated significant difference favouring azelaic acid over placebo cream. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 1989</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment, unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.027, the results demonstrated significant difference favouring azelaic acid over placebo cream. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term (split‐face trials)</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hayashi 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment, 59.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 5: Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0025">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0026"> <p> <div class="table" id="CD011368-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts (percentage reduction from baseline)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Iraji 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Papules number</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.003</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Iraji 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total lesion counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.002</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Iraji 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne severity index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Iraji 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comedones numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Iraji 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pustules number</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Katsambas 1989a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: three months after start of treatment, comedones numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>long term (split‐face trials)</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hayashi 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment, total lesion counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 6: Change in lesion counts (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0027"> <p> <div class="table" id="CD011368-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts (number of lesions post‐intervention)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>comedones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 6.12 ± 0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 30.02 ± 3.0, n = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>papules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 14.02 ± 0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 22.22 ± 1.64, n = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pustules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 5.9 ± 0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 12.22 ± 1.04, n = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 7: Change in lesion counts (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0027">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0028"> <p> <div class="table" id="CD011368-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Change in lesion counts ‐ comedones (reduction in number of lesions post‐intervention)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Barbareschi 1991</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: four months after start of treatment, 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, the author did not test the difference between groups.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Barbareschi 1991</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four months after start of treatment, number of lesions reduction post intervention, scanning electron microscopy measured comedones: 9.4±6.93 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1±3.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 8: Change in lesion counts ‐ comedones (reduction in number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical azelaic acid versus placebo, Outcome 9: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 9: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical azelaic acid versus placebo, Outcome 10: Minor adverse events" data-id="CD011368-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Topical azelaic acid versus placebo, Outcome 10: Minor adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Topical azelaic acid versus no treatment, Outcome 1: Participants' global self‐assessment of acne improvement" data-id="CD011368-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 1: Participants' global self‐assessment of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Topical azelaic acid versus no treatment, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 2: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Topical azelaic acid versus no treatment, Outcome 3: Change in lesion counts ‐ total (percentage reduction from baseline)" data-id="CD011368-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 3: Change in lesion counts ‐ total (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Topical azelaic acid versus no treatment, Outcome 4: Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline)" data-id="CD011368-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 4: Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Topical azelaic acid versus no treatment, Outcome 5: Change in lesion counts ‐ papules (percentage reduction from baseline)" data-id="CD011368-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 5: Change in lesion counts ‐ papules (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Topical azelaic acid versus no treatment, Outcome 6: Change in lesion counts ‐ pustules (percentage reduction from baseline)" data-id="CD011368-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 6: Change in lesion counts ‐ pustules (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0037"> <p> <div class="table" id="CD011368-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed (number of lesions post‐intervention)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pustules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 5.72 ± 0.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 8.21 ± 0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>papules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 8.53 ± 0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 10.62 ± 0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pustules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 4.2 ± 0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 8.06 ± 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>papules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 6.01 ± 0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 8.16 ± 0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pustules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 4.22 ± 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 7.12 ± 0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>papules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 6.27 ± 0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 11.04 ± 0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 7: Change in lesion counts ‐ inflamed (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0037">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0038"> <p> <div class="table" id="CD011368-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ comedones (number of lesions post‐intervention)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical azelaic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>comedones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 5.24 ± 0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 8.8 ± 0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>comedones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 2.22 ± 0.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 7.32 ± 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pazoki‐Toroudi 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>comedones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 2.28 ± 0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± SD: 5.36 ± 0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 0.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 8: Change in lesion counts ‐ comedones (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0038">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Topical azelaic acid versus no treatment, Outcome 9: Minor adverse events" data-id="CD011368-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Topical azelaic acid versus no treatment, Outcome 9: Minor adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 1: Participants' global self‐assessment of acne improvement" data-id="CD011368-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 1: Participants' global self‐assessment of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0041"> <p> <div class="table" id="CD011368-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Participants' global self‐assessment of acne improvement</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Duration</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Items</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bae 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild to good improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (92.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (84.6%) (Jessner's Solution)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported; Quote" "In terms of subject global assessment...there is no significant differences between the groups..." </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kessler 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>treatment duration of 10 weeks, measured at two months post‐treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patient self‐assessment questionnaire</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41%(glycolic acid peel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>parallel trial</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Chantalat 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>acne parameters and broad skin benefits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported (10% benzoyl peroxide, BPO)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported. Quote: "Subject self assessment results show that subjects treated with the microgel complex reported a greater improvement...compared to 10% BPO." </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 2: Participants' global self‐assessment of acne improvement </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0041">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 3: Withdrawal for any reason" data-id="CD011368-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 3: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 4: Change in lesion counts ‐ total (number of lesions post‐intervention)" data-id="CD011368-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 4: Change in lesion counts ‐ total (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 5: Change in lesion counts ‐ inflamed (number of lesions post‐intervention)" data-id="CD011368-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 5: Change in lesion counts ‐ inflamed (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0045"> <p> <div class="table" id="CD011368-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed (mean counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>parallel trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Babayeva 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐inflamed (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported. Quote: "...these differences were<br/>not statistically significant..." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bae 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average reduction of inflamed lesion (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7 (Jessner's solution peels)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported; Quote" Inflammatory acne lesion counts did not differ significantly between salicylic acid and Jessner's solution peels" </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Levesque 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean inflamed lesion counts post intervention (long term: 12 weeks after start of treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7 (lipohydroxyacid peels)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.111. Quote:"The mean number of inflammatory lesions was 6.1 and 6.6 at Day 14 (baseline) and 3.7 and 3.9 at Day 98 on the sides that received the LHA and salicylic acid peels..." </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 6: Change in lesion counts ‐ inflamed (mean counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0045">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 7: Change in lesion counts ‐ papules (number of lesions post‐intervention)" data-id="CD011368-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 7: Change in lesion counts ‐ papules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 8: Change in lesion count ‐ pustules (number of lesions post‐intervention)" data-id="CD011368-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 8: Change in lesion count ‐ pustules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 9: Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention)" data-id="CD011368-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 9: Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0049"> <p> <div class="table" id="CD011368-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ non‐inflamed (counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>parallel trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Babayeva 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported. Quote: "...these differences were<br/>not statistically significant..." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bae 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Average number reduction of non‐inflamed ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Levesque 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.6% (lipohydroxyacid peels)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.878</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 10: Change in lesion counts ‐ non‐inflamed (counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0049">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0050"> <p> <div class="table" id="CD011368-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ various types of acne lesions (counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>parallel trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Babayeva 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total lesions (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.6% (Tretinoin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported. Quote: "...these differences were<br/>not statistically significant..." </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ open comedones (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.26%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67% (Tretinoin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ papule (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.67% (Tretinoin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.031</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total lesions (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.20% (Tretinoin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.039</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ pustules (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.19% (Tretinoin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ closed comedones (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.05%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.94% (Tretinoin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.011</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kessler 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total lesion(treatment duration of 10 weeks, measured at one month post‐treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43% (30% glycolic acid peel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>cross‐over trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1989</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>number of lesions post intervention ‐ comedo counts (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.9 (10% benzoyl peroxide wash)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 11: Change in lesion counts ‐ various types of acne lesions (counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0050">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 12: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 12: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0052"> <p> <div class="table" id="CD011368-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Physicians' global evaluation of acne improvement (%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kessler 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good to fair improvement (treatment duration of 10 weeks, measured at two months post‐treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75% (30% glycolic acid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported. The author did not report whether there is any statistical difference between groups. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 13: Physicians' global evaluation of acne improvement (%) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0052">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 14: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 14: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 15: Minor adverse events" data-id="CD011368-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 15: Minor adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0055"> <p> <div class="table" id="CD011368-tblf-0017"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Quality of life (QoL) ‐ AQOL (score, post‐intervention)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid: mean ± sd</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments: mean ± sd (comparator)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Babayeva 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 ± 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 ± 1.64 (tretinoin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported. Quote: "there were no significant differences in AQOL between treatment groups at baseline and at the end of the study" </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Chantalat 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short term and medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported. Quote: "ARQL results show that subjects treated with novel microgel complex experienced a significant improvement in ARQL starting 2 weeks after baseline and continuing through the 6‐week study." </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4: Topical salicylic acid versus other topical treatments, Outcome 16: Quality of life (QoL) ‐ AQOL (score, post‐intervention) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0055">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Topical salicylic acid versus placebo, Outcome 1: Participants' global self‐assessment of acne improvement (score, high=well)" data-id="CD011368-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Topical salicylic acid versus placebo, Outcome 1: Participants' global self‐assessment of acne improvement (score, high=well) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Topical salicylic acid versus placebo, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Topical salicylic acid versus placebo, Outcome 2: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0058"> <p> <div class="table" id="CD011368-tblf-0018"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts (counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Eady 1996</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of whitehead reduction (short, medium and long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no difference; no difference; &lt; 0.002</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Eady 1996</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of total counts reduction (short, medium and long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no difference; &lt; 0.043; &lt; 0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Eady 1996</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of papules reduction (short, medium and long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no difference; no difference; 0.022</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1981</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐total (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report and the author did not state whether this difference is significant</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Techapichetvanich 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ noninflamed (long term: 10 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.77%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Techapichetvanich 2011</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total counts (long term: 10 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Topical salicylic acid versus placebo, Outcome 3: Change in lesion counts (counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0058">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0059"> <p> <div class="table" id="CD011368-tblf-0019"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed (counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Eady 1996</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number reduction ‐ short, medium and long term (12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no difference; no difference; &lt; 0.022</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1981</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>percent reduction ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report and the author did not state whether this difference is significant</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1981</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>percent reduction ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report and the author did not state whether this difference is significant</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1981</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>percent reduction ‐ long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report and the author did not state whether this difference is significant</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Topical salicylic acid versus placebo, Outcome 4: Change in lesion counts ‐ inflamed (counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0059">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0060"> <p> <div class="table" id="CD011368-tblf-0020"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ non‐inflamed (counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Eady 1996</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number reduction ‐ short, medium and long term (12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no difference; 0.047; &lt; 0.001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1981</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ open comedones (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported, but the author stated the difference is significant.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1981</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ closed comedones (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Topical salicylic acid versus placebo, Outcome 5: Change in lesion counts ‐ non‐inflamed (counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0060">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Topical salicylic acid versus placebo, Outcome 6: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Topical salicylic acid versus placebo, Outcome 6: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Topical salicylic acid versus placebo, Outcome 7: Minor adverse events" data-id="CD011368-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Topical salicylic acid versus placebo, Outcome 7: Minor adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Topical salicylic acid versus no treatment, Outcome 1: Participants' global self‐assessment of acne improvement" data-id="CD011368-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 1: Participants' global self‐assessment of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Topical salicylic acid versus no treatment, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 2: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0065"> <p> <div class="table" id="CD011368-tblf-0021"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ total (percentage reduction from baseline)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Akarsu 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote:"The mean percent reductions in NIL, IL and TL counts were significantly higher for patients in group 1 as opposed to the patients<br/>in group 2 at week 12". </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kar 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total (long term: 16 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report and the author did not state whether this difference is significant</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total lesions (long term: 12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.039</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 3: Change in lesion counts ‐ total (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0065">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0066"> <p> <div class="table" id="CD011368-tblf-0022"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed (percentage reduction from baseline)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Akarsu 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote:"The mean percent reductions in NIL, IL and TL counts were<br/>significantly higher for patients in group 1 as opposed to the patients<br/>in group 2 at week 12". </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>papules: 84.5%</p> <p>pustules: 90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>papules: 26.63%</p> <p>pustules:</p> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>papules: P = 0.031; pustules: P &gt; 0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 4: Change in lesion counts ‐ inflamed (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0066">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0067"> <p> <div class="table" id="CD011368-tblf-0023"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Akarsu 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote:"The mean percent reductions in NIL, IL and TL counts were<br/>significantly higher for patients in group 1 as opposed to the patients<br/>in group 2 at week 12". </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NilFroushzadeh 2009</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>open comedones:64.26%</p> <p>closed comedones:87.05%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>open comedones:58.33%</p> <p>closed comedones:31.28%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>open comedones: P &gt; 0.05</p> <p>closed comedones: P = 0.011</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 5: Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0067">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Topical salicylic acid versus no treatment, Outcome 6: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0068" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 6: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Topical salicylic acid versus no treatment, Outcome 7: Minor adverse events" data-id="CD011368-fig-0069" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 7: Minor adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0070"> <p> <div class="table" id="CD011368-tblf-0024"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Quality of life (QoL) ‐ AQOL (score, post‐intervention)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Salicylic acid (median, 95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment (median, 95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Akarsu 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 (0.6‐2.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1.5‐4.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "there were no significant differences in AQOL between treatment groups at baseline and at the end of the study". </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Topical salicylic acid versus no treatment, Outcome 8: Quality of life (QoL) ‐ AQOL (score, post‐intervention) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0070">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 1: Withdrawal for any reason" data-id="CD011368-fig-0071" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 1: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 2: Change in lesion counts ‐ inflamed (number of lesions post‐intervention)" data-id="CD011368-fig-0072" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 2: Change in lesion counts ‐ inflamed (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0073"> <p> <div class="table" id="CD011368-tblf-0025"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed counts (counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nicotinamide (mean, sd)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments (mean, sd)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ inflamed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ inflamed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.5±41.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7±41.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Weltert 2004</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of lesions post intervention ‐ inflamed lesion counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4±8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5±5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 3: Change in lesion counts ‐ inflamed counts (counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0073">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 4: Change in lesion counts ‐ comedones (number of lesions post‐intervention)" data-id="CD011368-fig-0074" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 4: Change in lesion counts ‐ comedones (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 5: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0075" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 5: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0076"> <p> <div class="table" id="CD011368-tblf-0026"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Physicians' global evaluation of acne improvement</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Items</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nicotinamide (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Clindamycin (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderately or much better improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shalita 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>moderately or much better improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 6: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0076">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 7: Minor adverse events" data-id="CD011368-fig-0077" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Topical nicotinamide versus other topical treatments, Outcome 7: Minor adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0078"> <p> <div class="table" id="CD011368-tblf-0027"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Participants' global self assessment of acne improvement (numerical point system defined by investigator, high = well) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Topical sulphur versus other topical treatments, Outcome 1: Participants' global self assessment of acne improvement (numerical point system defined by investigator, high = well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0078">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topical sulphur versus other topical treatments, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0079" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Topical sulphur versus other topical treatments, Outcome 2: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0080"> <p> <div class="table" id="CD011368-tblf-0028"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Change in lesion counts (scores, high = well)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulphur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulphur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numerical point system defined by investigator (high=well): comedone‐pustule (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported, the author did not state whether the difference is statistical significant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numerical point system defined by investigator (high=well): papule‐cyst (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Topical sulphur versus other topical treatments, Outcome 3: Change in lesion counts (scores, high = well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0080">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topical sulphur versus other topical treatments, Outcome 4: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0081" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Topical sulphur versus other topical treatments, Outcome 4: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0082"> <p> <div class="table" id="CD011368-tblf-0029"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Topical sulphur versus other topical treatments, Outcome 5: Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0082">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Topical sulphur versus other topical treatments, Outcome 6: Minor adverse events" data-id="CD011368-fig-0083" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Topical sulphur versus other topical treatments, Outcome 6: Minor adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0084"> <p> <div class="table" id="CD011368-tblf-0030"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high=well) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Topical sulphur versus placebo, Outcome 1: Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high=well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0084">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Topical sulphur versus placebo, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0085" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Topical sulphur versus placebo, Outcome 2: Withdrawal for any reason</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0086"> <p> <div class="table" id="CD011368-tblf-0031"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Change in lesion counts (scores, high = well)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulphur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulphur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numerical point system defined by investigator (high=well): comedone‐pustule (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported, the author did not state whether the difference is statistical significant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numerical point system defined by investigator (high=well): papule‐cyst (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Topical sulphur versus placebo, Outcome 3: Change in lesion counts (scores, high = well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0086">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Topical sulphur versus placebo, Outcome 4: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0087" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Topical sulphur versus placebo, Outcome 4: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0088"> <p> <div class="table" id="CD011368-tblf-0032"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Topical sulphur versus placebo, Outcome 5: Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0088">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Topical sulphur versus placebo, Outcome 6: Minor adverse events ‐ erythema and drying" data-id="CD011368-fig-0089" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Topical sulphur versus placebo, Outcome 6: Minor adverse events ‐ erythema and drying </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0090"> <p> <div class="table" id="CD011368-tblf-0033"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high = well) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Topical sulphur versus no treatment, Outcome 1: Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high = well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0090">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Topical sulphur versus no treatment, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0091" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Topical sulphur versus no treatment, Outcome 2: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0092"> <p> <div class="table" id="CD011368-tblf-0034"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Change in lesion counts (scores, high = well)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulphur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulphur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numerical point system defined by investigator (high=well): comedone‐pustule (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported, the author did not state whether the difference is statistical significant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numerical point system defined by investigator (high=well): papule‐cyst (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Topical sulphur versus no treatment, Outcome 3: Change in lesion counts (scores, high = well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0092">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Topical sulphur versus no treatment, Outcome 4: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0093" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Topical sulphur versus no treatment, Outcome 4: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0094"> <p> <div class="table" id="CD011368-tblf-0035"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high=well) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur‐benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sulfur</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Vasarinsh 1969</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not report, the author did not state whether the difference is statistical significant.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Topical sulphur versus no treatment, Outcome 5: Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high=well) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0094">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-010.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Topical sulphur versus no treatment, Outcome 6: Minor adverse events ‐ erythema and drying" data-id="CD011368-fig-0095" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-010.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-010.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10: Topical sulphur versus no treatment, Outcome 6: Minor adverse events ‐ erythema and drying </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-010.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Topical zinc versus other topical treatments, Outcome 1: Withdrawal for any reason" data-id="CD011368-fig-0096" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Topical zinc versus other topical treatments, Outcome 1: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Topical zinc versus other topical treatments, Outcome 2: Change in lesion counts ‐ papules (number of lesions post‐intervention)" data-id="CD011368-fig-0097" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Topical zinc versus other topical treatments, Outcome 2: Change in lesion counts ‐ papules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Topical zinc versus other topical treatments, Outcome 3: Change in lesion counts ‐ pustules (number of lesions post‐intervention)" data-id="CD011368-fig-0098" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Topical zinc versus other topical treatments, Outcome 3: Change in lesion counts ‐ pustules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Topical zinc versus other topical treatments, Outcome 4: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0099" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Topical zinc versus other topical treatments, Outcome 4: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Topical zinc versus other topical treatments, Outcome 5: Minor adverse events ‐ total events" data-id="CD011368-fig-0100" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Topical zinc versus other topical treatments, Outcome 5: Minor adverse events ‐ total events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0101"> <p> <div class="table" id="CD011368-tblf-0036"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Participants' global self‐assessment of acne improvement (visual analogue scale)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical zinc (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 16 weeks after start of treatment, unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value was not reported. Quote:" There were no significant difference."</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Topical zinc versus no treatment, Outcome 1: Participants' global self‐assessment of acne improvement (visual analogue scale) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0101">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Topical zinc versus no treatment, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0102" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Topical zinc versus no treatment, Outcome 2: Withdrawal for any reason</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0103"> <p> <div class="table" id="CD011368-tblf-0037"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Change in lesion counts ‐ total (lesion counts reduction)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical zinc (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.707</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 16 weeks after start of treatment, unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.707</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Topical zinc versus no treatment, Outcome 3: Change in lesion counts ‐ total (lesion counts reduction) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0103">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0104"> <p> <div class="table" id="CD011368-tblf-0038"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed (lesion counts reduction)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical zinc (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bojar 1994</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bojar 1994</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bojar 1994</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks after start of treatment, Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks after start of treatment, Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.626</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Topical zinc versus no treatment, Outcome 4: Change in lesion counts ‐ inflamed (lesion counts reduction) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0104">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0105"> <p> <div class="table" id="CD011368-tblf-0039"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Change in lesion counts ‐ non‐inflamed (lesion counts reduction)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical zinc (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>short term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bojar 1994</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>medium term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bojar 1994</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.769</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bojar 1994</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks after start of treatment, Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks after start of treatment, Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.769</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Topical zinc versus no treatment, Outcome 5: Change in lesion counts ‐ non‐inflamed (lesion counts reduction) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0105">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0106"> <p> <div class="table" id="CD011368-tblf-0040"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Physicians' global evaluation of acne improvement (visual analogue scale)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical zinc (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>long term</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks after start of treatment, Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference, no exact P value reported</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12: Topical zinc versus no treatment, Outcome 6: Physicians' global evaluation of acne improvement (visual analogue scale) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0106">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0107"> <p> <div class="table" id="CD011368-tblf-0041"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Minor adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical zinc (counts/n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No treatment (counts/n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cunliffe 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>long term (12 weeks after start of treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91/80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117/83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.7</div> <div class="figure-caption"> <p>Comparison 12: Topical zinc versus no treatment, Outcome 7: Minor adverse events</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0107">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 1: Participants' global self‐assessment of acne improvement" data-id="CD011368-fig-0108" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 1: Participants' global self‐assessment of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 2: Withdrawal for any reason" data-id="CD011368-fig-0109" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 2: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 3: Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention)" data-id="CD011368-fig-0110" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 3: Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 4: Change in lesion counts ‐ papules (number of lesions post‐intervention)" data-id="CD011368-fig-0111" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 4: Change in lesion counts ‐ papules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 5: Change in lesion counts ‐ pustules (number of lesions post‐intervention)" data-id="CD011368-fig-0112" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 5: Change in lesion counts ‐ pustules (number of lesions post‐intervention) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0113"> <p> <div class="table" id="CD011368-tblf-0042"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ total (counts or %)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alpha‐hydroxy acid, mean ± SD or %</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Topical treatments, mean ± SD or %</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P vaule</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>parallel trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short term ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gluconolactone 14% in solution, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>benzoyl peroxide 5% lotion, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gluconolactone 14% in solution, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>benzoyl peroxide 5% lotion, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium term ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gluconolactone 14% in solution, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>benzoyl peroxide 5% lotion, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kessler 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percent reduction ‐ total lesion(treatment duration of 10 weeks, measured at one month post‐treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% glycolic acid peel, 43%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% salicylic acid peel, 47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 6: Change in lesion counts ‐ total (counts or %) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0113">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0114"> <p> <div class="table" id="CD011368-tblf-0043"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ inflamed (counts)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alpha‐hydroxy acid (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>parallel trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short term ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium term ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzoyl peroxide was significantly better than gluconolactone at eight and twelve weeks (P &lt; 0.05) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzoyl peroxide was significantly better than gluconolactone at eight and twelve weeks (P&lt; 0.05) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ilknur 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: six months after start of treatment (number of lesions post intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.88±5.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.00±7.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ilknur 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short term (number of lesions post intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.08±5.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.67±4.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ilknur 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium term (number of lesions post intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.29±4.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.88±4.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 7: Change in lesion counts ‐ inflamed (counts) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0114">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0115"> <p> <div class="table" id="CD011368-tblf-0044"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Change in lesion counts ‐ non‐inflamed (counts)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alpha‐hydroxy acid (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Benzoyl peroxide (mean, SD)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>parallel trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium term ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: 12 weeks after start of treatment ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Hunt 1992</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short term ‐ lesion counts reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ilknur 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long term: six months after start of treatment (number of lesions post intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.29±12.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.13±14.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ilknur 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium term (number of lesions post intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.29±37.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.00±40.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ilknur 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short term (number of lesions post intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.67±50.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.17±50.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;0.05</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 8: Change in lesion counts ‐ non‐inflamed (counts) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0115">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-013.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 9: Physicians' global evaluation of acne improvement" data-id="CD011368-fig-0116" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-013.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.9</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 9: Physicians' global evaluation of acne improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0117"> <p> <div class="table" id="CD011368-tblf-0045"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Physicians' global evaluation of acne improvement (%)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Alpha‐hydroxy acid, %</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator, %</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>split‐face trials</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kessler 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good to fair improvement (treatment duration of 10 weeks, measured at two months post‐treatment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% glycolic acid peels, 75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30% salicylic acid peels, 81%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear, not reported. The author did not report whether there is any statistical difference between groups. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.10</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 10: Physicians' global evaluation of acne improvement (%) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0117">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011368-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-013.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 11: Minor adverse events" data-id="CD011368-fig-0118" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-013.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.11</div> <div class="figure-caption"> <p>Comparison 13: Topical alpha‐hydroxy acid versus other topical treatments, Outcome 11: Minor adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-013.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Topical alpha‐hydroxy acid versus placebo, Outcome 1: Withdrawal for any reason" data-id="CD011368-fig-0119" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Topical alpha‐hydroxy acid versus placebo, Outcome 1: Withdrawal for any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011368-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/urn:x-wiley:14651858:media:CD011368:CD011368-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Topical alpha‐hydroxy acid versus placebo, Outcome 2: Minor adverse events ‐ total events" data-id="CD011368-fig-0120" src="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_t/tCD011368-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Topical alpha‐hydroxy acid versus placebo, Outcome 2: Minor adverse events ‐ total events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/media/CDSR/CD011368/image_n/nCD011368-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Azelaic acid compared to adapalene</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to adapalene for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> industry‐sponsored, single‐site study in Germany (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical adapalene </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical adapalene</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Improved to very much improved</i><br/>(long term: treatment duration &gt; 8 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>842 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>749 per 1000</b><br/>(573 to 985) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/>(0.68 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b><br/>(17 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.64</b> <br/>(0.33 to 20.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>305 per 1000</b><br/>(124 to 750) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> <br/>(0.47 to 2.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported no "significant difference" in the incidence of erythema, dryness, and itching between treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>Dermatology Life Quality Index</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The authors reported that there was no "statistically significant" difference (P = 0.549) between azelaic acid and adapalene. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, and study had unclear allocation concealment and high risk of performance bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, with unclear allocation concealment and high risk of performance bias. Two levels for imprecision: very wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, with high risk of performance bias and unclear allocation concealment and blinding of outcome assessment. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>d</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear allocation concealment and high risk of performance bias. Two levels for imprecision: very small population size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Azelaic acid compared to adapalene</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azelaic acid compared to benzoyl peroxide</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres, recruitment in Germany, Netherlands, Norway, and Greece (1 study); not described (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good or very good improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>771 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>633 per 1000</b><br/>(555 to 733) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> <br/>(0.72 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b><br/>(147 to 317) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/>(0.60 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351<br/>(1 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(short term: treatment duration ≤ 4 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/>(7 to 659) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.50</b> <br/>(0.05 to 4.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported that people in the azelaic acid group experienced less dryness and desquamation, but more itching when compared to those in the benzoyl peroxide group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level to moderate quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance bias and other bias, and with high risk of attrition and reporting bias.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance bias and other bias, and with high risk of attrition and reporting bias. One level for imprecision: wide CI.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of detection bias and unclear risk of selection, performance, attrition bias.Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azelaic acid compared to benzoyl peroxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azelaic acid compared to clindamycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to clindamycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres, recruitment in Germany, Netherlands, Norway, and Greece (1 study); three clinics in Tehran (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical clindamycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical clindamycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good or very good improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>668 per 1000</b><br/>(544 to 816) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/>(0.92 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>134 per 1000</b><br/>(49 to 367) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b> <br/>(0.48 to 3.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.5</b> (0.67 to 3.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no difference in minor adverse events (such as scaling and dry skin) between azelaic acid 5% gel and clindamycin 2% gel. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, and other bias, and with high risk of attrition and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: both studies had unclear risk of selection and performance bias, and one study had a high risk of attrition and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance and detection bias. One level for imprecision: CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azelaic acid compared to clindamycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azelaic acid compared to tretinoin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to tretinoin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres in one study; not described (1 study)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical tretinoin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical tretinoin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good to excellent improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>586 per 1000</b><br/>(486 to 711) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> <br/>(0.78 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><br/>(26 to 132) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> <br/>(0.29 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>309<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. The rate of erythema and scaling was considerably higher in the tretinoin group than that in the azelaic acid group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level to moderate quality evidence. One level for risk of bias: only one study included with a high risk of attrition bias and unclear risk of selection and performance bias.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: both studies with unclear risk of selection and performance bias, one study with high risk of attrition bias and the other with high risk of reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Azelaic acid compared to tretinoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Salicylic acid compared to benzoyl peroxide</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither treatment group had any withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/>(1 to 391) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> <br/>(0.01 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors reported that zero out of 20 people in the 2% salicylic acid microgel group versus two out of 21 people in the benzoyl peroxide 10% cream group experienced minor adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>ARQL</i> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The authors stated that subjects treated with salicylic acid microgel experienced better improvement when compared to 10% benzoyl peroxide. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No numerical data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARQL</b> : acne‐related quality of life; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: very small total sample size.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear selection, performance, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: very small total sample size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Salicylic acid compared to benzoyl peroxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Salicylic acid compared to pyruvic acid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to pyruvic acid for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Al‑Zahra Hospital Dermatology Clinic and Isfahan Skin Research Centre<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> topical pyruvic acid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical pyruvic acid</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Good to excellent improvement</i> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>395 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b><br/>(269 to 727) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/>(0.68 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b><br/>(222 to 628) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/>(0.53 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. Although the authors did report no "significant difference" in minor adverse events (scaling in the first to fourth sessions, redness, burning, and itching) between the two peeling (30% salicylic acid and 50% pyruvic acid). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition and other bias and unclear risk of selection and performance bias. One level for imprecision: wide CI and optimal sample size is not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for imprecision: wide CI and optimal sample size not met. One level for risk of bias: only one study included with high risk of attrition and other bias, and unclear risk of selection and performance bias.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Salicylic acid compared to pyruvic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Salicylic acid compared to tretinoin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to tretinoin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Skin Disease and Leishmaniasis Research Center and Isfahan University of Medical Sciences clinics (1 study); not described (1 study)<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> topical tretinoin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical tretinoin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> <br/><i>Moderate to excellent improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b><br/>(920 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b> <br/>(0.92 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither study had any withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>741 per 1000</b><br/>(357 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.37</b> <br/>(0.66 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors in one study reported no "statistically significant" differences in the incidence of dryness, peeling, erythema, burning and itching between treatment groups at any study week. All side effects reported in the two studies were of mild to moderate intensity and transient. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>AQOL</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The authors reported no "significant differences" in AQOL between salicylic acid group (end of study: 0.95 ± 1.9) and tretinoin group (end of study: 0.91 ± 1.64) at baseline and at the end of the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AQOL</b> : acne quality of life; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of random sequence generation, allocation concealment, and blinding of participants and personnel. One level for imprecision: optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: both studies with unclear risk of selection bias, one with unclear risk of performance bias and the other with high risk of performance and unclear risk of reporting bias. One level for imprecision: small total sample size.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: two studies with unclear risk of selection bias and high risk of detection bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>d</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of random sequence generation, allocation concealment, and blinding of participants and personnel. Two levels for imprecision: very small population size and wide CI.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Salicylic acid compared to tretinoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Nicotinamide compared to clindamycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nicotinamide compared to clindamycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> multicentres in USA (1 study); a teaching clinic of dermatology in Iran (1 study); St‐Alzahra hospital, Isfahan University of Medical Sciences, Isfahan, Iran (1 study)<br/><b>Intervention:</b> topical nicotinamide<br/><b>Comparison:</b> topical clindamycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical clindamycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical nicotinamide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/>(36 to 193) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/>(0.49 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two trials had no withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b><br/>(135 to 369) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.20</b> <br/>(0.73 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Local application site reactions (e.g. itching, burning, crusting) were reported in two studies. In the third study, the authors reported no side effects during the treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: three studies included and all with unclear risk of bias, two with unclear risk of performance bias, one with high risk of attrition bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: all three studies with unclear risk of selection and detection bias, two out of three studies with unclear risk of performance bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Nicotinamide compared to clindamycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Nicotinamide compared to erythromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nicotinamide compared to erythromycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Laboratoire Dermscan (Villeurbanne)<br/><b>Intervention:</b> topical nicotinamide<br/><b>Comparison:</b> topical erythromycin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical erythromycin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical nicotinamide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b><br/>(29 to 267) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> <br/>(0.46 to 4.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. There was "no difference" in occurrence of pertinent clinical signs and functional or physical signs between treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with unclear risk of selection and performance bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Nicotinamide compared to erythromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011368-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Glycolic acid (alpha‐hydroxy acid) compared to salicylic‐mandelic acid</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Glycolic acid (alpha‐hydroxy acid) compared to salicylic‐mandelic acid for acne</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Dermatology and Andrology Department of Beha University hospital, Egyptian patients (only study); recruitment in India (1 study)<br/><b>Intervention:</b> topical glycolic acid (alpha‐hydroxy acid)<br/><b>Comparison:</b> topical salicylic‐mandelic acid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic‐mandelic acid</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical glycolic acid</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Fair to good improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>900 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>954 per 1000</b><br/>(792 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/>(0.88 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither study had any withdrawals.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>409 per 1000</b><br/>(164 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.80</b> <br/>(0.72 to 4.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four (20%) participants in salicylic‐mandelic acid peel experienced a burning or stinging sensation against two (10%) in glycolic acid peel. Sixteen participants (80%) in salicylic‐mandelic acid peel developed visible desquamation against eight (40%) in glycolic acid peel (P = 0.025). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: two studies included, one with unclear risk of selection, performance and reporting bias, the other with unclear risk of performance bias. One level for imprecision: small total sample size.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of detection bias and unclear risk of selection, performance bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Glycolic acid (alpha‐hydroxy acid) compared to salicylic‐mandelic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0011"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of medical terms</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Medical term</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Explanation</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acne vulgaris</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A common chronic skin disorder of sebaceous follicles, mainly affecting the face, chest, and back<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chemokine</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A group of small cytokines that act as chemical messengers to induce chemotaxis in leukocytes<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comedone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clogged hair follicle in the skin. It can present as a blackhead or whitehead<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cytokine</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A small protein released by cells that function as molecular messengers between cells<sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythema</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Redness of the skin, caused by vascular congestion or increased perfusion<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hyperkeratosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thickening of the outer layer of skin often associated with a quantitative abnormality of keratin<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Keratinocytes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The predominant cell type in the epidermis, forming a touch protective layer<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Microcomedones</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early and small plugging of the follicle with excess keratin and sebum<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nodule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A solid mass in the skin, more than 0.5 cm in diameter<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Papule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A circumscribed palpable elevation, less than 0.5 cm in diameter<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pilosebaceous unit</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A structure consisting of a hair follicle, sebaceous gland, and an arrector pili muscle<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Propionibacterium acnes</b> </p> <p><b>(Cutibacterium acnes)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gram‐positive bacterium related to acne development<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pustule</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A visible accumulation of free pus<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scar</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin areas of fibrous tissue replacing normal skin after injury<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sebum</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The oily, waxy substance produced by sebaceous glands<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stratum corneum</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outermost layer of the epidermis, where cells have lost nuclei and cytoplasmic organelles<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Toll‐like receptor</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A class of proteins that recognise conserved products unique to microbial metabolism in immune response<sup>c</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><sup>a</sup><i>Andrews' Diseases of the Skin: Clinical Dermatology</i>, 11th Edition, 2011, Elsevier Inc.<br/><sup>b</sup><i>Rook's Textbook of Dermatology</i> , Eighth Edition, 2010, Blackwell Publishing Ltd.<br/><i><sup>c</sup>Immunology</i>, Sixth Edition, 2001, Harcourt Asia Pte Ltd. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of medical terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0012"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Clinical classification of acnea </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Acne vulgaris</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p>Acne variants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neonatal acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infantile acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne conglobata</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne fulminans</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAPHO syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAPA syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne excoriee des jeunes filles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne mechanica</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne with solid facial oedema</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne with associated endocrinology abnormalities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p>Acneiform eruptions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steroid folliculitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug‐induced acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epidermal growth factor receptor inhibitor associated eruption</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Occupational acne and chloracne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gram‐negative folliculitis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiation acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tropical acne</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne aestivalis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pseudoacne of the nasal crease</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apert syndrome</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><sup>a</sup><i>Fitzpatrick's Dermatology in General Medicine</i>, Eighth edition, 2012, The McGraw‐Hill Companies, Inc. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Clinical classification of acnea </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0013"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Acne severity for all studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Acne severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Notes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0001" title="AkarsuS , FetilE , YücelF , GülE , GüneAT . Efficacy of the addition of salicylic acid to clindamycin and benzoyl peroxide combination for acne vulgaris. Journal of Dermatology2012;39(5):433-8. [CENTRAL: CN-00882159] [PMID: 22035285]">Akarsu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "10‐50 inflamed lesions and 10‐100 non‐inflamed lesions above the mandibular line, no cystic or nodular lesions." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0002" title="AksakalAB , KoruyucuM , OnderM , OztasMO , GurerMA . A comparative study of metronidazole 1% cream versus azelaic acid 20% cream in the treatment of acne. Gazi Medical Journal1997;8(4):144-7. [CENTRAL: CN-00195442] ">Aksakal 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded by using the Allen‐Smith Scale (grades of 4 to 8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0003" title="BabayevaL , AkarsuS , FetilE , GüneAT . Comparison of tretinoin 0.05% cream and 3% alcohol-based salicylic acid preparation in the treatment of acne vulgaris. Journal of the European Academy of Dermatology and Venereology2011;25(3):328-33. [CENTRAL: CN-00787953] ">Babayeva 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "10‐50 inflamed lesions and 10‐100 non‐inflamed lesions above the mandibular line, no cystic or nodular lesions." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0004" title="BaeBG , ParkCO , ShinH , LeeSH , LeeYS , LeeSJ , et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. Dermatologic Surgery2013;39(2):248-53. [CENTRAL: CN-00878368] ">Bae 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique) (grades of 0.25 to 3.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0005" title="BarbareschiM , HendricksI , AngiusA , CattaneoM , MontiM . The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. Journal of Dermatological Treatment1991;2(2):55-7. [CENTRAL: CN-00191948] ">Barbareschi 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with comedonic acne included, no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0006" title="BojarRA , EadyEA , JonesCE , CunliffeWJ , HollandKT . Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329-36. [CENTRAL: CN-00100271] ">Bojar 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique) (grades of 0.5 to 3.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0007" title="CavicchiniS , CaputoR . Long-term treatment of acne with 20% azelaic acid cream. Acta Dermato-venereologica. Supplementum1989;69(143):40-4. [CENTRAL: CN-00351262] ">Cavicchini 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with papulopustular acne included, median number of inflamed lesions was less than 20 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0008" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN-00602613] ">Chantalat 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0009" title="ChantalatJ , LiuJC . Six-week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN-00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602548] ChantalatJ , StamatasG , LiuJC , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN-00602574] ">Chantalat 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0010" title="ChantalatJ , ChenT , StephensTJ , PappertAS . Salicylic acid microgel complex provides significant acne benefits in foaming cleanser formulations. Journal of the American Academy of Dermatology2007;56(2):AB24. [CENTRAL: CN-00615939] ">Chantalat 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0011" title="ChenT , HerndonJH , StephensTJ , AppaY . Rapid and lasting acne reduction by an oil free cleanser containing salicylic acid microgel complex. Journal of the American Academy of Dermatology2007;56(2):AB20. [CENTRAL: CN-00616006] ">Chen 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0012" title="CunliffeWJ , HollandKT . Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermato-venereologica. Supplementum1989;69(Suppl 143):31-4. [CENTRAL: CN-00062182] ">Cunliffe 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, only mentioned "the trial was for the treatment of mild to moderate acne" in the Discussion section, no details </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0013" title="CunliffeWJ , BojarR , KanisR , FernandezC . An observer-blind, randomized, multicentre study of a topical zinc-clindamycin gel (Zindaclin) or clindamycin lotion (Dalacin T) applied twice daily in patients with acne. British Journal of Dermatology2002;147(Suppl 62):46. [CENTRAL: CN-00487814] CunliffeWJ , FernandezC , BojarR , KanisR , WestF , Zindaclin Clinical Study Group. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. Journal of Dermatological Treatment2005;16(4):213-8. [CENTRAL: CN-00553078] [PMID: 16302325]">Cunliffe 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds Revised Acne Grading Scale (grades of 2 to 7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using a simple system (based on the predominant lesions present: mild, moderate, severe, cystic) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0015" title="DraelosZD , ErtelK , RomD . Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. Journal of Cosmetic Dermatology2016;15(4):350-7. [CENTRAL: CN-01300011] NCT02052752. A five day clinical study to examine the effects of a benzoyl peroxide treatment on facial acne lesions. clinicaltrials.gov/show/nct02052752 (first received 3 February 2014). ">Draelos 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, a minimum of 10 non‐inflamed lesions and a minimum of 10 inflamed lesions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0016" title="DunlapFE . An investigator blinded randomized study comparing a 3% eryhtromycin / 5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN-00355137] ">Dunlap 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably moderate to severe<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade Ⅱ or Ⅲ, Pillsbury classification system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0017" title="EadyEA , BurkeBM , PullingK , CunliffeWJ . The benefit of 2% salicylic acid lotion in acne - a placebo-controlled study. Journal of Dermatological Treatment1996;7(2):93-6. [CENTRAL: CN-00169967] ">Eady 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds technique, no details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0018" title="ElRefaeiAM , Abdel SalamHA , SorourNE . Salicylic-mandelic acid versus glycolic acid peels in Egyptian patients with acne vulgaris. Journal of the Egyptian Women's Dermatologic Society2015;12(3):196-202. [CENTRAL: CN-01306696] ">ElRefaei 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded according to the Hayashi classification system (mild, moderate, severe, or very severe) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0019" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2009;35(1):59-65. [PMID: 19076192]">Garg 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably moderate to severe/cystic<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean baseline Michaelsson acne severity index score &gt; 80, the improvement of comedones, papules, pustules, nodules and cysts was assessed </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0020" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0021" title="GollnickHP , GraupeK , ZaumseilRP . Azelaic acid 15 % gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]2004;2(10):841-7. [PMID: 16281587]">Gollnick 2004b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0022" title="HayashiN , KoyanagiE , NogitaT , FujiyamaM , KawashimaM . A randomized placebo-controlled investigator-blinded face split study of 20% azelaic acid cream to evaluate the efficacy and safety in Japanese patients with acne vulgaris. Journal of Dermatology2012;39(Suppl 1):249-50. [CENTRAL: CN-01032268] ">Hayashi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total lesion counts &gt; 30, no further details, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0023" title="HuntMJ , BarnetsonRS . A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1992;33(3):131-4. [CENTRAL: CN-00093199] ">Hunt 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique), no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0024" title="IlknurT , DemirtasogluM , BiçakMU , OzkanS . Glycolic acid peels versus amino fruit acid peels for acne. Journal of Cosmetic and Laser Therapy2010;12(5):242-5. [CENTRAL: CN-00769352] ">Ilknur 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique), grades of 0.25 to 2.0, participants with non‐inflamed lesions and superficial inflamed lesions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0025" title="IrajiF , SadeghiniaA , ShahmoradiZ , SiadatAH , JooyaA . Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology2007;73(2):94-6. [CENTRAL: CN-01093647] IrajiF . Efficacy of topical azelaic acid gel (20%) for acne. In: 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia; 2005 September 28-October 1. 2005:329. [CENTRAL: CN-00602212] ">Iraji 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Burke and Cunliffe Scale (Leeds technique), no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0026" title="JaffaryF , FaghihiG , SaraeianS , HosseiniSM . Comparison the effectiveness of pyruvic acid 50% and salicylic acid 30% in the treatment of acne. Journal of Research in Medical Sciences2016;21(2):31. ">Jaffary 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "no more than five pustules forms and no cysts, nodules, and colloidal deep scar" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0027" title="KarBR , TripathyS , PandaM . Comparative study of oral isotretinoin versus oral isotretinoin + 20% salicylic acid peel in the treatment of active acne. Journal of Cutaneous &amp; Aestheic Surgery2013;6(4):204-8. [PMID: 24470716]">Kar 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average baseline Michaelsson acne severity index in the two treatment arms was 64.1 ± 4.4 and 63.0 ± 5.1 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0028" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree Ⅱ or Ⅲ, Plewig‐Kligmann classification system, participants with papulopustular acne were included </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0029" title="KatsambasA , GraupeK , StratigosJ . Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermato-Venereologica. Supplementum1989;69(Suppl 143):35-9. [CENTRAL: CN-00062183] ">Katsambas 1989b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with comedonal acne, no further details</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0030" title="KesslerE , FlanaganK , ChiaC , RogersC , GlaserDA . Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatologic Surgery2008;34(1):45-50; discussion 51. [CENTRAL: CN-00621503] ">Kessler 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderately severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, a minimum of 10 papules and/or pustules</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0031" title="KhodaeianiE , FouladiRF , AmirniaM , SaeidiM , KarimiER . Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. International Journal of Dermatology2013;52(8):999-1004. [CENTRAL: CN-00919313] ">Khodaeiani 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade Ⅲ, the Leeds technique</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0032" title="KimSW , MoonSE , KimJA , EunHC . Glycolic acid versus Jessner's solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatologic Surgery1999;25(4):270-3. [PMID: 10417580]">Kim 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds technique, grades of 0.25 to 2.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0033" title="LevesqueA , HamzaviI , SeiteS , RougierA , BissonnetteR . Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. Journal of Cosmetic Dermatology2011;10(3):174-8. [CENTRAL: CN-00806039] ">Levesque 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably mild to moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subjects with comedonal acne (at least 5 non‐inflamed lesions on each side of the face and &lt; 30 inflamed lesions on entire face) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0034" title="NilFroushzadehMA , SiadatAH , BaradaranEH , MoradiS . Clindamycin lotion alone versus combination lotion of clindamycin phosphate plus tretinoin versus combination lotion of clindamycin phosphate plus salicylic acid in the topical treatment of mild to moderate acne vulgaris: a randomized control trial. Indian Journal of Dermatology, Venereology and Leprology2009;75(3):279-82. [CENTRAL: CN-00729040] ">NilFroushzadeh 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0035" title="OzkanM , DurmazG , SabuncuI , SaracogluN , AkgunY , UrerSM . Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative staphylococci. Turkish Journal of Medical Sciences2000;30(5):483-7. [CENTRAL: CN-00424538] ">Ozkan 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using the Leeds technique, ≤ 3.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0036" title="Pazoki-ToroudiH , Nassiri-KashaniM , TabatabaieH , AjamiM , HabibeyR , ShizarpourM , et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. Journal of Dermatological Treatment2010;21(3):212-6. [CENTRAL: CN-00748446] ">Pazoki‐Toroudi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Defined as "at least 10 inflammatory lesions on the face and with a maximum of three nodules" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0037" title="Pazoki-ToroudiH , NilforoushzadehMA , AjamiM , JaffaryF , AboutalebN , Nassiri-KashaniM , et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutaneous and Ocular Toxicology2011;30(4):286-91. [CENTRAL: CN-00882826] ">Pazoki‐Toroudi 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clinical diagnosis of mild to moderate acne, ≥ 10 facial lesions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0038" title="PicosseFR , Dos Santos GuadanhimLR , NascimentoLS , PaivaJM , BagatinE . Azelaic acid as an option for maintenance treatment after oral isotretinoin: a comparative and longitudinal study-preliminary results. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB5. [EMBASE: 71894787]">Picosse 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0039" title="EUCTR2013-004158-81-Outside-EU/EEA. A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-004158-81-Outside-EU/EEA (first received 21 September 2017). NCT02058628. Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/show/nct02058628 (first received 10 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016;30(6):966-73. [CENTRAL: CN-01369030] ">Schaller 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators' static global assessment score of mild or moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0040" title="ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA , NilforoushzadehMA . Comparison of topical 5% nicotinamid and 2% clindamycin gels in the treatment of the mild to moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Isfahan Medical School2015;32(316):2279-85. [CENTRAL: CN-01070524] ShahmoradiZ , IrajiF , SiadatAH , GhorbainiA . Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial. Journal of Research in Medical Sciences2013;18(2):115-7. [CENTRAL: CN-00908552] ">Shahmoradi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐defined grading system (mild acne: the presence of non‐inflammatory lesions, and the number of the papules, and pustules to be &lt; 10 without any nodules or cysts; moderate acne: the presence of non‐inflammatory lesions and the number of the papules and pustules to be &lt; 20 without any nodules or cysts) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0041" title="ShalitaAR . Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis; Cutaneous Medicine for the Practitioner1981;28(5):556-8, 561. [CENTRAL: CN-00269323] ">Shalita 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grade Ⅰ or Ⅱ, Pillsbury classification system</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0042" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264-7. [CENTRAL: CN-00185376] ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Revista Brasileira de Medicina1998;55(3):143-5. [CENTRAL: CN-00200583] ">Shalita 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐defined grading system (the presence of at least 10 papulopustular lesions on the face accompanied by a minimum of 5 comedones, as well as a grade of 4 to 6 on the Allen‐Smith Acne Severity Scale) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0043" title="ShalitaAR , ChalkerDK , ParishLC , BernsteinJE , EvansCS . The effects of topical nicotinamide on acne vulgaris. Journal of Investigative Dermatology1992;98(4):604. [CENTRAL: CN-00324761] ShalitaAR , SmithJG , ParishLC , SofmanMS , ChalkerDK . Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. International Journal of Dermatology1995;34(6):434-7. [CENTRAL: CN-00117614] ">Shalita 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐defined grading system (the presence of at least 15 papules and/or pustules on the face) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0044" title="SharquieKE , NoaimiAA , Al-SalihMM . Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution. Saudi Medical Journal2008;29(12):1757-61. [CENTRAL: CN-00686729] ">Sharquie 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild acne: the count of pustules &lt; 20 and the count of papules &lt; 10; moderate acne: the count of pustules ranged between 20 and 40 and the count of papules ranged between 10 and 30 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0045" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320-5. [CENTRAL: CN-00586948] ">Stinco 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with mild or moderate comedonic or papulopustular acne, a minimum of 20 facial non‐inflammatory lesions and 10 inflamed lesions </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0046" title="TechapichetvanichT , RajatanavinN , SahawatwongS . The combination of salicylic acid peel with 5% benzoyl peroxide and 1% clindamycin lotion in a treatment of acne vulgaris: a randomized, doubleblind, placebo controlled study. Journal of the American Academy of Dermatology2011;64(2 Suppl 1):AB13. [CENTRAL: CN-00843979] ">Techapichetvanich 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne severity grading method not reported, this study was published as an abstract</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0047" title="DRKS00003170. An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren® 15% gel and Differin® 0.1% gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00003170 (first received 20 July 2011). NCT01387048. Study for long-term treatment of acne vulgaris with Skinoren versus Differin. clinicaltrials.gov/show/nct01387048 (first received 4 July 2011). ThielitzA , LuxA , WiedeA , KropfS , PapakonstantinouE , GollnickH . A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. Journal of the European Academy of Dermatology and Venereology2015;29(4):789-96. [CENTRAL: CN-01254690] ">Thielitz 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Graded using a modified Investigators' Static Global assessment (grades of 2 to 4) and the Leeds Revised Acne Grading Scale (grades of 2 to 7) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0048" title="VasarinshP . Benzoyl peroxide- sulfur lotions in acne vulgaris- a controlled study. Cutis; cutaneous medicine for the practitioner1969;5(1):65-9. [CENTRAL: CN-00269401] ">Vasarinsh 1969</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011368-bbs2-0049" title="WeltertY , ChartierS , GibaudC , CourauS , PechenartP , SirventA , et al. Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component. Nouvelles Dermatologiques2004;23(7 I):385-94. [CENTRAL: CN-00516675] ">Weltert 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate inflammatory acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with moderate inflammatory ance on face (≥ 5 inflammatory elements, papules or pustules) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Possible acne severity, graded by using a simple system based on the predominant lesions present (<a href="./references#CD011368-bbs2-0014" title="DayalS , AmraniA , SahuP , JainVK . Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. Journal of Cosmetic Dermatology2017;16(1):43-51. [CENTRAL: CN-01367383] ">Dayal 2017</a>), grade 1 (mild): comedones, occasional papules; grade 2 (moderate): papules, comedones, few pustules; grade 3 (severe): predominant pustules, nodules, abscesses; grade 4 (cystic): mainly cysts, abscesses, widespread scarring. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Acne severity for all studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0014"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Azelaic acid compared to benzoyl peroxide/clindamycin</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to benzoyl peroxide/clindamycin for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> 11 study centres in Germany<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> topical benzoyl peroxide/clindamycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide/clindamycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> <br/><i>Much to very much improved</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>559 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>419 per 1000</b><br/>(318 to 553) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.75</b> <br/>(0.57 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.15</p> <p>(0.43 to 3.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>559 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>693 per 1000</b><br/>(564 to 849) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> <br/>(1.01 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The common application site reactions include pruritus, pain, erythema and dryness.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>CDLQI</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The authors reported that a greater mean (SD) change in CDLQI was noted with benzoyl peroxide 3% + clindamycin 1% gel (‐60.5% ± 70.6, n = 107) versus azelaic acid 20% cream (‐36.8% ± 74.8, n = 108). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skewed data reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CDLQI</b> : Children's Dermatology Life Quality Index; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and with unclear risk of allocation concealment and other bias. One level for imprecision: optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and with unclear allocation concealment and other bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of allocation concealment and other bias. One level for imprecision: total population size is less than 400 and wide CI.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Azelaic acid compared to benzoyl peroxide/clindamycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0015"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Azelaic acid compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Azelaic acid compared to placebo for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described (4 studies)<br/><b>Intervention:</b> topical azelaic acid<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical azelaic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>101 per 1000</b><br/>(35 to 295) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.60</b> <br/>(0.55 to 4.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 19.00</b><br/>(1.16 to 312.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/30 versus 0/30 experienced minor adverse events. In the other studies in this comparison, events such as scaling, dry skin, erythema, oiliness, and pruritus were reported, but the number of participants with these events were low and similar across groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: three studies included, two with unclear risk of selection bias and one with unclear risk of allocation concealment, one study with high risk of reporting bias and one with high risk of attrition bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included, and study with unclear random sequence generation and allocation concealment. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Azelaic acid compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0016"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Salicylic acid compared to no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Salicylic acid compared to no treatment for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Skin Disease and Leishmaniasis Research Center and Isfahan University of Medical Sciences clinics (1 study); a tertiary care hospital of Eastern India (1 study); not described (1 study)<br/><b>Intervention:</b> topical salicylic acid<br/><b>Comparison:</b> no treatment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical salicylic acid</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> <br/><i>Moderate to excellent improvement</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>960 per 1000</b><br/>(860 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/>(0.86 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin/benzoyl peroxide was a co‐intervention given in both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.0</b> <br/>(0.13 to 70.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies had no withdrawals.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>436 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> <p>(61 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.43</b> <br/>(0.14 to 82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All side effects reported in the study were of mild to moderate intensity and transient.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>AQOL</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The authors reported no "significant differences" in AQOL between treatment groups (salicylic acid/clindamycin/benzoyl peroxide group versus clindamycin/benzoyl peroxide group) at baseline and the end of the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median and 95% CI reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AQOL</b> : acne quality of life; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: optimal sample size not met.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: three studies included and all with unclear risk of allocation concealment and high risk of performance bias, two studies with unclear risk of random sequence generation. Two levels for imprecision: very wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: two studies included and both with unclear risk of selection and high risk of performance bias, one with unclear risk of reporting bias. Two levels for imprecision: very wide CI and optimal sample size not met.<br/><sup>d</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: very small total sample size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Salicylic acid compared to no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0017"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sulphur compared to benzoyl peroxide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulphur compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Wayne State University Health Service<br/><b>Intervention:</b> topical sulphur<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical sulphur</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Numerical point system defined by investigator, high = well</i> <br/>(medium term: treatment duration from 5 to 8 weeks) </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The score (high = well) was 0.75 in sulphur group and 0.66 in benzoyl peroxide group.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SDs were missing.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>334 per 1000</b><br/>(78 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.67</b> <br/>(0.62 to 11.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. But the authors reported that five patients in the benzoyl peroxide group (5/16) versus zero in sulphur group (0/18) developed erythema and drying. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by four levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: very small sample size.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sulphur compared to benzoyl peroxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0018"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Sulphur compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulphur compared to placebo for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Wayne State University Health Service<br/><b>Intervention:</b> topical sulphur<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical sulphur</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Numerical point system defined by investigator, high = well</i> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The score (high = well) was 0.75 in participants receiving sulphur treatment and 0.53 in placebo group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SDs were missing.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b><br/>(112 to 989) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.58</b> <br/>(0.53 to 4.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants who experienced at least one adverse event not reported. Two participants in the placebo group (2/19) versus zero in sulphur group (0/18) developed erythema and drying. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by four levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, and reporting bias. Two levels for imprecision: very small sample size.<br/><sup>b</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with high risk of attrition bias and unclear risk of selection, performance, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Sulphur compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0019"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Zinc compared to tea</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc compared to tea for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> Department of Dermatology and Venereology, Baghdad Teaching Hospital, Baghdad, Iraq<br/><b>Intervention:</b> topical zinc<br/><b>Comparison:</b> topical tea </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical tea</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical zinc</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(33 to 520) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/>(0.20 to 3.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(medium term: treatment duration from 5 to 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>304 per 1000</b><br/>(113 to 823) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/>(0.54 to 3.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Five people experienced burning and two experienced itching in the zinc sulphate treatment group, in contrast, five people had mild itching in the tea lotion treatment group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels to very low quality evidence. One level for risk of bias: only one study included with unclear risk of selection, performance, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by four levels to very low quality evidence. Two levels for risk of bias: only one study included with high risk of attrition bias and with unclear risk of selection, performance, detection, and reporting bias. Two levels for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Zinc compared to tea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0020"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Zinc compared to no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc compared to no treatment for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> eight centres in the UK, one in France and one in Germany<br/><b>Intervention:</b> topical zinc plus clindamycin 1% gel<br/><b>Comparison:</b> no treatment plus clindamycin 1% gel </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical zinc</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> <p><i>Visual analogue scale</i> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>The study authors only reported no significant difference between treatment groups.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin 1% gel was a co‐intervention given in both arms. No numerical data provided.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b><br/>(31 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/>(0.43 to 3.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin 1% gel was a co‐intervention given in both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin 1% gel was a co‐intervention given in both arms.</p> <p>The authors only report number of adverse events, not number of participants ‐ 91 adverse events in 80 zinc/clindamycin participants and 117 adverse events in 83 clindamycin participants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: small sample size.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>c</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of performance bias and unclear risk of selection bias. One level for imprecision: small sample size.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Zinc compared to no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0021"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Gluconolactone (alpha‐hydroxy acid) compared to benzoyl peroxide</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gluconolactone (alpha‐hydroxy acid) compared to benzoyl peroxide for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described<br/><b>Intervention:</b> topical gluconolactone (alpha‐hydroxy acid)<br/><b>Comparison:</b> topical benzoyl peroxide </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical benzoyl peroxide</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical gluconolactone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(32 to 306) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/>(0.27 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(135 to 425) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b> <br/>(0.27 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dryness was the most commonly reported problem in treatment groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias, and with unclear risk of selection bias and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias and unclear risk of selection and reporting bias. One level for imprecision: optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Gluconolactone (alpha‐hydroxy acid) compared to benzoyl peroxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011368-tbl-0022"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Gluconolactone (alpha‐hydroxy acid) compared to placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gluconolactone (alpha‐hydroxy acid) compared to placebo for acne</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with acne<br/><b>Settings:</b> not described<br/><b>Intervention:</b> topical gluconolactone (alpha‐hydroxy acid)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no treatment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Topical gluconolactone</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global self‐assessment of acne improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(29 to 350) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.25</b> <br/>(0.36 to 4.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total number of participants who experienced at least one minor adverse event</b> </p> <p>(long term: treatment duration &gt; 8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(91 to 631) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.40</b> <br/>(0.91 to 6.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in gluconolactone group reported more erythema, burning and stinging, pruritus and scaling than those in the placebo group, but these differences were not "significant". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias and unclear risk of selection and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>b</sup>Downgraded by two levels to low quality evidence. One level for risk of bias: only one study included with high risk of other bias and unclear risk of selection and reporting bias. One level for imprecision: wide CI and optimal sample size not met.<br/><sup>*</sup>We choose a mean baseline risk from the studies included in meta‐analysis, calculated as number of participants in the control groups with event divided by total number of participants in control groups (study population) as assumed risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Gluconolactone (alpha‐hydroxy acid) compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/full#CD011368-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical azelaic acid versus other topical treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Participants' global self‐assessment of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 azelaic acid versus adapalene ‐ improved to very much improved (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 azelaic acid versus adapalene ‐ improved to very much improved (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 azelaic acid versus benzoyl peroxide ‐ good or very good improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 azelaic acid versus clindamycin ‐ good or very good improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 azelaic acid versus clindamycin ‐ moderately satisfied to very satisfied improvement (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.6 azelaic acid versus erythromycin ‐ moderately satisfied to very satisfied improvement (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.7 azelaic acid versus tretinoin ‐ good to excellent improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.8 azelaic acid versus benzoyl peroxide/clindamycin ‐ much to very much improved (short term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.9 azelaic acid versus benzoyl peroxide/clindamycin ‐ much to very much improved (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.10 azelaic acid versus benzoyl peroxide/clindamycin ‐ much to very much improved (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 azelaic acid versus adapalene (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.05, 12.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 azelaic acid versus adapalene (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [0.33, 20.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 azelaic acid versus benzoyl peroxide (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.04, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 azelaic acid versus benzoyl peroxide (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.60, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 azelaic acid versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 azelaic acid versus clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.48, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.7 azelaic acid versus metronidazole (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.8 azelaic acid versus tretinoin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.29, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.9 azelaic acid versus benzoyl peroxide/clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.43, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in lesion counts ‐ total (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 azelaic acid versus clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 azelaic acid versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 azelaic acid versus clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 azelaic acid versus benzoyl peroxide/clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 azelaic acid versus benzoyl peroxide/clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 azelaic acid versus benzoyl peroxide/clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in lesion counts ‐ total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Change in lesion counts ‐ inflamed (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 azelaic acid versus benzoyl peroxide/clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 azelaic acid versus benzoyl peroxide/clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 azelaic acid versus benzoyl peroxide/clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Change in lesion counts ‐ inflamed (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 azelaic acid versus adapalene (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 azelaic acid versus benzoyl peroxide (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Change in lesion counts ‐ inflamed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Change in lesion counts ‐ papules (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 azelaic acid versus clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 azelaic acid versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 azelaic acid versus clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Change in lesion counts ‐ papules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 azelaic acid versus erythromycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 azelaic acid versus erythromycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 azelaic acid versus erythromycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Change in lesion counts ‐ pustules (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 azelaic acid versus clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 azelaic acid versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 azelaic acid versus clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Change in lesion counts ‐ pustules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 azelaic acid versus erythromycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 azelaic acid versus erythromycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 azelaic acid versus erythromycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Change in lesion counts ‐ non‐inflamed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 azelaic acid versus clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 azelaic acid versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 azelaic acid versus clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 azelaic acid versus benzoyl peroxide/clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.5 azelaic acid versus benzoyl peroxide/clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.6 azelaic acid versus benzoyl peroxide/clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 azelaic acid versus erythromycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 azelaic acid versus erythromycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 azelaic acid versus erythromycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 azelaic acid versus adapalene (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.5 azelaic acid versus benzoyl peroxide (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 azelaic acid versus benzoyl peroxide ‐ good or very good improvement (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 azelaic acid versus clindamycin ‐ good or very good improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 azelaic acid versus tretinoin ‐ good to excellent improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.4 azelaic acid versus benzoyl peroxide/clindamycin ‐ clear to almost clear (short term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.5 azelaic acid versus benzoyl peroxide/clindamycin ‐ clear to almost clear (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.6 azelaic acid versus benzoyl peroxide/clindamycin ‐ clear to almost clear (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 total events ‐ azelaic acid versus adapalene (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.47, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 total events ‐ azelaic acid versus benzoyl peroxide (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 total events ‐ azelaic acid versus benzoyl peroxide/clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.01, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.4 total events ‐ azelaic acid versus clindamycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.67, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.5 total events ‐ azelaic acid versus erythromycin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.51, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.6 application site pain ‐ azelaic acid versus benzoyl peroxide/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [1.41, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.7 burning ‐ azelaic acid versus benzoyl peroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.61, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.8 burning ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.22 [1.51, 420.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.9 burning ‐ azelaic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.38, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.10 scaling ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.20, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.11 scaling ‐ azelaic acid versus erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.35, 9.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.12 scaling ‐ azelaic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.37, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.13 erythema ‐ azelaic acid versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.30, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.14 erythema ‐ azelaic acid versus benzoyl peroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.21, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.15 erythema ‐ azelaic acid versus benzoyl peroxide/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.41, 6.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.16 erythema ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.17 erythema ‐ azelaic acid versus erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.16, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.18 erythema ‐ azelaic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.41, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.19 dryness ‐ azelaic acid versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.20 dryness ‐ azelaic acid versus benzoyl peroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.27, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.21 dryness ‐ azelaic acid versus benzoyl peroxide/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.26, 8.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.22 dryness ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.96, 6.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.23 dryness ‐ azelaic acid versus erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.09, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.24 oiliness ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.36, 4.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.25 oiliness ‐ azelaic acid versus erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.19, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.26 itching ‐ azelaic acid versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.84, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.27 itching ‐ azelaic acid versus benzoyl peroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [0.24, 45.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.28 itching ‐ azelaic acid versus benzoyl peroxide/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [1.49, 6.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.29 itching ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [0.68, 9.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.30 itching ‐ azelaic acid versus erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.29, 4.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.31 red skin ‐ azelaic acid versus benzoyl peroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.36, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.32 red skin ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.05 [1.39, 26.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.33 desquamation ‐ azelaic acid versus benzoyl peroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.08, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.34 eczema ‐ azelaic acid versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical azelaic acid versus other topical treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical azelaic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Change in lesion counts ‐ &gt; 50% inflamed reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Change in lesion counts ‐ inflamed (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 long term (split‐face trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Change in lesion counts ‐ &gt; 50% non‐inflamed reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 long term (split‐face trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Change in lesion counts (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 long term (split‐face trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Change in lesion counts (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Change in lesion counts ‐ comedones (reduction in number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Good to excellent improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 burning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [0.53, 39.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 scaling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.16, 13.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.39, 9.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.4 dryness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.15, 57.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.5 oiliness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.08 [0.22, 75.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.6 itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.45 [0.68, 43.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.7 total events (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.00 [1.16, 312.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical azelaic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical azelaic acid versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Participants' global self‐assessment of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 moderately satisfied to very satisfied improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.94, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Change in lesion counts ‐ total (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Change in lesion counts ‐ papules (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Change in lesion counts ‐ pustules (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Change in lesion counts ‐ inflamed (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Change in lesion counts ‐ comedones (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 scaling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.15, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.12, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.3 dryness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.20, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.4 oiliness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.27, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.5 itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.23, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.6 total events (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.36, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical azelaic acid versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topical salicylic acid versus other topical treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Participants' global self‐assessment of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 salicylic acid versus tretinoin ‐ moderate to excellent improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 salicylic acid versus pyruvic acid ‐ good to excellent improvement (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Participants' global self‐assessment of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 parallel trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 salicylic acid versus pyruvic acid (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 salicylic acid versus benzoyl peroxide (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 salicylic acid versus benzoyl peroxide (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 salicylic acid versus tretinoin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.5 salicylic acid versus Jessner's solution (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Change in lesion counts ‐ total (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 salicylic acid versus tretinoin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 salicylic acid versus tretinoin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 salicylic acid versus tretinoin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Change in lesion counts ‐ inflamed (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 salicylic acid versus tretinoin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 salicylic acid versus tretinoin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.3 salicylic acid versus tretinoin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Change in lesion counts ‐ inflamed (mean counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 parallel trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Change in lesion counts ‐ papules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 salicylic acid versus pyruvic acid (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 salicylic acid versus pyruvic acid (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Change in lesion count ‐ pustules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 salicylic acid versus pyruvic acid (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 salicylic acid versus pyruvic acid (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 salicylic acid versus tretinoin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 salicylic acid versus tretinoin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.3 salicylic acid versus tretinoin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.4 salicylic acid versus pyruvic acid (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.5 salicylic acid versus pyruvic acid (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Change in lesion counts ‐ non‐inflamed (counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 parallel trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.2 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Change in lesion counts ‐ various types of acne lesions (counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 parallel trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.2 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.3 cross‐over trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 salicylic acid versus tretinoin ‐ moderate to excellent improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.2 salicylic acid versus Jessner's solution ‐ fair to good improvement (long term))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.3 salicylic acid versus pyruvic acid ‐ good to excellent improvement (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Physicians' global evaluation of acne improvement (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.1 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 salicylic acid versus lipohydroxy acid ‐ 3‐point scale defined by investigator, high = well (short term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.2 salicylic acid versus lipohydroxy acid ‐ 3‐point scale defined by investigator, high = well (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.3 salicylic acid versus lipohydroxy acid ‐ 3‐point scale defined by investigator, high = well (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.1 dryness ‐ salicylic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.70, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.2 peeling ‐ salicylic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.40, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.3 erythema ‐ salicylic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.38, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.4 burning ‐ salicylic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.50, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.5 itching ‐ salicylic acid versus tretinoin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.16, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.6 postpeel burning and stinging ‐ salicylic acid versus Jessner's solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.81, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.7 postpeel erythema ‐ salicylic acid versus Jessner's solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.50, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.8 postpeel hyperpigmentation ‐ salicylic acid versus Jessner's solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.9 total events ‐ salicylic acid versus benzoyl peroxide (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.10 total events ‐ salicylic acid versus benzoyl peroxide (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.11 total events ‐ salicylic acid versus tretinoin (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.66, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.16 Quality of life (QoL) ‐ AQOL (score, post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topical salicylic acid versus other topical treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topical salicylic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Participants' global self‐assessment of acne improvement (score, high=well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Change in lesion counts (counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Change in lesion counts ‐ inflamed (counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Change in lesion counts ‐ non‐inflamed (counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 good or excellent improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 total events (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.2 total events (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topical salicylic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topical salicylic acid versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Participants' global self‐assessment of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 moderate to excellent improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Change in lesion counts ‐ total (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Change in lesion counts ‐ inflamed (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Change in lesion counts ‐ non‐inflamed (percentage reduction from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 moderate to excellent improvement (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 dryness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [1.25, 5.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.2 peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.74, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.3 erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.94, 17.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.4 burning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.71, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.5 itching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.45, 6.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.6 total events (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [0.14, 82.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Quality of life (QoL) ‐ AQOL (score, post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topical salicylic acid versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Topical nicotinamide versus other topical treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 nicotinamide versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 nicotinamide versus erythromycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Change in lesion counts ‐ inflamed (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 nicotinamide versus clindamycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 nicotinamide versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Change in lesion counts ‐ inflamed counts (counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Change in lesion counts ‐ comedones (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 nicotinamide versus erythromycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 nicotinamide versus clindamycin ‐ moderately or much better improvement (short term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 nicotinamide versus clindamycin ‐ moderately or much better improvement (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 itching ‐ nicotinamide versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.32, 5.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.2 burning ‐ nicotinamide versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.77, 15.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.3 crusting ‐ nicotinamide versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.4 greasy skin ‐ nicotinamide versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.5 dermatitis ‐ nicotinamide versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.6 total events ‐ nicotinamide versus clindamycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.73, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.7 pertinent clinical signs ‐ nicotinamide versus erythromycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.60, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.8 pertinent clinical signs ‐ nicotinamide versus erythromycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.50, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.9 functional or physical signs ‐ nicotinamide versus erythromycin (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.61, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.10 functional or physical signs ‐ nicotinamide versus erythromycin (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.38, 1.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Topical nicotinamide versus other topical treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topical sulphur versus other topical treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Participants' global self assessment of acne improvement (numerical point system defined by investigator, high = well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 sulphur versus benzoyl peroxide (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Change in lesion counts (scores, high = well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 sulphur versus benzoyl peroxide ‐ moderate to good improvement (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.1 erythema and drying ‐ sulphur versus benzoyl peroxide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topical sulphur versus other topical treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Topical sulphur versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high=well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Change in lesion counts (scores, high = well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 moderate to good improvement (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high = well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Minor adverse events ‐ erythema and drying <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Topical sulphur versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Topical sulphur versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Participants' global self‐assessment of acne improvement (numerical point system defined by investigator, high = well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Change in lesion counts (scores, high = well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 moderate to good improvement (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Physicians' global evaluation of acne improvement (numerical point system defined by investigator, high=well) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.6 Minor adverse events ‐ erythema and drying <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Topical sulphur versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Topical zinc versus other topical treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 zinc versus tea (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Change in lesion counts ‐ papules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 zinc versus tea (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Change in lesion counts ‐ pustules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 zinc versus tea (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 zinc versus tea ‐ moderate or good response (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Minor adverse events ‐ total events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 zinc versus tea (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Topical zinc versus other topical treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Topical zinc versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Participants' global self‐assessment of acne improvement (visual analogue scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Change in lesion counts ‐ total (lesion counts reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Change in lesion counts ‐ inflamed (lesion counts reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Change in lesion counts ‐ non‐inflamed (lesion counts reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.3 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.6 Physicians' global evaluation of acne improvement (visual analogue scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6.1 long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.7 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Topical zinc versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Topical alpha‐hydroxy acid versus other topical treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Participants' global self‐assessment of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 glycolic acid versus salicylic‐mandelic acid ‐ fair to good improvement (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 gluconolactone versus benzoyl peroxide (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 glycolic acid versus salicylic‐mandelic acid (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Change in lesion counts ‐ non‐inflamed (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 glycolic acid versus salicylic‐mandelic acid (short term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.2 glycolic acid versus salicylic‐mandelic acid (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Change in lesion counts ‐ papules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 glycolic acid versus salicylic‐mandelic acid (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Change in lesion counts ‐ pustules (number of lesions post‐intervention) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5.1 glycolic acid versus salicylic‐mandelic acid (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.6 Change in lesion counts ‐ total (counts or %) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.1 parallel trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6.2 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.7 Change in lesion counts ‐ inflamed (counts) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7.1 parallel trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7.2 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.8 Change in lesion counts ‐ non‐inflamed (counts) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8.1 parallel trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.8.2 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.9 Physicians' global evaluation of acne improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.9.1 glycolic acid versus salicylic‐mandelic acid ‐ fair to good improvement (short term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.9.2 glycolic acid versus salicylic‐mandelic acid ‐ fair to good improvement (medium term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.9.3 glycolic acid versus salicylic‐mandelic acid ‐ fair to good improvement (long term) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.10 Physicians' global evaluation of acne improvement (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.10.1 split‐face trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.11 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.11.1 total events ‐ gluconolactone versus benzoyl peroxide (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.27, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.11.2 total events ‐ glycolic acid versus salicylic ‐ mandelic acid (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.72, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.11.3 burning or sensation ‐ glycolic acid versus salicylic ‐ mandelic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.11.4 desquamation ‐ glycolic acid versus salicylic ‐ mandelic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.11, 9.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.11.5 dryness ‐ glycolic acid versus salicylic ‐ mandelic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.11.6 acne flare ‐ glycolic acid versus salicylic ‐ mandelic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.22, 4.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Topical alpha‐hydroxy acid versus other topical treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011368-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Topical alpha‐hydroxy acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 gluconolactone versus placebo (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Minor adverse events ‐ total events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 gluconolactone versus placebo (long term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Topical alpha‐hydroxy acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011368.pub2/references#CD011368-tbl-0036">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011368.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011368-note-0032">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011368-note-0029">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011368-note-0031">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011368-note-0028">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD011368-note-0026">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011368-note-0027">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011368-note-0030">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011368-note-0025">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011368\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011368\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011368\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011368\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011368\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011368.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011368.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011368.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011368.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011368.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713845639"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011368.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713845642"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011368.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d60310c7c936e',t:'MTc0MDcxMzg0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 